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ABSTRACT 
 
Vibha Anand 
 
A PROBABILISTIC APPROACH TO DATA INTEGRATION IN BIOMEDICAL 
RESEARCH: THE IsBIG EXPERIMENTS 
Biomedical research has produced vast amounts of new information in the last 
decade but has been slow to find its use in clinical applications. Data from disparate 
sources such as genetic studies and summary data from published literature have been 
amassed, but there is a significant gap, primarily due to a lack of normative methods, in 
combining such information for inference and knowledge discovery.  
In this research using Bayesian Networks (BN), a probabilistic framework is built 
to address this gap. BN are a relatively new method of representing uncertain 
relationships among variables using probabilities and graph theory. Despite their 
computational complexity of inference, BN represent domain knowledge concisely.  In 
this work, strategies using BN have been developed to incorporate a range of available 
information from both raw data sources and statistical and summary measures in a 
coherent framework.  As an example of this framework, a prototype model (In-silico 
Bayesian Integration of GWAS or IsBIG) has been developed.  IsBIG integrates 
summary and statistical measures from the NIH catalog of genome wide association 
studies (GWAS) and the database of human genome variations from the international 
HapMap project.  IsBIG produces a map of disease to disease associations as inferred by 
genetic linkages in the population.  
Quantitative evaluation of the IsBIG model shows correlation with empiric results 
from our Electronic Medical Record (EMR) – The Regenstrief Medical Record System 
vi 
 
(RMRS).  Only a small fraction of disease to disease associations in the population can 
be explained by the linking of a genetic variation to a disease association as studied in the 
GWAS.  None the less, the model appears to have found novel associations among some 
diseases that are not described in the literature but are confirmed in our EMR. Thus, in 
conclusion, our results demonstrate the potential use of a probabilistic modeling 
approach for combining data from disparate sources for inference and knowledge 
discovery purposes in biomedical research. 
 
 Mathew J. Palakal, Ph.D., Chair 
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Chapter 1 INTRODUCTION 
 
Opportunities for Informatics in Biomedical Research 
The past few years have witnessed major advances in the area of biomedical 
research due to rapid advances in technology like database management and the 
availability of open source software tools to name a few. Due to the latter, the research in 
this area has become increasingly collaborative and several major initiatives including the 
mapping of entire human genome have been successfully completed in the last decade. 
[1] 
Informatics, which is viewed as a science of information, is often studied as a 
branch of computer science and information technology relating to databases, ontology 
and software engineering and is primarily concerned with transformation of information 
by computation or communication; by machines or people. Health informatics or 
Biomedical informatics is an emerging discipline engaged in study, invention and 
implementation of structures and algorithms to improve understanding and management 
of medical information. The end objective of biomedical informatics is coalescing of 
data, knowledge and the tools necessary to apply the data and knowledge in the decision 
making process at the time and place that a decision needs to be made. 
Thus, in the post genome era the role of biomedical informatics has shifted from 
managing and integrating genetic sequence databases to discovering knowledge from 
biomedical databases. More recently integrating this knowledge from disparate sources 
such as from biological databases and clinical data from electronic medical records 
(EMR) for applications such as personalized medicine has received an increasing amount 
of interest from both the National Institutes of Health (NIH) and individual researchers.  
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Challenges for Informatics in Biomedical research 
However, in biomedical research, to make inferences based on data especially 
using traditional statistical methods, one requires a unified dataset, i.e. a dataset where all 
variables are measured on the same set of individuals. Furthermore, making new 
discoveries depends on having access to these original datasets. However, in the current 
research paradigm the variables of interest are being measured in separate studies and on 
different study populations. They are being stored in silos of specialized databases that do 
not relate to each other on an individual level. Therefore a significant gap exists in our 
ability to draw inference from these datasets in order to further our understanding of the 
outcomes of such research and its applicability for instance to clinical care.  
For example, Figure 1-1 on the next page shows a model for a common disease 
like asthma that is known to have many causes. To gain a full understanding of the 
disease and its management, one has to account for all the causes –environmental, 
clinical, genetic, socio economic and demographic factors along with any sub clinical 
symptoms (phenotypes) that may be presented. Thus asthma presents as a common but a 
complex disease involving many risk factors. To apply cutting edge research to this 
disease in a clinical application, for example, on how environment or genes may affect an 
individual’s disease status, one needs to integrate all such information in a coherent 
model and draw inference from it. Thus, finding methods to integrate information from 
disparate sources – biological databases, clinical databases, and published literature in a 
coherent model for purposes of prediction and eventually pre-emption of disease has 
become the goal of biomedical informatics researchers in this decade.  
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Figure 1-1 A complex dataset example 
 
However, at present no such coherent model can be built because data collected 
from disparate study populations reside in silos of biomedical databases, with each of 
them focused on one of a number of causes, for example, how environmental factors like 
tobacco smoke exposure may affect asthma. Due to lacking unified datasets, our best 
hope of linking information is by using informatics tools that employ non-traditional 
statistical methods, for example, to combine information from available datasets such as 
EMR with sources such as summary or statistical measures from published literature.  
Environment
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In this work, we approach the integration problem with probabilistic modeling 
tools. We outline a methodology to move beyond the boundary of a dataset that is limited 
by a set of variables.  Assuming independence of causal influences (ICI) among many 
causes that lead to a common effect, we strategically combine disparate sources of 
information with a Bayesian Network (BN) framework for identifying associations 
among the disparate datasets. Our approach uses available summary and statistical 
measures of correlations (r2) and odds ratio (OR) from published literature when no 
unifying dataset is present to build a model that integrates information in a systematic and 
normative form for further knowledge discovery.  Figure 1.2 outlines our conceptual 
model for data-information-knowledge discovery. 
 
Figure 1-2 In-silico Bayesian Integration – Conceptual Model 
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We demonstrate our approach by integrating information from at least two 
disparate sources in a coherent model - 1) statistical correlation on genetic linkages 
(associations) between Single Nucleotide Polymorphisms (SNP) in the human genome, 
and 2) data from multiple genome wide association studies (GWAS) where the 
magnitude of the association between a SNP and a disease phenotype is measured as an 
odds ratio (OR) in each GWAS.  SNPs and diseases are modeled as nodes in a BN and 
the edges that connect the nodes represent the strength of the relationship between nodes 
(i.e. SNP to SNP and SNP to disease). We demonstrate that as the effect of the SNP 
nodes from this model are averaged out, i.e. absorbed out, a disease to disease association 
map emerges as inferred from genetic linkages and discovered by the integration of these 
two disparate sources. We call the methodology In-silico Bayesian Integration and the 
model In-silico Bayesian Integration of GWAS (IsBIG).  
Thus, IsBIG combines information from various GWAS in a coherent model 
which otherwise is not available from a unified dataset. IsBIG therefore also presents a 
qualitative and quantitative structure that can be used for further knowledge discovery, 
for example, for generating new hypotheses for future studies associating diseases as 
inferred by genetic linkages.   
This thesis is organized into several major chapters. We first introduce the 
background of this research in Chapter 2. We describe existing methods for statistical 
analysis and modeling that have been employed for such research and their limitations. 
We then describe probabilistic modeling methods as a knowledge representation tool and 
give a brief literature review of their use in modeling healthcare data with emphasis on 
Bayesian networks.  
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In Chapter 3, we describe our data integration strategy using a series of 
experimental studies within the clinical domain. We learn BN from large clinical datasets 
and compare their performance with an expert’s version to assess the feasibility of this 
modeling technique. When the data available are sparse, we use the causal independence 
assumption using the Noisy-OR formalism to learn the conditional probability 
distributions in our model BN. We apply the above to a feasibility study in the area of 
childhood asthma case finding from our electronic medical record (EMR), the 
Regenstrief Medical Record System (RMRS), [2] and find that the results are comparable 
to an expert’s model in real world datasets. To model domain causal relationships, over 
and above causal independence, we test a recently published algorithm – Recursive Noisy 
OR (RNOR) and evaluate it with our previous childhood asthma case finding application. 
We find no statistically significant differences between the RNOR and causal 
independence approaches with this real world dataset. Therefore we stick to using the 
causal independence approach as a data integration strategy for successive experiments. 
In Chapter 4, we extend beyond our clinical domain to apply the causal 
independence assumption to an experimental study where data from our EMR for 
childhood asthma is integrated with statistical and summary data published in one study 
of asthma, linking a genotype and environmental tobacco smoke exposure to the risk of 
the disease. We develop this approach into a formal method – In-silico Bayesian 
Integration and demonstrate its applicability to generate a phenotype to phenotype map 
(IsBIG) from statistical and summary data on diseases and / or traits linked to Single 
Nucleotide Polymorphisms (SNPs) found in Genome Wide Association Studies (GWAS).   
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In Chapter 5 we empirically evaluate the IsBIG model using data derived from 
our EMR, the Regenstrief Medical Record System (RMRS) [2] and literature search. 
In Chapter 6, we summarize our work, discuss limitations of our approach as a 
knowledge representation tool and data integration strategy and outline some possible 
future directions. 
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Chapter 2  BACKGROUND 
 
This chapter introduces the background of our research, including a brief 
introduction on Bayesian Networks and their comparison to other statistical and machine 
learning techniques and their applicability to our research as a knowledge representation 
tool for building a probabilistic framework for biomedical research. 
Bayesian Networks (BN) 
Bayesian networks are a modeling and inference tool for problems involving 
uncertainty.  They have been shown to represent domain knowledge with natural 
perception of cause and effect. [3] A BN is a graphical model that both represents a 
qualitative structure and encodes quantitative parameters of the structure by defining a 
unique probability distribution. Because of their concise representation and their ability 
for belief propagation; BN have been widely used in many real world problems, [4] for 
example, in modeling probabilistic relationships in medical diagnoses. [5] 
Computational Methods of BN 
A Bayesian network is represented as a directed acyclic graph (DAG). The nodes 
within the DAG of BN denote relevant entities or random variables and the directed 
edges denote probabilistic relationships among them. For example, the DAG in Figure 2-
1 below models a structure encoding relationships between History of Smoking (H), 
Lung Cancer (L), Bronchitis (B), Fatigue (F) and Chest X-ray results (C), as described in 
[6]. The numerical values of these relationships are encoded as a joint probability 
distribution (JPD) over a set of these random variables. 
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Figure 2-1 A Directed Acyclic Graph (DAG) 
 
In probability theory, the notation P(X | Y) denotes the conditional probability of 
a variable X given (denoted by symbol “|”) another variable Y.  Two variables X and Y 
are independent if the probability of X given Y is the same as the probability of X 
occurring alone (i.e. P (X | Y) = P(X)) and vice versa, and when both events are known to 
occur with a certain probability, i.e. P(X) ≠ 0 and P(Y)  ≠ 0.  However there may be times 
when two variables are not independent by themselves but independent when conditioned 
upon a third variable, say Z, i.e., X and Y are conditionally independent given Z. A 
variable X is conditionally independent of Y given Z if  
0)|(0)|(),|()|(  ZYPandZXPwhenYZXPZXP   
 
i.e. if Z is given, the probability of X will not be affected by the discovery of Y. [3]  At 
the core of BN is this notion of conditional independence. For example, in the example 
above in Figure 2-1, the node Bronchitis (B) is conditionally independent of nodes Lung 
cancer (L) and Chest X-ray (C) given that we know about History of smoking (H). Table 
2-1 below gives other conditional independencies in this DAG. 
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Table 2-1 Conditional Independencies in Figure 2-1 
 
 
 
 
 
 
Another notion that BN model encodes is that of the Markov condition, also 
called the Markov independence assumption. This assumption says that each variable is 
conditionally independent of the set of all its non-descendents given the set of all its 
parents [3, 6], for example, Fatigue (F) is independent of History of Smoking (H) and 
Chest X-ray (C) given that we know about Bronchitis (B) and Lung Cancer (L). 
Under these two assumptions, i.e. conditional independence and Markov 
assumption, the factorization theorem as described by Pearl encodes a unique probability 
distribution for a graph G which is described by the following equation (1) [3]  
 )1()|(
1
),....,1( 
 GiPaXP
n
i
nXXP i                
 
Where PaG are the parent nodes of the variables, Xi, in G. Equation (1) is called the chain 
rule for Bayesian Networks. [3] As an example, the graph structure G in Figure 2-1 of a 
BN encodes independence assumptions while the conditional probability distributions 
(CPD), of the form P(Xi | iPa ) where iPa  are parents of Xi, provide the quantitative 
parameters for the joint probability distribution (JPD) of the BN represented by this graph 
G. The JPD of the DAG shown in Figure 2-1 can be calculated as follows by equation (2) 
as follows – 
(L), (B) | (H)(H) L 
(F), (H, C) | (B, L)(B, L) F 
(B), (L, C) | (H)(H) B 
(C), (H, B, F) | (L)(L) C 
Conditional 
Independence
Parent Node 
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P (f,c,b,l,h) = P(f|b,l)*P(c|l)*P(b|h)*P(l|h)*P(h)           (2) 
 
In a BN, the DAG defines the structure and the CPD values for each variable are 
called the parameters. Inference refers to the query for finding the probability 
distribution score of a node (node in question) given values of a subset of nodes 
(instantiated nodes) in the DAG. For example in Figure 2-1, if we know a patient has 
history of smoking and positive chest x-ray, we may be interested in finding the 
probability of that patient having lung cancer, i.e. (P(l | h, c) and having bronchitis, i.e. 
P(b | h, c). Exact inference is a non-deterministic polynomial time hard (NP-hard) 
problem [7]. Algorithms developed earlier such as message passing [3] in DAG, 
Symbolic Probabilistic Inference (SPI) [8], arc reversal / node reduction operations [9-
10], and the Junction Tree algorithm, [11-12] all have NP hard computational complexity 
in a multiply connected DAG and can become intractable for inference [6] in large 
networks. Following this, Cooper [7] obtained a result that the problem of determining 
the conditional probabilities is tractable in multiply connected networks and belongs to 
the class of problems that is P – complete if the remaining variables in a BN are restricted 
to having no more than two states per node and no more than two parents per node but 
with no restriction on number of children per node, given that certain variables are 
instantiated. Therefore, approximate inference algorithms such as stochastic simulation 
and deterministic search [13], finding the most probable explanation also called abductive 
inference methods [7] have been developed by many researchers in the field. 
Besides the development of approximate algorithms for inference, approximate 
algorithms to learn the structure and parameters of BN from data have been developed as 
well. When the variable X or its parents are discrete valued (i.e. binary or multinomial), 
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to learn the CPD of a single variable, a beta density function or a dirichlet density 
function is used. In case of binary variables, a beta density function is used; in the case of 
multinomial variables, a dirichlet density function is used. [6] Unlike the case of discrete 
variables, when variable X or its parents are real valued, linear Gaussian conditional 
densities [14] or other appropriate density functions [6] are used to represent the 
underlying data for assessing CPD values. 
In case of discrete variables a conditional probability table (CPT) is defined to 
represent the probability of Xi conditioned on each of its parents Pai. Together, the CPTs 
of all variables and the DAG define the JPD. For example, if the number of parents of a 
node denoted by Pai consists of K binary variables, the table (CPT) for the node defines 
2K rows of distributions. Therefore, while a full table form can describe any discrete 
conditional probability distribution (CPD), the number of parameters required grows 
exponentially in the number of parents Pai.. [3] Therefore methods to reduce the 
complexity of parameter estimation for local CPTs have been developed.  These methods 
all involve independence of causal influence assumption (ICI). Below, we describe these 
methods in detail. 
Causal Independence and ICI models 
A major difficulty in model building using Bayesian networks (BN) arises when 
numerical parameters to quantify them for conditional probability tables (CPT) are 
needed [15]. The complete CPT for a binary variable with n binary predecessors in a BN 
requires 2n independent parameters [3]. Hence the number of parameters in a CPT grows 
exponentially with the number of parents and can become prohibitive for model building.  
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The BN however, does not constrain how a variable depends upon its parents; one 
interpretation is that the directed edges between parent and the child represent causal 
relationships [16]. Nonetheless, as shown previously by other researchers, there is some 
structure in the dependencies and probability functions of parents and child that can be 
exploited for knowledge acquisition and inference. The dependencies can be stated as 
rules [17], trees [18], multinets [19] or some form of binary operation that can be applied 
to values from each of the parent variables. Independence of Causal Influence (ICI) or 
Causal Independence [3, 20-21] is one such dependency and refers to the situation where 
multiple causes independently contribute to the common effect. An assumption of causal 
independence among the parent nodes that affect the child node greatly reduces the 
number of parameters required. 
Noisy-OR Model 
The Noisy-OR gate [3, 22], or distribution,  is a member of the ICI family. [21, 
23-24] The Noisy-OR model [3] makes this assumption and provides a logarithmic 
reduction in the number of parameters required relative to the CPT. This model has been 
shown to perform reasonably well in the field of medical diagnosis. [5] The word ‘noisy’ 
reflects the fact that the interaction among the cause(s) and the effect is not deterministic 
thus allowing the presence of the effect in presence or absence of any modeled causes. 
One can think of Noisy-OR as a probabilistic extension of the deterministic binary OR 
model.  In practice, it is often impossible to capture all the possible causes for an effect. 
To address this issue and help the domain experts in the knowledge engineering process, 
Henrion proposed an extension of the Noisy-OR by introducing the concept of “leak” or 
14 
 
background probability [23]. Leak can be formally considered as one of the causes of the 
effect.  
In Figure 2-2 below, the nodes Xi denote independent causes and Y is the 
common effect. The nodes Ui are called the inhibitor nodes [3] and encode individual 
effect (via their CPTs) of corresponding Ui on Y. A leaky Noisy-OR model can be 
described (Figure 2-2) using the following equations for several possible causes (X1, 
X2….Xn) of an effect Y under the two assumptions – 
(a) Each of the causes Xi has a probability of producing the effect in the absence of all 
other causes and (b) each cause is sufficiently independent of the presence of other 
causes – i.e. – 
                )3(       ),,...... ,|() |( 121 nniii xxxxxyPonlyxyPp   
 
 
 
 
 
 
 
 
 
 
 
 
 
                               Figure 2-2 A Noisy-OR model 
 
Using a deterministic mapping function such as Boolean OR, the CPT of Y 
defines how individual causes Xi interact to produce the effect Y.  Therefore, the 
probability pi as defined by equation (3) is also called the link probability and determines 
the causal strength between the cause, i, and the effect, Y, in the absence of all other 
X1 X2
U1 U2 Un
Y
Xn
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causes. It has been shown [3] that the probability of  Y = y given a subset Xp (xi present), 
i.e. a set consisting of causes that are present, is given by the following equation (4) –  
                           4)(                                 11     
 X x
)p(Xp)|P(y
pi
i

   
Under the assumption that causes produce the common effect independently, 
equation (4) can calculate the probability value for an effect solely based on the causal 
strength pi of each cause to the effect. Therefore using the assumption of causal 
independence, the number of values required for CPT elicitation of effect Y reduces from 
exponential to linear in number of causes. 
Further the leak probability p0 which models un-modeled causes can be defined as  
)5(                          ),,.........,...,|( 1210 nni xxxxxyPp   
Let p΄ define the probability that Y is present when xi is present and all other causes of Y 
including un-modeled causes (leak) are absent. From [3] for the leaky Noisy-OR model 
following is defined –  
(6)                                              ) 1( ) 1(  ´1 0p-p-p i   
(7)               00  pp´ - pp´  only)x|yP(  p ii   
The two ways of parameterization of CPD using Noisy-OR gate equation (4) is credited 
to Henrion [23] and Diez [22]. For calculating the link probability, the difference 
between the Henrion method and the Diez method lies in learning Noisy-OR parameters 
from equation 7. [15] The Henrion method seeks the pi parameter where as the Diez 
method seeks the p΄ parameter. 
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Among the studies in the past, where the Noisy-OR gate model  has been 
successfully applied are – reformulation of the rule based expert INTERNIST-1/QMR 
system into a probabilistic system by combining probabilities from disease profiles and 
hospital discharge statistics [5], deriving parameters from small data sets for converting 
from single-disorder to multiple-disorder liver disease diagnostic system (HEPAR-II) 
[15] and to an artificial domain for comparison of human expert’s judgment of 
parameters using the two ways of parameterization credited to Diez [22] and Henrion 
[23] in using [25] the Noisy-OR assumption.  The result of this last study [25] claims that 
the Henrion method is better at providing Noisy-OR parameters from data [15] when the 
underlying distribution follows the Noisy-OR assumption, and the Diez method is better 
when human experts provide the parameters. 
Thus the Noisy-OR model may be suitable for parameter estimation in large scale 
domains, such as medical diagnosis, where an observation such as a symptom can be 
triggered independently by a number of causes (diseases), or a number of causes can 
independently lead to a common complex disease. Similar to Noisy-OR, other forms of 
noisy deterministic functions (Noisy-AND, Noisy-MAX, Noisy-MIN, Noisy-ADD) [22-
24, 26-27] have been defined and proposed for assessing values for CPD in a BN using 
the assumption of causal independence. 
Other Related Models 
While these models greatly reduce the complexity of parameter estimation in CPT 
and can serve as a good first approximation (Chapter 3) for modeling, the conditional 
probability distributions (CPD) in themselves do not account for interactions among 
causes that lead to the common effect. Although all of the above models take into account 
17 
 
the probability of an effect given each single cause as an input, the interactions defined 
among causes (by virtue of the noisy deterministic function) are considered to be 
synergistic or reinforcing. [28] Therefore, when multiple causes are present, the causes 
may reinforce each other (i.e. making the effect more likely to be present) or may 
undermine the impact of each other (i.e. the effect becomes less likely when more causes 
are present). As pointed by Xiang et al, [28] all of the above distributions (Noisy-AND, 
Noisy-MAX, Noisy-MIN, Noisy-ADD) can only express one type of causal interaction in 
a model, i.e. reinforcing.  
To address the possibility of reinforcing interactions between causes, recently 
Lemmer and Gossink [29] proposed the Recursive Noisy-OR (RNOR) distribution which 
allows elicitation of probability parameters of the effect given subsets of causes as input.  
RNOR defines the concept of positive causality and how the dependent causes can work 
together as being either “synergistic” or “interfering.” The RNOR model can incorporate 
an expert provided probability distribution for an effect as well as a subset of values of 
causes given as input, wherever applicable and claims to be a generalization of Noisy-OR 
model. The RNOR model does not handle expert assertions of interference between 
causes.  If an expert-provided subset of values implies inhibitions or interference, and the 
causes are undermining, RNOR can produce probability values that are greater than one. 
[29] Its application to problem domains such as medical diagnosis looks promising 
because of its ability to represent a subset of causes but it needs empiric evaluation.  
More recently, Xiang and Jia have proposed a variation of this model. The non-
impeding Noisy-AND tree (or NIN-AND tree) model [28] can represent both types of 
causal interactions among a set of causes, some of which can be reinforcing and others 
18 
 
undermining.  However, this model also has limitations in expressing all possible causal 
interactions.  For example, to model grouped causes that can selectively reinforce and 
grouped causes that can selectively undermine. Druzdzel et al. [30] have proposed yet 
another theoretical model – Probabilistic Independence of Causal Influences (PICI) as an 
extension of ICI models that leads to more expressive parametric models that are able to 
cope with a combination of positive and negative influences. To the best of our 
knowledge, RNOR distributions, PICI and NIN-AND tree models have not been studied 
extensively in real world problems but hold promise for medical domain applications.  
BN Vs Other Methods 
Our decision to use a BN framework, as opposed to other methods, for this 
research is best explained if we compare BN with some of the other statistical and 
computational methods available for analysis and model formation. BN belongs to a class 
of generative models. Generative models differ from discriminative models in that a 
generative model contains a full probability distribution of all variables, whereas a 
discriminative model provides a model only of the outcome variable(s) conditioned on 
the observed variables. Therefore, BN models are both diagnostic and predictive at the 
same time. They offer several advantages when compared to other computational 
methods for knowledge representation such as Neural Networks or even traditional 
statistical methods such as linear regression models for data analysis.  We describe some 
of the differences briefly below. 
Artificial Neural Network (ANN) models need large numbers of complete cases 
for training to be used in prediction and classification problems. They often overfit the 
data to the problem and, unlike BN, lack explanation capabilities. Therefore, they have 
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limited use in a domain like biomedical research. BN models on the other hand are 
probabilistic and can take personal (expert) beliefs (using a subjectivist approach) for 
model building – they are well suited to derive prior probability values from small sample 
sizes and are able to handle missing data values reasonably well while avoiding over 
fitting of data to the model. [4] They model cause and effect in a normative way [3] and 
therefore provide a framework for incorporating all available information in a systematic 
manner for both model and parameter estimation to produce a predictive distribution.  
Linear regression models are non-parametric (distribution free) statistical models 
and can also be used for prediction and classification problems like ANN and BN.  
However, they do not handle missing data well in the input, and due to their susceptibility 
to noise in the data, their use for model building is limited, particularly in the biomedical 
domain where data are noisy. As with ANN, linear regression models lack normative 
explanation capabilities and also suffer from the “curse of dimensionality” i.e. an 
exponential increase in model space with addition of extra dimensions, as is the case in 
domains with large number of variables such as the biomedical domain.  
Other methods of knowledge acquisition such as systematic review and meta– 
analysis aim to more precisely estimate the true “effect size” from a group of studies as 
opposed to the less precise estimates derived in a single study under a given set of 
assumptions. But these are not computational methods to synthesize a prediction model.  
Therefore, despite the computational complexity of inference, BN methods offer 
several advantages over traditional methods of knowledge acquisition and representation. 
They have been shown to represent domain knowledge with conciseness and normative 
form. The product form of equation (1), i.e. the chain rule and the conditional 
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independence assumption makes the BN representation of the JPD compact. Their ability 
to handle missing data values and ability to calculate probability scores from small data 
sets is another reason to choose BN methods. Most of all, BN methods provide a strategic 
framework for our research to incorporate all available information in a systematic 
manner for both model and parameter estimation to produce a predictive distribution that 
can be used for inference and hypotheses generation. In this research we develop a 
methodology using the BN framework and summary and statistical measures from 
published studies for integration of information from disparate sources of data in the 
biomedical domain. 
Challenges for Knowledge Representation and Inference in Biomedical Domain 
To gain full understanding of the implications of the research thus far in the 
biomedical domain, we first need to understand how we could represent the existing 
information, derive knowledge and inference from it. In light of the data gathered from 
separate environmental and genetic studies and not on the same individual, a unifying 
model is desperately needed to represent such information perhaps in a computational 
model (In-silico). Such a model, once constructed could also be used for knowledge 
discovery or in clinical applications. 
For instance, it is believed that both genetic and environmental risk factors have 
an important role to play in most common diseases. [31-32] A 2003 review article titled 
“Genomics as a Probe for Disease Biology” in the New England journal of Medicine 
highlights the importance of understanding genetics together with the pathology of a 
disease in order to unravel the underlying disease processes. [33] Asthma, which is best 
considered as a cluster of related disorders, [34] is one such common complex disease. 
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The prevalence of asthma has risen dramatically in the last few decades, [35] suggesting 
that environmental risk factors have a key role to play together with genetic factors in 
developing a risk of the disease [35-37] in early childhood. As is the case with asthma, 
there is also evidence suggesting the role of environmental and genetic factors for most 
other common diseases such as diabetes, obesity and heart disease. [38-39] 
Recently, it has also been argued that the current classification of human disease 
has significant shortcomings as reflected in its lack of sensitivity in identifying pre-
clinical disease and lack of specificity in defining disease unequivocally. [40] Therefore, 
it has been proposed that an approach using network principles and linking phenotype or 
clinical data with the genotype and environmental data associated with the risk of 
disease, can lead to more accurate identification and classification of disease diagnostic 
and treatment options. [40] For example, in the field of cancer biology, bioinformatics 
methods that integrate diverse data (clinical and genotype) in their analysis for predicting 
survival rates have achieved higher accuracy than use of clinical data alone, even when 
the data analyzed are from different sources. [41-42] 
Given the example above, we believe that the challenges of knowledge 
representation and inference in this domain are three fold.  
Existence of silos of datasets  
First, data are being amassed in silos of biomedical databases. Currently, there are 
major initiatives underway by the National Institutes of Health (NIH) to address the rise 
in common diseases (like asthma and diabetes) by studying their genetic linkages and 
disease-environment interactions [43-47] in Genome Wide Association Studies (GWAS) 
and Environment Wide Association Studies (EWAS) respectively.   Due to the interplay 
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of environment, lifestyle and small effects of many genes, researchers have focused on 
very different aspects, for example pharmacogenetics / pharmacogenomics, [37, 48-49] 
gene-environment interaction [47, 50] and clinical environmentally focused [51-52] 
studies. Despite their best efforts, researchers find it hard to conduct unbiased studies in 
well defined populations that have sufficient power to detect small effects attributed to 
genetic or environmental factors. [49, 53-54]  Therefore, to date these studies are being 
conducted in sub populations and patient level data are being collected and stored within 
the individual institution’s repository.  
Access Rights 
Second, due to lack of data sharing agreements among institutions and patient 
privacy concerns, [55-56] the data are not accessible in their raw form to outside entities 
like researchers in other institutions for any secondary analysis. The only publicly 
accessible results from these studies are published summary and statistical results. Thus, 
if any form of computational model needs to be developed to unify the information it 
most likely will have to use the published results. 
Inference in Patient’s Context 
Third, there is a big gap in application of knowledge gained from biomedical 
research and its use in patient’s context, for example from an EMR. Research that applies 
to clinical management of diseases and many rare disorders which are governed by 
straightforward Mendelian rules of inheritance have been known for some time. 
However, teasing out the genetic and environmental components for complex disorders 
such as diabetes, heart and lung disease, autoimmune and psychiatric disorders and their 
clinical management remains challenging [33] due to this application gap.  
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Therefore, there are many practical challenges for application of existing research 
in the biomedical domain. In the next chapter we discuss how, based on our background 
research, we can use BN for building a probabilistic framework for knowledge 
representation and inference in this domain. We specifically develop strategies using this 
framework to incorporate all available knowledge in a coherent model from various 
sources for example as presented in Figure 1-1 – environmental, genetic, demographic, 
socio-economic and clinical phenotypes. 
Our hypothesis in building such a model is to 1) find associations across the  
domain that are not apparent in the silos of datasets and 2) confirm these associations by 
testing – a) against data from our EMR and b) by evaluating against what has been 
published in the literature so far. We are interested to know how much of explanation is 
provided by a subset of data, for example how well genetic associations can explain the 
risk of a complex disorder like asthma or diabetes.  
To test our model we use Area under the Curve (AUC) of Receiver Operator 
Characteristics (ROC) curves as a performance measure. We describe the ROC 
performance measure below. 
Receiver Operating Characteristic (ROC) Curve  
A ROC curve is a plot of pairs of true positives (Sensitivity) vs. false positives (1 
– Specificity) for various cut points of a binary classifier as its discrimination threshold is 
varied. The ROC curve has its roots in Signal Detection Theory from World War II and 
since then they have been extensively applied as an analysis tool in areas of medicine, 
radiology [57], and many other fields. [58] 
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Since ROC curve analysis is a non-parametric method and does not rely on the 
underlying distribution, their use as an analysis tool is particularly attractive to the 
machine learning community; especially for use as a model comparison tool to select an 
optimal model given the data. The area under the curve (AUC) of an ROC curve is equal 
to the probability that a classifier will rank a randomly chosen positive instance higher 
than a randomly chosen negative one [58] and therefore measures the performance of the 
model. A ROC with AUC of 0.5 score has no predictive value and is as good as chance. 
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Chapter 3 EXPERIMENTAL STUDIES on BNs and ICI MODELS 
 
A Bayesian approach to represent domain knowledge  
 
Based on our background research on Bayesian Networks and the breadth of the 
challenges involved in building a coherent model in the biomedical domain, we evaluate 
the use of a probabilistic framework, combining BN fundamentals of conditional 
independence and the Markov condition to encode domain knowledge both qualitatively 
and quantitatively.  We then evaluate the use of the Independence of Causal Influence 
(ICI) assumption as a potential data integration strategy.  In this chapter, we describe our 
experiments in the clinical domain using data on childhood asthma from our EMR, the 
Regenstrief Medical Record System (RMRS) [2] and another independent test data 
source from our pediatric decision support system in practice – Child Health 
Improvement through Computer Automation (CHICA) system [59] described below. 
In experiment 1, we compare performance of a data derived DAG to a domain 
expert’s model DAG by testing it on the same test datasets to evaluate the sensitivity of 
the BN function to the structure of the DAG with real world datasets. 
In experiment 2, we test the validity of the Independence of Causal Influence 
(ICI) assumption in particular the Noisy-OR model using the same datasets from 
experiment 1. To model domain causal relationships, over and above causal 
independence, we test the validity of Recursive Noisy-OR (RNOR) rule.  
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Experiment 1: Bayesian Networks from Electronic Medical Records 
 
Probabilistic Asthma Case Finding - A Pilot Study using the CHICA system [60] 
 
Introduction 
One of the most useful characteristics of BN is the ability to construct DAG 
models based on expert knowledge of causal relationships or entirely empirically, using 
large datasets.  In fact, this feature makes BN ideally suited for our goal of merging 
information from different sources.  However, the comparability of DAGs derived in 
these different ways has not been tested.  In this series of experiments, we use Bayesian 
Networks as a strategy for modeling patients’ clinical status with the goal of comparing 
two DAGs: the one developed by the domain expert with the one mined from data.  A 
large retrospective cohort consisting of 16,187 children having wheezing prior to age two 
was mined from data to derive a DAG to predict asthma after age five.  We compare the 
predictive power of this mined network with a domain expert’s DAG using two test 
scenarios – (a) using a test dataset from our EMR and (b) using an independent dataset 
from our clinical decision support system (CDSS).  
Methods 
Our goal is to derive these BNs from data in our clinical data repository. To 
achieve this we considered two possibilities 1) use a clinical expert to define the nodes 
and arcs in the BN and train the resulting BN to derive parameters using data or 2) use 
data mining techniques to derive the BN structure and parameters from data.  In this 
chapter we describe an experiment in which we compare these approaches in the domain 
of childhood asthma.  Pediatric Asthma cases and controls were identified from RMRS 
and from the CHICA system [59] for an independent test set.  CHICA is a Clinical 
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Decision Support System (CDSS) used in our Pediatric Primary Care (PCC) practice in 
conjunction with RMRS, [2] and we briefly describe it below.   
CHICA Overview 
The CHICA system went live on Nov. 5th, 2004 at the Pediatric Primary Care 
Center (PCC) of Wishard Hospital, Indianapolis, Indiana, and now has data from over 
25,000 patients.  The system provides decision support for well child care and 
management of common childhood problems.  The user interface consists of scannable 
paper forms called adaptive turnaround documents (ATD). [61]  Data collected on ATDs 
are used to generate questions to the patient and reminders to physicians at the point of 
care.  CHICA uses a knowledge base encoded as Arden Syntax medical logic modules 
(MLM) [62] and patient data from the RMRS [2] and CHICA databases to generate 
dynamic content on the ATD forms.  The MLMs are prioritized using a global priority 
scheme to address the most relevant questions and reminders on the ATD. [59, 63] The 
CHICA system electronically receives a record of all clinical observations from the 
RMRS database for every patient visit.   
We analyzed data for all children over 5 years of age in our system.  Children 
were classified as cases or controls based on the presence of an ICD-9 code for asthma 
(493.*) or more than two prescriptions of an asthma medication.  From the filtered set we 
were able to extract the variables listed in Table 3-1 to get an “Asthma Status,” sex and 
race for each patient (ages 5 years or older) who had a visit to the PCC clinic. The 
CHICA system in its current state has been described in detail in previous manuscripts. 
[59, 64-66]  
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Model  
We used Netica software [67] (Norsys Software Corporation, Vancouver BC, 
www.norsys.com) to construct BN for our expert model and WinMine toolkit [68] 
(http://research.microsoft.com/~dmax/WinMine/Tooldoc.htm) for mining a directed 
acyclic graph (DAG) from data.  Netica allows network construction and parameter 
learning from data. The WinMine toolkit provides software for learning a DAG from 
data. Table 3-1 below lists the data variables used for modeling expert BN and data 
mining the DAG.  
Data  
To compare the two DAGs – expert BN and mined BN we compared the 
performance of the BNs on two datasets.  First, the data from 16,187 cases from 
Regenstrief Medical Record Systems (RMRS) were split randomly into 2/3 of cases for a 
training set and 1/3 for a test set.  For the second dataset, the CHICA system 
electronically receives a record of all clinical observations from the RMRS database for 
every patient visit.  We filtered these observations and preprocessed them to extract the 
data variables listed in Table 3-1. These data were collected for children ages 5 and 
above to predict childhood asthma.  At the time of the study, the CHICA system had data 
for 1984 cases. Table 3-2 lists the baseline characteristics of the datasets used in these 
experiments. 
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Table 3-1 Data Variables for Model – Experiment 1 
 
Variable Values 
Race White, Black, Hispanic, Other, Unknown 
Sex Male, Female 
Eczema True, False 
Wheeze ICD9 or clinic billing diagnosis before age 2 (True, False) 
Asthma ICD9 (493.*) or any clinic billing diagnosis after age 5 or at 
least 3 drugs from a specified list within 12 months after age 
5 (True, False) 
X-ray Chest x-ray before age 2 (True, False) 
Drug  
 
Drugs from a specified list before (True, False) 
Wz_hosp Inpatient admission with hospital ICD9 as wheezing (True, 
False) 
Wz_er Any ER visit with billing ICD9 as wheezing (True, False) 
Ins_cat Insurance category - first available insurance in the same 
year of the first wheezing diagnosis (True, False) 
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Figure 3-1 Expert’s BN trained with data from RMRS 
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    Table 3-2  Baseline characteristics of training and test sets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
         Training Set  from  
                   RMRS 
                   (n = 11,000) 
Test Set from 
RMRS 
(n = 5,187) 
Test Set from  
CHICA 
(n = 1,984) 
  # % # % # % 
Race        
 Hispanic   98 1% 373 7% 429 22% 
 Unknown   115 1% 220 4% 24 1% 
 Black      6859 62% 3116 60% 1156 58% 
 White      3806 35% 1385 27% 327 16% 
 Other      122 1% 93 2% 48 2% 
Sex        
 Female      5357 49% 2503 48% 916 46% 
 Male          5641 51% 2684 52% 1068 54% 
Eczema        
 True 4021 37% 2021 75% NA NA 
 False 6979 63% 3166 61% NA NA 
Wheeze        
 True 1661 15% 1431 28% 187 9% 
 False 9339 85% 3756 72% 1797 91% 
Asthma        
 True 1561 14% 548 11% 536 27% 
 False 9439 86% 4639 89% 1448 73% 
X-ray        
 True 4015 37% 1900 37% 1529 77% 
 False 6985 64% 3287 63% 455 23% 
Drug        
 True 3013 27% 1488 29% 529 27% 
 False 7987 73% 3699 71% 1455 73% 
Wz_hosp        
 True 433 4% 247 5% 159 8% 
 False 10567 96% 4940 95% 1825 92% 
Wz_er        
 True 102 1% 98 2% 143 7% 
 False 10898 99% 5089 98% 1841 93% 
Ins_cat        
 Medicaid   4762 43% 4051 78% 1631 82% 
 Unknown   5276 48% 182 4% 64 3% 
 Private    844 8% 893 17% 160 8% 
 Self-pay    118 1% 61 1% 0 0% 
rsv_pos        
 True 244 2% 114 2% 17 1% 
 False 10756 98% 5073 98% 1967 99% 
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Expert’s Design of BN with training using Netica 
Using the predictor data variables of Table 3-1 as nodes and the domain 
knowledge for joining them with arcs, the domain expert (SMD) created a BN as shown 
in Figure 3-1. This BN was trained with the training set and compiled using Netica 
software.  In Figure 3-1 the BN shows marginal probabilities of each node with an 
asthma prior probability of 18.6%. 
BN Derived using Data Mining Techniques  
The training set from RMRS data was used to derive the DAG for this approach.  
The software from WinMine toolkit was used to preprocess the data from raw format 
(excel tab delimited) to WinMine XML format, which was then used for creating and 
editing a plan file to instruct the learning algorithm to model each predictor variable 
based on a) the role of each variable – input (used to predict other variables), output 
(predicted by other variables) and input-output (both predicted and used to predict) or 
ignored (not used); b) the model distribution used for each variable – specifies the tree 
versus the table representation and the local distribution of the variable, the 
representation chosen in this case is tree for discrete variables and the distribution chosen 
is binary multinomial to accommodate missing values; c) Model-as-binary information 
(missing vs non-missing values for binary variable or one state vs all other states for 
discrete variables.).  Figure 3-2 shows the roles, the distributions used and model-as-
binary information for each of the predictor variables for our model in the WinMine 
toolkit. 
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Figure 3-2 Plan file for deriving the WinMine model 
 
We replicated the DAG derived by the WinMine software in Netica.  This DAG is 
shown in Figure 3-3.  We then trained this BN using the same training set as the expert 
BN and compiled it to get the prior probabilities for each node in the model.  The asthma 
prior probability in this model was 13.9%. 
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Figure 3-3 BN mined and trained with data from RMRS 
 
Testing the Two Models 
The two BN models were evaluated, first, using data from our test set from 
RMRS data (1/3 split from the large cohort study) and, second, using the CHICA data set 
derived from CHICA database.  
Netica provides an interface to test the BN using a case file of test data.  The 
node(s) of interest for prediction are treated as “unobserved nodes”.  Asthma was used as 
an unobserved node in our tests.  The software reports several measures for each 
unobserved node.  We chose to use the quality of test results, which gives a performance 
measure in the form of a table for sensitivity, specificity, positive predictive value and 
negative predictive value.  
We compared BNs using Receiver Operating Characteristics (ROC) curves [57].  
The area under the curve was used as a measure of overall test performance.  The ROC 
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curve was obtained by plotting pairs of true positive rate (sensitivity) and false positive 
rate (1 - specificity).  
Results 
We had 5188 cases in our RMRS test set and 2000 cases in the CHICA test set. 
Both the Expert and the Mined BN were tested using these sets, the results of which are 
listed below in Table 3-3, Figure 3-4 and Table 3-4, Figure 3-5 for RMRS and CHICA 
test sets respectively. 
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                                                 Using RMRS Test Set 
  Table 3-3 Operational Characteristics with RMRS test set 
            (* Expert BN                + Mined BN ) 
Sensitivity 
(%) 
Specificity
(%) 
Predictive
(%) 
Predict-Neg 
(%) 
1 - specificity
(%) 
*84.77 *38.11 *16.28 *94.63 *61.89 
*63.31 *68.4 *22.15 *92.92 *31.6 
*50.07 *78.8 *25.12 *91.74 *21.2 
*36.03 *88.05 *29.99 *90.65 *11.95 
*15.76 *95.6 *33.71 *88.88 *4.4 
*6.89 *96.82 *23.53 *87.98 *3.18 
*1.99 *99.53 *37.5 *87.73 *0.47 
     
+82.38 +44.51 +17.41 +94.68 +55.49 
+53.91 +77.16 +25.11 +92.18 +22.84 
+43.71 +83.97 +27.92 +91.31 +16.03 
+26.09 +93.38 +35.88 +89.89 +6.62 
+10.86 +98.34 +48.24 +88.6 +1.66 
+0.93 +99.68 +29.17 +87.63 +0.32 
 
 
                                  Figure 3-4 ROC curves using test data from RMRS 
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                                              Using CHICA Test Set  
Table 3-4 Operational Characteristics with CHICA test set 
Sensitivity 
(%) 
Specificity 
(%) 
Predictive
(%) Predict-Neg (%) 
1-Specificty 
(%) 
*75.56 *38.05 *31.11 *80.79 *61.95 
*56.53 *64.3 *36.95 *79.98 *35.7 
*48.69 *73.69 *40.65 *79.51 *26.31 
*30.04 *90.81 *54.76 *77.81 *9.19 
*25.56 *93.99 *61.16 *77.33 *6.01 
*1.31 *99.93 *87.5 *73.23 *0.07 
     
+77.43  +27.97 +28.46 +77 +72.03 
+44.59 +76.66 +41.42 +78.89 +23.34 
+40.11 +80.18 +42.83 +78.34 +19.82 
+26.87 +89.92 +49.66 +76.86 +10.08 
+15.49 +97.24 +67.48 +75.66 +2.76 
+5.97 +99.65 +86.49 +74.11 +0.35 
* Expert BN    + Mined BN  
 
             
    Figure 3-5 ROC curves using test data from CHICA 
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Discussion 
The results of AUC for the ROC for both BNs using the same test set are 
comparable.  Both the expert BN and the mined BN performed better with the test set 
from the RMRS data set when compared with the CHICA data set.  We attribute 
degraded performance when testing with CHICA data set due to our less stringent 
inclusion criteria in the CHICA test set.  For example, any chest x-ray observation will 
satisfy the inclusion criteria for CHICA data, where as for the RMRS test set only a chest 
x-ray finding before age 2 will satisfy the inclusion criteria. 
Similar performance of each BN in each test scenario suggests that the mined BN 
has a predictive value similar to the DAG derived by the expert.  Furthermore, the two 
compared BNs in this experiment were derived from two different data sources – a 
subjective model based on a clinical expert’s judgment and from data from our EMR.  
The data derived BN was as good as the subjective model suggesting the BN method 
presents a knowledge representation and inference tool where subjective decisions can be 
incorporated to approximate the domain knowledge.   
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Experiment 2: Strategies for Learning BN parameters 
Probabilistic asthma case finding: A Noisy-OR reformulation [69] 
 
An Empirical Validation of Recursive Noisy-OR (RNOR) Rule  
for Asthma Prediction [70] 
 
Introduction 
Development of a BN to represent the relationships between GWAS results and 
gene disequilibrium data requires assumptions about independent causal associations.  As 
a preliminary evaluation, we wanted to evaluate the Noisy-OR and Recursive Noisy-OR 
formalisms by comparing the predictive power of BN developed using these methods to a 
“gold standard” BN trained on clinical data. 
Noisy-OR: In combining disparate data sets in which one data set describes the 
relationship between some causes or risks and their consequences, and another data set 
describes the relationship between other causes or risks and the same consequences, there 
are no cases from which to infer the combined effect causes recorded in the different 
datasets.  One approach to this challenge is to assume causal independence among 
predecessors (parents) of a given node.  In this case, it may be reasonable to apply a 
Noisy-OR calculation [3] to estimate the probability of the child node given a particular 
combination of values for the parents [22-24].  By assuming these variables have 
independent causal effects, the Noisy-OR allows us to assign posterior probabilities 
conditioned on causes from these different sets.  However, the validity of the 
independence assumption is rarely tested.  We wanted to test this assumption by applying 
the Noisy-OR to combinations of conditioning variables for which we knew the joint 
probability distributions.   
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RNOR:  To test the Noisy-OR model against a “gold standard,” we need a BN 
trained on a data set that represents the joint probability distributions.  Several, 
algorithms have been developed for training BN by learning their conditional probability 
distributions (CPD) from such datasets. [27, 71]  However, a challenge arises when the 
training data set has no cases representing a particular combination of values for variables 
that condition a particular CPD. This is a common problem in complex BN even when 
large training sets are available. [22] A common strategy in this situation is to assign a 
uniform (uninformed) distribution to the dependent variable, conditioned by this 
combination of variables.  For example, when the probability of asthma is conditioned on 
the sex, race, insurance and past wheezing history of a patient, there may be no cases in 
the training data that are male, white, on Medicaid and with a positive history of 
wheezing.  Under the uniform distribution strategy, the probability of asthma would have 
a 50-50 distribution. 
The ideal strategy would retain posterior distributions for combinations of parent 
node values that exist in the training set while applying the Noisy-OR rule when there are 
no cases representing a combination of conditioning variables.  In 2004, a potential 
solution to this problem was published by Lemmer and Gossink. [29] The Recursive 
Noisy-OR (RNOR) rule described by these authors was intended to incorporate expert 
estimates of probabilities conditioned on more than one node while applying the Noisy-
OR rule when these higher order conditional probabilities were not available.  We 
reasoned that the RNOR algorithm might be a successful strategy for training a BN from 
a data set that did not contain cases representing all combinations of variables 
conditioned on a given node.  We hypothesized that this RNOR approach would produce 
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a BN with better predictive power than either a Noisy-OR formulated or traditionally 
trained BN.  This chapter describes the development and evaluation of this strategy. 
Methods 
We constructed a BN in the domain of asthma prediction in children, using expert 
knowledge to derive a directed acyclic graph (DAG) and applied a commercially 
available software package to learn the CPDs (parameters) from a large clinical dataset. 
This empiric BN has been described before in Chapter 3 (Figure 3-1). [60] For this study, 
we reformulated the CPDs in our domain expert’s BN using both Noisy-OR and the 
RNOR rule. Our empiric BN, Noisy-OR BN and RNOR BN were tested against two 
independent clinical data sets described below.  
EMR Data and Variables 
Clinical data for this study were derived from two datasets – RMRS and CHICA 
as described in experiment 1 in Tables 3-1 and 3-2.  
Bayesian Network and Noisy-OR model 
We took the Expert’s BN from Figure 3-1 and reformulated it as a Noisy-OR 
model (Figure 3-6). The expert BN was trained with data to derive a CPT for each node. 
Since the Noisy-OR model inherently assumes binary causes (absent / present; true/false), 
we dichotomized the non-binary nodes i.e. race and, insurance category) into “true” and 
“false” condition by assigning “true” to the state that minimized the global leak (p0) when 
all the other nodes are in a “false” state.  Thus, because boys were more likely to have 
asthma, male sex was coded as the “true” state. Similarly, race = Black and ins_cat = 
Private were coded as “true” states. The marginal probabilities of all the causal nodes 
(sex, eczema, wheeze, xray, drug, rsv_pos, wz_er, wz_hosp) remain the same from our 
42 
 
expert BN. For the study, we only wished to compute the local CPT of the node asthma 
using the Noisy-OR parameters.  
 
Figure 3-6 BN with Noisy-OR parameters 
 
Obtaining Noisy-OR Parameters from Data 
To derive the leak parameter for the network in Figure 3-6, we set all the nodes in 
the network that had an arc to the node asthma to a state false. The resulting posterior 
probability for the node asthma was our leak parameter, p0 (0.014). Using this leak 
probability, we calculated the parameter pi (the causal strength when no other cause is 
present) of each node (node = True) to the effect (asthma). 
We used Netica to compute the posterior probability pi of the effect given only 
one of the causes at a time.  This is equivalent to eliciting the Henrion parameter which 
includes the leak parameter in the posterior probability. From there, we were able to 
derive the probability p΄ (Diez parameter) for each cause alone, using equation (7) in 
chapter 2.   
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Netica provides an interface to input Noisy-OR parameters for a given node and is 
able to calculate the conditional probability distribution for the node from these input 
parameters – effect node’s leak, individual link probabilities of causes.  We used this 
feature to calculate the CPD for the asthma node. This Noisy-OR calculation is achieved 
with the function in Figure 3-7. The link parameters are listed in Table 3-5. 
P (asthma | sex, eczema, wheez, drug, xray, rsv_pos, wz_er, wz_hosp, race, ins_cat) =  
NoisyOrDist (asthma, 0.014, sex == M, 0.022, eczema, 0.048, wheez, 0.17, drug, 0.117, 
xray,0.072, rsv_pos, 0.4, wz_er, 0.37, wz_hosp, 0.104,  race == Black, 0.042, ins_cat == 
Private, 0.058) 
 
The prior probability of the node asthma computed is slightly different in the two 
BNs - Noisy-OR reformulation vs. the Expert BN (16.8% Vs 18.6%). 
Testing of Noisy-OR model 
The two BN models – Expert (empiric) BN (Figure 3-1) and Noisy-OR 
Reformulation (Figure 3-6) were evaluated, first, using data from our test set from RMRS 
data (1/3 split, 5187 cases ) and, second, using the CHICA data set derived from the 
prospectively collected CHICA database (1984 cases).  Netica provides an interface to 
test the BN using a case file of test data.  The node(s) of interest for prediction are treated 
as “unobserved nodes”.  Asthma was used as an unobserved node in our tests. We 
compared the sensitivity, specificity, positive predictive value and negative predictive 
value of the Noisy-OR and the expert BN.  
We compared the BNs using Receiver Operating Characteristic (ROC) curves. 
[57]  The ROC curve was obtained by plotting pairs of true positive rate (sensitivity) and 
  Figure 3-7 Calculation of Noisy-OR parameters
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false positive rate (1–specificity). The area under the curve (AUC) was used as a measure 
of overall test performance. AUCs were compared using the methods of Hanley, J.A. and 
B.J. McNeil. [72] 
Results of Noisy-OR Reformulation 
We had 5187 cases in our RMRS test set and 1984 cases in the CHICA test set.  
The empiric BN and the Noisy-OR reformulation of the empiric BN were tested using 
these sets.  Results for these tests are plotted in Figures 3-8 and Figure 3-9 respectively. 
When comparing the BN that utilized the Noisy-OR assumption to the BN with 
the fully data derived CPD (empiric BN), we saw a modest decrement in the AUC (0.697 
vs. 0.726) when applied to the evaluation dataset from RMRS. When applied to the 
prospectively collected CHICA dataset, the decrement was about the same as before 
(0.612 vs. 0.637). However, neither BN (empiric or Noisy-OR reformulated) was 
particularly effective with the independent CHICA dataset. 
Bayesian Network and Recursive Noisy-OR (RNOR) model 
From experiment 1, the Expert (empiric) BN (Figure 3-1) had an 18.6% marginal 
probability of asthma. On examining the CPD of asthma in this empiric BN, we found the 
majority of its rows contained uninformed priors (i.e., uniformly distributed probability 
score – asthma = 50-50). We attributed this to the lack of cases satisfying the particular 
combination of causes in the training set (e.g., race = Other, Sex = male, Ins_cat = 
selfpay, Eczema = true, Wz_hosp = true). We hypothesized that by using the RNOR rule 
(described below) to calculate conditional probability for the CPD row value for asthma 
in such cases, the RNOR reformulated BN will outperform the empiric BN.                                
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Recursive Noisy-OR Rule 
In 2004, a rule for estimating complex probabilistic interactions was published. 
[29] The rule builds upon the Noisy-OR equation (4) in Chapter 2, to accommodate non-
independent causes of an effect for calculating RNOR probability pR(x). Interested 
readers are encouraged to refer to the original paper [29]. The RNOR rule is a 
generalization of Noisy-OR and reduces to Noisy-OR in cases where |x| = 1, i.e. a subset 
of a single cause is provided by the expert pE(x). Furthermore, the rule preserves certain 
ratios (synergies and interference, see below), and the authors claim a major advantage of 
the rule is that it allows for arbitrary causally dependent subsets of probability scores to 
be incorporated in the estimation of pR(x), the probability score of effect.  
The rule states that as long as the expert provided values for a subset of causes do 
not imply inhibition (i.e. abides positive causality, see synergy and interference below) it 
can be applied. Expert provided values implying inhibition among a set of causes will 
cause RNOR to produce probability scores greater than one, rendering the rule 
inapplicable.  The RNOR rule is summarized in the following equation 1– 
(1)otherwise ,         
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Synergy and Interference  
To judge the rule for semantic correctness (i.e. the numbers produced make 
sense), the authors introduce the notion of positive causality. Positive causality refers to 
the idea that additional causes always increase the probability of achieving an effect. 
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Synergy of causes satisfies positive causality and produces an effect (probability) greater 
than the Noisy-OR calculation. Interference of causes also satisfies positive causality but 
produces an effect less than the Noisy-OR calculation. However, inhibition, in contrast to 
interference, violates positive causality and will produce probability scores greater than 
one.  Therefore, the “information on the probability of an effect from a combination of 
causes provided by an expert (or derived from data) can be represented as a scalar 
multiple of the regular Noisy-OR.” This can be represented using equation (2) as defined 
in the original paper. [29] 
                            )2())(1)(()( -1 xpxxp
NR    
where pR(x) represents the probability from a RNOR estimation and pN(x) represents the 
standard Noisy-OR estimation. The factor δ(x) represents a scalar gain or attenuation 
coefficient between the two estimates. If δ(x) is less than one then it represents a biased 
amplifying coefficient of the probability and hence synergy.  Conversely if δ(x) is greater 
than one then it represents a biased attenuating coefficient and hence interference. 
Finally, if it is equal to one then an independent product combination could hold 
implying causal independence. 
Application of RNOR rule to the Asthma case finding BN 
We took the expert’s BN from Figure 3-1 and calculated the CPD of the asthma 
node using the RNOR rule as follows.  
Deriving link probabilities for RNOR rule  
To apply the RNOR rule to the network for CPD computation of asthma, we 
individually calculated the link probabilities (p’) of each cause of the effect (asthma)  
This was a two step process – (a) reduce the network by absorbing all nodes (see below 
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node absorption) except the node in question (e.g. eczema), looking up the “true” 
conditional probability score of the effect given the cause (i.e. asthma = True given 
eczema =True), then looking up its “false” conditional probability score to find leak p0 
for this reduced network and (b) using equation (7) in Chapter 2 as before to find the 
Diez probability (p’) in absence of all un-modeled causes including the leak calculated in 
(a). We repeated this two step process for all causal nodes for asthma thus first deriving 
the Henrion parameter (pi) which includes the leak parameter in the posterior probability. 
From there, we derived the link probability p΄ (Diez parameter) for each cause alone. 
Table 3-5 lists the values for each link probability (p΄) to asthma.  
     Table 3-5 Link probability of each node to asthma 
 
P(eczema=True)=0.048 P(drug= True) = 0.117 
P(rsv_pos=True) = 0.4 P(wheez=True) = 0.17 
P(wz_er=True) = 0.37 P(ins_cat=Private)= 0.058 
P(wz_hosp=True)=0.104 P(race=Black)=0.042 
P(xray=True) = 0.072 P(sex=Male) = 0.022 
 
Node absorption  
Node absorption is a network transform which removes nodes from a BN and 
makes any necessary adjustments to the resulting network.  Also known as averaging out 
or “summing out a variable”, this transform leaves the full joint probability distribution 
of the remaining nodes unchanged. 
Node absorption is part of the network transform for solving decision problems 
using influence diagrams (Bayesian networks with decision nodes) and is described in 
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detail in Shachter’s algorithm [9-10]. Shachter’s algorithm involves three simple 
reductions. First, any nodes that have no direct successors or “barren” nodes are removed 
as their value do not influence the successors and are irrelevant to the decision problem 
at hand, second, the propagation of the deterministic node, i.e. if any direct successor j of 
a node i  has a CPD for which node i  is a conditioning variable, that function is 
substituted in the distribution of  j and in the process, node i is replaced as a conditional 
predecessor to node j by the conditional predecessors of the node i, i.e. node i  is 
absorbed out.  This may introduce new directed edges or links if not present between the 
predecessors of node i and node j. Third, arc reversal – if there is an arc or a directed 
edge from i to j, it is possible to transform the net into an arc from j to i instead and both 
i and j inherit each other’s conditional predecessors. The CPD for node i is found by 
summing out and the new CPD for node j is calculated from Bayes theorem. 
Applying RNOR rule using link probabilities 
Using the Java programming language and the Netica application programming 
interface, we programmed the RNOR algorithm as defined in [29].  Appendix A.8 details 
the code. The algorithm calculated the probability score of asthma in each row of the 
CPD using equation (1). An example combination – (s)ex = Male, (r)ace = White, 
(w)heez = True is given  here – 
)3(
P(r)1
)P(s, -1
P(s)1
s) P(w, -1
P(w)1
)P(r, -1
 1 





 rw(x)P R  
In the example above (equation 3), the RNOR algorithm calculated the row value 
for the CPD by first calculating each of the subsets, multiplying them and subtracting 
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from 1.  For this experiment, the probability score for asthma for each combination of 
conditioning variables was calculated in three different ways–  
Using RNOR rule 
The algorithm recursively calculated the probability score for successive 
combinations; using the original scores, pE(x), from data learnt CPD wherever they 
existed (i.e., not 50-50), using equation (3).  For example, if P (Wheez, Sex) was non-
uniform (i.e., not 50-50) in the original data learnt CPD of asthma (from the empiric 
BN), it was used in successive calculations for higher order combinations.  When the 
resulting probability was negative or exceeded 1, suggesting inhibition, the CPD row 
was left with 50-50.   
Noisy-OR approach  
Starting with link probabilities listed in Table 3-5, the algorithm recursively 
calculated a probability score of asthma for successive combinations of conditioning 
variables without using any values from the original data learnt CPD from the empiric 
BN. This essentially reduced the model to a Noisy-OR model. 
Adaptive Noisy-OR approach  
As with the RNOR calculations, the algorithm computed CPD values recursively 
using pE(x) where applicable.  However, for those scores resulting in negative values, 
instead of leaving a uniform distribution, we used the Noisy-OR value, reasoning that it 
would be a better approximation than the 50-50 value in the CPD row.  We termed this 
“Adaptive Recursive Noisy-OR” or Adaptive RNOR (ARNOR). 
BNs with probability tables calculated from these three methods were used in two 
separate tests, comparing their predictive abilities in the two test sets.  
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Testing the Models  
The BN models were evaluated, first, using data from our original test set of 
RMRS data (1/3 split from the large cohort study 5187 cases) and, second, using the data 
set derived from the prospectively collected CHICA database (1982 cases), utilizing 
Netica’s test interface.  We compared the sensitivity, specificity, positive predictive 
value, and negative predictive value using Receiver Operating Characteristic (ROC) 
curves. [57] The ROC curve was obtained by plotting pairs of true positive rate 
(sensitivity) and false positive rate (1 - specificity).  The area under the ROC curve 
(AUC) was used as a measure of overall test performance.  AUCs were compared using 
the method of Hanley and McNeil [72] which specifically accounts for comparing ROC 
derived from same cases.  
Results of RNOR rule Reformulation 
We had 5187 cases in our RMRS test set and 1984 cases in the independent test 
set (CHICA).  Results for the tests are shown in Figures 3-8 and 3-9 respectively.  There 
were no statistically significant differences between the predictive ability of the RNOR 
or Adaptive RNOR and that of the empirically trained BN.  Both RNOR and Adaptive 
RNOR had larger AUC than the Noisy-OR BN in both RMRS and CHICA datasets but 
the difference did not reach statistical significance (Figures 3-8 and 3-9 respectively and 
Table 3-6).  
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                  Figure 3-8 Evaluation using test data from RMRS 
 
 
 
Figure 3-9 Evaluation using test data from CHICA 
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Empiric BN = 0.726  
RNOR BN = 0.724 
Adaptive NOR = 0.724 
Noisy-OR = 0.697 
Empiric BN = .637 
RNOR BN = .629 
Adaptive NOR = .630 
Noisy-OR = .612
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                         Table 3-6 Statistical comparison of models 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
In case of Noisy-OR reformulation, the predictive power of the BN decayed 
significantly when applied to another dataset (CHICA), it did not decay as much when 
we made the Noisy-OR assumption in the original dataset. This is somewhat surprising 
since we wouldn’t necessarily expect the predecessors to the asthma node (xray, drugs, 
wheeze) to be independent causes (or even causes at all).  Nonetheless, the relatively 
small decrement in AUC suggests that the Noisy-OR may be a robust assumption to 
make in an array of situations, even if BNs trained in one setting may be less effective in 
another.  We believe that the Noisy-OR formalism provides sound theoretic background 
for combining a number of causes leading to a common disease manifestation if the 
underlying distribution follows the assumptions.   
In case of RNOR rule reformulation, we had anticipated that the RNOR would 
perform better than the empirically trained BN.  The RNOR retains the higher level 
Dataset AUC1 AUC2 P-value 
RMRS Empiric BN RNOR 0.956 
RMRS Empiric BN ARNOR 0.968 
CHICA Empiric BN RNOR 0.620 
CHICA Empiric BN ARNOR 0.625 
RMRS Noisy-OR RNOR ~1.0 
RMRS Noisy-OR ARNOR ~1.0 
CHICA Noisy-OR RNOR ~1.0 
CHICA Noisy-OR ARNOR 0.851 
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posterior distributions that can be extracted from the data, but in the absence of cases in 
the data, the RNOR estimates posterior distributions that are more reasonable than a 
uniform distribution.  This is especially true for a variable like asthma where the 
posterior probability would never be expected to reach 50%.  We observed such a trend, 
but the differences were not statistically significant. 
In our application of the RNOR we ignored any negative probability scores that 
are produced (as a result of recursive calculations in the algorithm).  We believe these 
negative scores are produced where inhibition exists between subsets of dependent causes 
and the scores produced by the algorithm are greater than one.  One such example is – sex 
= Male, drug = True, xray = True – inhibition between drug and xray (subset 
score=1.0034) and sex and drug (subset score = 1.03), though x-ray and sex subset has a 
score within bound (subset score = 0.969).   
The implication is that the domain chosen for this study may not be an ideal 
application of the RNOR strategy but the RNOR algorithm can be used to detect 
inhibition in large datasets. Additionally, we have evaluated conditions in our dataset 
which render the RNOR rule inapplicable and discussed our use of Noisy-OR 
calculations in such situations.  
For our domain, the Noisy-OR formalism produced results comparable to the 
empirically trained BN.  Surprisingly, the RNOR did not contribute significantly more 
predictive power than the Noisy-OR.  Therefore, we conclude that the Noisy-OR 
approach to combine information can serve as a satisfactory strategy for merging data in 
the IsBIG experiments described in the next chapter. 
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Chapter 4 PROBABILISTIC INTEGRATION: IsBIG EXPERIMENTS  
 
Using causal independence and statistical measures  
In this chapter, we describe experiments that extend the use of causal 
independence assumption, using the Noisy-OR approach to link disparate sources in a 
normative form. In the absence of complete datasets of all the domain variables, we 
present a methodology using summary and statistical measures and the causal 
independence assumption.   
In experiment 3, we apply the concept of linking disparate data sources for 
knowledge representation and inference with BN, again in the domain of childhood 
asthma.  We combine data from our EMR (RMRS) with published data on the interaction 
of genotype and smoking to the risk of asthma using the causal independence assumption. 
Our aim is to leverage the BN representation and causal independence assumption 
beyond the use case of learning conditional probability distributions from independent 
causes. We use causal independence as a data integration strategy to learn and inference 
from disparate sources, for example, for testing genetic hypotheses in large clinical data 
sets from an EMR.  We demonstrate this use case using an experimental study where data 
from RMRS and CHICA system are combined with statistical and summary data 
published in one study linking a particular genetic variant and an environmental variable 
(tobacco smoke exposure) to asthma in an integrated model. We evaluate the integrated 
model against our EMR data using a “goodness of fit” metric as a performance measure. 
Our aim in experiment 4 is to integrate several published studies. For the purposes 
of this research, we choose the domain of genome wide association studies (GWAS) 
where findings link a genetic variation of Single Nucleotide Polymorphism (SNP) type 
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with a disease or a trait. However, as discussed in the background chapter (chapter 2), we 
have no publicly accessible primary data source for these studies to link with each other 
or with a data source like an EMR.  
Therefore, in experiment 4, in the absence of any primary data source in the 
domain of genome wide association studies, we extend our methodology to integrate 
statistical measures of correlations and effect sizes from published studies to incorporate 
all available information in a data integration framework – In-silico Bayesian Integration 
as previously described in Figure 1-2.  Using statistical measures of correlation, we learn 
conditional probability distributions of disparate BNs; these BNs are linked to each other 
by effect size of common nodes.  The common nodes are then “absorbed” because they 
are hidden and not the primary variables of interest. The result of the transformation of 
absorbing nodes is that it preserves the joint probability distribution of the BN but may 
introduce new edges to preserve its quantitative structure. Therefore the integrated BN 
may find new relationships which otherwise may be hidden knowledge. 
We believe this approach has three main advantages: 1) It can incorporate all 
available information across boundaries of individual datasets by either learning directly 
from data or assuming certain independencies in the dataset or from secondary sources 
such as summary and statistical measures. 2) Once a model is built, it can make 
inferences in context, for example, from patient data from an EMR. 3) It creates the 
capacity to keep adding more information as it becomes available using the same 
framework.  
We hypothesize that this approach will discover hidden associations across silos 
of biomedical data, for example predictive distributions which are otherwise unknown.  
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We also believe that this approach can demonstrate the state of the current research by 
putting it in context with the patient data, for example, from our EMR. This would allow 
us to quantify from a domain like GWAS, for example, how much risk of common 
disease(s) is explained by genetic linkages. With this aim of linking disparate studies, we 
conduct experiment 4 detailed in following pages. 
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Experiment 3: Integrating Published and EMR Data 
 
In-Silico Testing of Genotype-Phenotype Associations with Electronic Medical Records [73] 
 
Introduction 
In recent years, several published studies have reported associations of a given 
genetic polymorphism with a particular common complex disease.  In separate clinical 
studies these associations are also stratified by various demographic, racial, ethnic and 
environmental factors. However, due to the challenges discussed in the Chapter 2, the 
two separate sources of information are almost never combined for use in clinical 
practice. Therefore, informatics methods are needed to integrate them with clinical data, 
for example, from an EMR to a) validate findings in larger populations and b) generate 
higher order hypotheses to study separately and c) for future use in data from an EMR for 
application in patient’s context.   
In this experiment, we developed a BN methodology to integrate summary and 
statistical data from full-text published biomedical literature with records identified from 
our EMR system RMRS to test genotype-phenotype associations in our clinical 
population. Here we report our results with the methodology in the domain of asthma 
risk. 
With the advent of microarray technologies, clinical effects can be predicted 
based on functional effect(s) of a gene. [40]  It has been shown that DNA mutations in 
coding regions effect the function or the efficiency of the protein that the gene encodes, 
which can lead to physiologic effects that are clinically relevant. [33]  Therefore, 
strategies applied to genetic diseases like sickle cell anemia (a pure genetic disease) can 
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also be applied to common diseases like asthma, but the task is more complex due to 
gene-gene and gene-environment interactions. [33]  However, for complex diseases like 
asthma, genetics studies can contribute to better healthcare outcomes in one or more 
ways. 
A considerable number of studies point to a lack of consensus on asthma clinical 
subtypes. [40]  Therefore a classification of asthma based on genetics and environment 
could provide more accurate clinical subtypes. [33, 40]  Genetic classification can 
provide improved prognostic information including identification of patients who are at 
highest risk for severe life threatening episodes of asthma.  In addition, a more detailed 
understanding of the pathophysiology of the disease can lead to a more precise definition 
of the environmental modifications which can most likely reduce the risk of asthma. 
Finally, such studies could lead to genetic testing to predict a patient’s response to a drug 
or development of new drug therapies. [74]  
We report our experimental findings for an asthma case finding application that 
integrates summary and statistical data derived from the full-text biomedical literature 
and RMRS.  The published paper details the association of asthma with the Beta 2 
Adrenergic Receptor (β2AR, also referred to as ADRB2 genotype) gene polymorphism 
and cigarette Smoking. [50]  Our methods utilize Bayesian Networks (BN) to integrate 
disparate data sources – a) summary data from literature b) pediatric data from RMRS 
and c) self reported smoke exposure data by families from CHICA system.  We use a 
“goodness to fit” metric [75] as a measure to compare our integrated  model with a 
clinical only model.  
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Methods 
Pediatric Asthma cases and controls were identified from the RMRS and the 
CHICA system, [59] a Clinical Decision Support System (CDSS) used in our Pediatric 
Primary Care (PCC) practice in conjunction with RMRS. An overview of CHICA system 
is described in Chapter 3, experiment 1. 
Data  
The CHICA system electronically receives a record of all clinical observations 
from the RMRS database for every patient visit.  For this study, we analyzed data for all 
children over 5 years of age in our system.  Children were classified as cases or controls 
based on the presence of an ICD-9 code for asthma (493.*) or more than two 
prescriptions of an asthma medication.  From the filtered set we were able to extract the 
variables listed in Table 4-1 to get an “Asthma Status,” sex and race for each patient 
(ages 5 years or older) who had a visit to the PCC clinic. We combined these data with 
the self reported data on environmental tobacco smoke exposure collected from the 
CHICA pre-screener form (PSF), a computer generated questionnaire that is given to the 
patient family to complete in the waiting room.  The combined data set is used to build 
our clinical model using a Bayesian Network (Figure 4-1). Table 4-2 details the 
characteristics of the dataset used to build the model. 
Table 4-1 Data Variables – Experiment 4 
Variable Values 
Race White, Black, Hispanic, Other, Unknown 
Sex Male, Female 
Asthma ICD9 (493.*) or any clinic billing diagnosis for asthma 
after age 5 (True, False) 
Smoke 
Exposure 
“Does anyone in [your child’s] home smoke” (yes, no) 
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    Figure 4-1 Clinical Model (with limited nodes) 
 
 
Table 4-2 Baseline Characteristics – Clinical model 
Variables          Training Set  (n = 2609) 
                                                                  #                                
% 
Race Hispanic (H)  597 23% 
  Spanish (S) 89 3% 
  Asian (X) 29 1% 
  Islander (I) 3                   <  1% 
  Unknown (U) 6 0% 
  Black (B)    1408 54% 
  White (W)   382 15% 
  Other (O)  95 4% 
   
Sex Female (F)        1246 48% 
  Male (M)   1363 52% 
   
Asthma True (T) 666 26% 
  False (F) 1943 75% 
   
Smoke Exp True (T) 579 22% 
  False (F) 2030 78% 
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Bayesian Network for Clinical Model 
We used Netica software [67] (www.norsys.com) to construct BN for our clinical 
model (Figure 4-1). Netica allows network construction and parameter learning from 
data.  The model parameters were obtained using data from the CHICA database as 
specified in the data section.  At the time of this experiment the CHICA system provided 
data on both asthma and smoke exposure status for about 2600 patients.  The baseline 
characteristics of the cohort for the training set are shown in Table 4-2.  The prior 
probability of asthma from this model is 26% (Figure 4-1). 
Bayesian Network for the Genetic Model  
We used a published case-control study – “Association of Asthma with Beta 2-
Adrenergic Receptor (β2AR) Gene Polymorphism and Cigarette Smoking” [50] to build 
a genetic model linking genotype to smoke exposure and asthma.  The study reported an 
interaction between cigarette smoking and β2AR-16 genotype. It showed a synergistic 
relationship between tobacco smoke exposure and the Arg-16 homozygous genotype with 
respect to asthma.  When compared with Gly-16 homozygotes who never smoked, the 
smokers who were Arg-16 homozygotes had a significantly increased risk of asthma 
(Odds ratio = 7.81).  We used summary data from this study, adjusted for our 
population’s asthma prevalence (26%), in our clinical model.  Since the study reported 
128 cases, our experiment required 364 controls (for a total of 492 subjects, resulting in a 
26% prevalence).  Therefore, we multiplied the number of controls in each genotype and 
smoking status group by a factor*** (f = 2.68) (Table 4-3).  We constructed a BN using 
Netica software and learnt its parameters using the summary data in Table 4-3.  This 
constituted our genomic BN (Figure 4-3). 
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Table 4-3 Literature Summary data adjusted for Asthma prevalence 
     (From our EMR) 
 
β2AR-16 
genotype 
Smoking Status Cases 
(n) 
Controls 
(n) 
Adjusted 
Controls (Asthma 
prevalence = 26%) 
*** 
GG Never-smokers 16 28 75.04 
AG Never-smokers 43 52 139.36 
AA Never-smokers 30 33 88.44 
GG Ever-smokers 6 6 16.08 
AG Ever-smokers 11 12 32.16 
AA Ever-smokers 22 5 13.4 
Total   128 136 364 
 
***
68.2
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The prevalence of β2AR-16 allele frequencies in the genomic network from this cohort is 
Arg-16 (A) – 56.4% and Gly-16 (G) – 43.6% (Figure 4-4).  
Integration of the two models 
 The β2AR genotype can be considered a risk factor or hidden node affecting 
asthma for the clinical model; specifically accounting for the effect of smoke exposure.  
In order to integrate this genetic relationship into a clinical model, we needed an 
observable proxy for genotype status.  For this experiment, race was considered as a 
surrogate for the β2AR genotype in absence of actual genotype data for the patient.  
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  Figure 4-2 Genomic Model (Genotype) 
 
 
     Figure 4-3 Genomic Model (Alleles) 
 
 
               Table 4-4 Allele Distribution by Race from public sources 
 
Race Allele A (%) Allele G (%) 
White (W) 34.0 66.0 
Black (B) 45.0 55.0 
Hispanic (H) 44.0 56.0 
Other (O)* 50.0 50.0 
Spanish (S) 44.0 56.0 
Asians (X) 55.0 45.0 
Unknown (U)* 50.0 50.0 
Islander (I)* 50.0 50.0 
  *Uniform distribution assumed since no info found 
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Table 4-4 lists the distribution of alleles A and G by race for β2AR genotype. We 
obtained this distribution from publicly available databases – ALFRED 
(http://alfred.med.yale.edu), PharmGKB (http://www.pharmgkb.org) and entrez SNP 
(http://www.ncbi.nlm.nih.gov/snp) databases.  Using this observable proxy, we did three 
things to integrate as follows – 
We first inserted the two explicit nodes for β2AR alleles (Figure 4-3) in the 
clinical model (Figure 4-1) and used the distribution described in Table 4-4 to obtain the 
conditional probability distribution (CPD) of allele1 and allele2 given race.  
Second, since the CPD of asthma in the genetic model reflects the findings that 
are reported in the presence or absence of smoke exposure in the study, we used the 
adjusted published distribution (i.e. Figure 4-3) to replace the CPD of the asthma node in 
our clinical model (Figure 4-1.).  In the integrated model, we kept the CPD for smoke 
exposure node from the clinical model since this is our population of interest. 
Third, we compiled the integrated model using Netica’s compilation tool.  This 
operation creates a “junction tree” for “belief updating” and also calculates the full joint 
probability distribution (JPD) of the resulting network – our integrated model is shown in 
Figure 4-4. 
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Figure 4-4 Integrated model – Clinical and Genomic 
 
The resulting prior probabilities of β2AR-16 alleles in this integrated model are – 
Arg-16 (A) – 43.4%, Gly-16 (G) – 56.6%.  They are different from the prevalence found 
in the published study (A - 56.4% and G - 43.6%) and reflect the inferred distribution in 
our population based on racial distribution. The network also compiled a resulting prior 
probability of asthma (25%); quite close to the marginal prevalence in our clinical model 
(26%), suggesting that the relationship between race and asthma could be mediated by 
β2AR-16 genotype.  In order to compare the two models – clinical with integrated, we 
absorbed the allele nodes in the integrated model (Figure 4-5). 
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Figure 4-5 Model (with Allele nodes absorbed) 
 
Also known as “averaging out” or “summing out a variable,” a node absorption 
transform leaves the full joint probability distribution of the remaining nodes unchanged 
and results in the final integrated model (Figure 4-5) that could be used for comparison. 
 Comparing the two models 
We compared the CPD of asthma node for the clinical and integrated models to 
see how well the two distributions match.  Our hypothesis was that associations between 
genotype and phenotype could explain, at least in part, the clinical findings that we 
observed in our population, specifically as the relationship between asthma and tobacco 
smoke exposure. Table 4-5 lists the distribution of the asthma node in both models. 
Goodness of fit Metric 
We used a “Goodness of fit” as the comparison metric. [75] This metric is based 
on the Chi-square distribution and the method of least squares. [75] The chi-square test 
compares the observed frequencies with the expected frequencies, giving the probability 
of observed differences under the null hypothesis (there is no difference). [76]  The 
method of least squares is built on the hypothesis that the optimum description of a set of 
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data is one which minimizes the weighted sum of squares of deviations of data (yi) from 
the fitting function y(xi). [75]   The variance of the fit s2, which is an estimate of the 
variance of data σ2, characterizes this sum for v = N – n – 1 number of degrees of 
freedom, where n coefficients fit to N data. Variance of fit s2 is also characterized by the 
statistic χ2 as described in equation 1 below. Equation 2 describes the reduced chi-square 
χ2v  
   }2)]([2
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{2 ixyiy
     (1) 
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22
2
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 s
v
v                 (2) 
where σ2 in equation 2 is the weighted average of individual variances.  However, the 
estimated variance of fit s2 is also a characteristic of both the spread of the data and the 
accuracy of the fit. [75]  Therefore its definition as a ratio of the estimated variance s2 to 
the parent variance σ2 (times the number of degrees of freedom) from equation 2 makes it 
a convenient measure of the “goodness of fit.”  If the fitting function is a good 
approximation to the parent function, the estimated variance s2 should agree well with the 
parent variance σ2 and the value of the reduced chi-square should be approximately unity 
χ2v = 1. [75]  Furthermore, the Q-Statistic defines the probability that a function Q(χ2/ν, 
v) for a set of deviations obtained by randomly sampling N observations from normal 
distribution would exceed the value for χ2/ν that was obtained by the fitting function. [75] 
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Results 
Table 4-5 CPD of Asthma node in clinical and integrated models 
 
Smoke 
Exposure Race 
     
Clinical 
Model 
y(xi)
                    Integrated 
                     Model 
(yi)
 
Chi Square 
F W 27.21 21.68 0.71
F H 19.00 22.52 0.29
F S 14.59 22.52 1.45
F B 30.70 22.60 1.52
F O 23.75 22.99 0.01
F U 22.61 22.99 0.00
F I 36.94 22.99 4.50
F X 24.63 23.35 0.04
T W 21.59 31.86 2.44
T H 25.80 34.32 1.68
T S 36.94 34.32 0.16
T B 27.49 34.61 1.17
T O 31.92 36.17 0.42
T U 42.04 36.17 0.80
T I 42.04 36.17 0.80
T X 30.45 37.91 1.29
   Variance (σ2) =   43.25           Х2  =  17.28
  
v = # of 
degrees 
of 
freedom
v = N – n – 1  
   = 16 - 2 - 1 = 13
Х2v =  Х2 /v  =  1.33 
 
 
We calculated the value of reduced chi-square χ2v = 1.33, (p-value = 0.187) for 13 
degrees of freedom (N = 16 for n = 2 coefficients- race and smoke exposure) and Q(χ2/ν, 
v) to be 0.10 < Q < 0.20. A p-value of 0.187 suggests the two distributions for clinical 
and integrated models may be similar.  Q is “small” (0.10 < Q < 0.20) therefore the fit is 
“poor”.  Only 10–20 % of large number of trials would result in a chi-square value as 
large as observed.  Therefore, β2AR genotype (ADRB2 status), as inferred by race, 
explains only a fraction of the risk of asthma association with smoke exposure in our 
suggested integrated model. 
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Discussion 
Our results are consistent with a minor contribution of the β2AR gene to the 
association between asthma and smoke exposure observed in our EMR.  One explanation 
is that the association between the genotype (ADRB2 or β2AR) and the clinical condition 
(asthma) in the literature was reported with “active smoking” in an adult population.  Our 
experiment models these associations for a pediatric population where the children are 
exposed to environmental tobacco smoke or “passive smoking.”  Asthma is also thought 
to have a multigenic etiology.  The incorporation of other associated genes into the model 
is likely to improve its predictive power.  Finally, the data associating race with genotype 
is crude and incomplete.  Therefore, race (the only surrogate available to us) is a poor 
surrogate for genotype. A better surrogate would be helpful.   
Conclusion 
We have developed and demonstrated a methodology for integrating a published 
data source with a primary data source – EMR. This methodology can be useful for 
testing genetic hypotheses in large clinical data sets. The approach is applicable to a wide 
range of genotypes that are associated with two or more clinically observed phenomena 
(in this case asthma and smoke exposure).  We believe this approach is worth 
investigating for other common diseases like diabetes and obesity and their associations 
with genomic and environmental findings. 
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Experiment 4: Integrating Disparate Sources of Summary Data  
 
In-silico Bayesian Integration of GWA Studies (IsBIG) 
Introduction 
Our aim for this research is to develop probabilistic methods to integrate disparate 
sources of data to form a coherent model even when no primary data are available using 
secondary sources of information such as published summary and statistical measures for 
knowledge discovery.  In the last experiment, we demonstrated integration of genetic, 
clinical and environmental sources using both data and published data summaries. To 
demonstrate how this approach can be used to link secondary sources of data, we choose 
the domain of genome wide association studies (GWAS). Using the NIH compiled 
catalog of GWAS (www.genome.gov) and the database of human genome variations 
from the international HapMap project (www.hapmap.org), we combine information 
from these two secondary sources using BN framework as described in our previous 
experiments. We call this model – In Silico Bayesian Integration of GWAS or IsBIG. In 
this experiment we describe the methodology and report our preliminary results. In the 
next chapter we formally evaluate the IsBIG model using data from our EMR and 
published literature identified in the Pubmed database.  
Genome Wide Association Studies (GWAS) 
Genome Wide Association Studies (GWAS) have become the standard to report 
associations of a genetic variation type – Single Nucleotide Polymorphism (SNP) with a 
particular disease such as diabetes, heart and lung disease, autoimmune and psychiatric 
disorders. It is only in very recent years with the advent of microarray technology and the 
mapping of the variations of human genome (http://www.hapmap.org) [77-78] that the 
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tools to conduct genome wide scans for finding associations of gene to disease have 
become available.  The first results of the genome wide scans started to appear in 2005 
[79] and since have become increasingly sophisticated in the number of gene loci that 
they can address.  Since the genome wide scans follow a specific methodology, they are 
now known as Genome Wide Association Studies (GWAS).  
At the heart of any GWA study is a cohort of individuals with a known disease or 
trait status and a comparable control group without the disease or trait.  Their whole 
genome is genotyped for known variations of Single Nucleotide Polymorphism (SNP). 
Such SNP variations have been cataloged among diverse populations in the international 
HapMap [78] project.  The results from the GWAS are analyzed for strong statistically 
significant (below p < 5 x 10-8) associations between each SNP and the disease or trait 
status of interest.   
Thus, GWAS differ from traditional genetic linkage studies of the past where a 
hypothesis driven candidate gene approach was being used.  GWAS, to date, have 
amassed large datasets linking genotype to phenotype and have provided many useful 
insights [80] into certain diseases such as specific forms of cancer [81] and drug 
metabolism, for example warfarin. [82]  However, they are resource intensive and require 
large sample sizes to detect even modest effect sizes, and yet their applications for 
defining new therapies or preventive measures are largely unknown. [83]  This is mainly 
because the influence of the genetic variation to the phenotype is unclear and there is a 
need to point to the causal variants; to move beyond the process of gene identification. 
[84]   
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But as GWAS (often conducted by individual groups) reported ever more 
potential etiologic and functional implications for similar diseases or traits [85-88], there 
was a need to share the results beyond publication. Therefore, summary and statistical 
results from these studies have been cataloged as an online resource for future 
investigations at http://www.genome.gov/gwastudies [83] at NIH.  
This catalog contains the following details on each study – population 
characteristics, initial sample size, sub population type, strength of statistical association 
as odds ratio (OR) or a beta coefficient (Beta), and the frequency of the risk allele in the 
study. [83]  However, to the best of our knowledge no secondary use of this catalog has 
been reported. 
In this catalog, the risk allele is the marker for the SNP that is found to be strongly 
associated with the disease or trait. Additionally, from previous knowledge, the reported 
SNPs in GWAS are known to follow non-random patterns of association between alleles 
from different markers. [89] This is also known as linkage disequilibrium (LD) [90], 
which we describe below. 
Linkage Disequilibrium (LD)  
LD is non-random association between SNP alleles from different markers, i.e. 
SNP loci on the same or different chromosomes.  Different geographic populations have 
different allele frequencies, and therefore, LD differs between them.  Thus the non-
random pattern of allele associations varies by sub populations – for example European 
descent, Japanese ancestry, etc. [89, 91] LD is measured using correlation coefficient (r2) 
[90] and varies between 0-1.  Two alleles have a high LD score if the r2 value between 
them is greater than 0.5 meaning that they are associated with each other in the population. 
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The international HapMap consortium (http://www.hapmap.org) [77] has developed a 
haplotype map of the human genome, the HapMap, describing common patterns of human 
DNA sequence variation.  It has enabled LD data to be readily cataloged and available in 
sub populations. Thus LD data quantitatively associates SNPs with other SNPs and can be 
measured in a sub population using a tool such as SNP annotation and proxy search 
(SNAP). 
The SNAP tool, [92] available from Broad Institute at 
(http://www.broadinstitute.org/mpg/snap) computes LD scores (r2) between SNPs up to 
500 kilo base pairs apart and takes as input a list of SNPs of interest, a threshold value for 
r2 above which to search the database and the sub population of interest.  The output of the 
tool is a paired list consisting of the input SNP and another SNP henceforth called “proxy” 
SNP that exists in a non-random association above the given threshold cutoff value of r2 in 
the HapMap database for the desired sub population.  
Disparate Sources of information 
We reasoned if diseases can be linked with SNPs and SNPs with one another, 
then it should be possible to predict associations among diseases that could be mediated 
through linked genetic determinants. Predicting quantitatively the associations among 
diseases and traits that would be predicted by genetic patterns alone would allow us to 
undertake three novel studies: (1) Validate the associations among diseases and traits 
with electronic health record data (2) quantify the amount of variation among disease 
linkages that can be explained by currently cataloged GWAS and linkage studies, (e.g. 
heart disease and obesity) and (3) predict novel associations among diseases that could be 
tested in future genetic studies. 
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In this experiment, we build a computational model (IsBIG) to integrate the two 
disparate sources – 1) results from the studies cataloged in the NIH catalog [83] linking 
SNPs to diseases or traits and 2) HapMap (www.hapmap.org) data associating SNPs to 
other SNPs. With the IsBIG model, we hoped to find a disease map linking diseases to 
other diseases that would be similar to what one would find in a clinical database such as 
our EMR. 
Methods 
In-silico Bayesian Integration of GWAS (IsBIG) model  
The IsBIG model was assembled in the following four steps.  1) Extract Gene-
Disease associations from the NIH catalog for a sub population to form a model catalog; 
2) for the SNPs listed in this model catalog, compute genome wide LD scores (r2) from a 
comparable sub population from the HapMap database to form a SNP-SNP (proxy) 
association dataset; 3) for the SNPs linked by LD in the SNP-SNP (proxy) dataset, find 
diseases or traits linked to each other pair wise as a result of LD. This formed the SNP-
SNP-Disease-Disease dataset for input to the IsBIG algorithm described in the following 
sections. 4) Using this input, the IsBIG algorithm computes a BN with two separate 
components in steps – a) SNP-SNP BN using LD (r2) to calculate CPDs. b) SNP-Disease 
BN, using OR to calculate CPDs. Finally, the algorithm absorbs the SNP nodes (as 
described below) to compute the disease-disease BN or the output of disease map.  The 
algorithm is coded using Java API and a commercially available software package for 
modeling Bayesian networks – Netica’s API (www.norsys.com) [67].  The details of each 
step are listed as follows. 
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Extract Gene-Disease Association  
A copy of the GWAS catalog from the http://www.genome.gov/gwastudies/ 
website was downloaded on 12-28-09. The GWAS catalog contains information from a 
wide range of GWAS studies associating specific SNPs to diseases or traits.  From the 
variables included in the catalog we chose the variables listed in Table 4-6 for the 
experiment.  Table 4-7 lists sample studies from the GWAS catalog.  Appendix A.1 
gives a summary of the studies from the GWAS catalog we used. 
Table 4-6 Variables for Model Catalog  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-7 Sample Studies in GWAS catalog 
 
Disease 
/Trait 
Risk 
Allele 
SNP Risk Allele 
Freq 
OR
  
Initial Sample 
Size 
Type 1 
diabetes G rs4900384 0.29 1.09
7,514 cases, 
9,045 controls
Type 2 
diabetes C rs4607103 0.76 1.09
4,549 cases, 
5,579 controls
Multiple 
sclerosis 
A rs1335532 0.87 1.28 1,618 cases 
3,413 European 
ancestry controls
 
We planned to evaluate the model disease map with data from our EMR, the 
RMRS [2]. Therefore we decided to use only those studies from the downloaded catalog 
DISEASE/TRAIT  Disease or trait examined in study 
SNPS Strongest SNP 
INITIAL SAMPLE SIZE Sample size for Stage 1 of GWAS, population subtype 
RISK ALLELE 
FREQUENCY 
 Reported risk allele frequency associated with strongest   
SNP 
OR or BETA  Reported odds ratio or beta-coefficient associated with 
strongest SNP risk allele 
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where the initial population originated from European ancestry.  Thus, we filtered studies 
where the initial sample size variable did not contain population from European descent 
(i.e. Japanese, Chinese, Korean, Gambian and other sub populations in the NIH catalog).  
Where the sub population was not defined, we assumed it to be of European ancestry.   
2564 GWAS studies consisting of 1708 unique SNPs from the GWAS catalog 
were downloaded (in Dec. 2009). Of these 807 GWAS studies (Appendix A.1) qualified 
as conducted in population with European ancestry.  These studies contributed 182 
unique disease traits and 850 unique SNPs in this sub population for our Model Catalog. 
Gene (SNP) – Gene (SNP) Association  
We extracted gene-gene associations from linkage disequilibrium data in the 
HapMap database. [77] Since we decided to use studies with European ancestry 
population, we used the HapMap CEU dataset (phase 3 release r2). Using the SNAP tool 
[92] we derived LD between SNPs reported in our Model Catalog and other SNPs present 
genome wide.   
For our experiment, we used a LD score (r2) cutoff threshold value of 0.3.  This 
threshold was chosen empirically to capture weaker associations between SNPs and yet 
keep our SNP to SNP (proxy) dataset computationally tractable. Higher and lower values 
of cutoff threshold brought in fewer and more SNPs with stronger and weaker associations 
respectively.  However, empirically, this threshold (r2 = 0.3) provided an optimum set for 
this experiment. Table 4-8 gives a snippet of the output from the SNAP tool for our input 
SNP (e.g. rs2191566). 
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Table 4-8 Sample output from SNAP tool 
 
SNP  SNP (proxy) Distance r2 
rs2191566 rs7255512 63311 0.616 
rs2191566 rs8104605 77627 0.604 
rs2191566 rs4803675 78327 0.561 
 
Pair wise disease-disease associations using LD   
When we searched in the HapMap phase 3 release 2 CEU dataset using the SNAP 
tool, the 850 unique SNPs were in LD (r2 >= 0.3) with more than 16,000 proxy SNPs.  
From these 16,879 proxy SNPs, we were only interested in the proxy SNPs that were also 
reported in our Model Catalog and their associated diseases or traits.  Therefore, we 
imported the proxy SNP data produced by the SNAP tool and our Model Catalog in a 
database.  From there, we were able to do association mining to obtain SNPs that were 
both in our model catalog and had a LD >= 0.3 with another SNP (proxy) in the Model 
Catalog and obtain its associated disease or trait.  
This resulted in 397 unique SNP to SNP pair-wise associations and their 
associated disease or trait relationships (Appendix A.6) where LD between SNPs was < 1 
(i.e. r2≠1). The lowest LD found in this association mining step was 0.302 and the highest 
LD was 0.983 between two SNPs. Association mining with LD data from HapMap 
provided us the ability to examine the model GWAS catalog beyond the pair wise single 
SNP to disease or trait association. Table 4-9 shows some associations found between 
diseases or traits using the LD scores of correlations (r2) derived from HapMap.   
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      Table 4-9 Pair wise associations from GWAS catalog (by association mining) 
 
Disease or Trait associated 
with a SNP 
Disease or Trait associated 
with a SNP (proxy) 
r2 
Coronary Disease Glioma 0.384 
Rheumatoid arthritis Inflammatory bowel 
disease 
0.389 
Celiac disease Schizophrenia 0.400 
Schizophrenia Celiac disease 0.400 
Primary biliary cirrhosis Systemic lupus 
erythematosus 
0.425 
Type 1 diabetes Rheumatoid arthritis 0.796 
      
However, traditional statistical methods like correlation can only examine pair 
wise relationships, and additionally carry the burden of identifying the actual functional 
relationships (in this case between the SNP and the proxy SNP) and suffer from multiple 
testing issues as well. Therefore, for analyzing functional relationships between common 
diseases studied in GWAS, we need methods that handle complexity beyond the pair 
wise paradigm. This is where Bayesian methods are useful – they compute the probability 
of hypotheses rather than probability of committing an error [93] and model multiple 
random variables whose probability distributions can be factorized into smaller 
conditional probability distributions (CPD). [21] 
We use this property of BN, to compute CPDs from available subsets of data, i.e. 
from statistical data reported in the GWAS and from LD measure of correlations from 
HapMap database, to form smaller BNs which, on absorbing the SNP nodes, combine in 
one large BN – our disease map. We describe the In-silico Bayesian Integration of 
GWAS (IsBIG) algorithm below. 
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In-Silico Bayesian Integration of GWAS (IsBIG) Algorithm (Figure 4-10) 
We used the BN approach and causal independence assumption described in 
Chapter 2 to draw a DAG of the SNP to SNP and SNP to disease or trait relationship. 
The qualitative structure of this model is assembled from the input SNP-SNP-
Disease-Disease dataset (formed from association mining as described above) as 
follows. The complete table is listed in Appendix A.6. 
A directed edge connecting a SNP to another SNP (proxy) node is drawn 
programmatically (using Netica API) if the SNPs are correlated (LD correlation) in 
the input dataset. They assume a parent-child relationship from SNP to SNP (proxy). 
Similarly a directed edge connecting each SNP to one or more diseases or traits is 
drawn if they are correlated in the input GWAS data. Please note that in this dataset, 
there are several SNP to SNP links, and therefore, there are N way interactions 
because each SNP may be correlated with several others. Similarly, multiple SNPs 
can be correlated with a disease. These multiply connected SNPs present a problem in 
computing the conditional probability distributions (CPD) of the nodes that have 
more than one parent because the data sources only describe one to one association 
metrics. We address this problem of multiply connected SNPs with the method of 
partial correlations described below. 
Figure 4-6 below depicts the DAG of the model GWAS catalog constructed for 
this study. In this figure S1, S2… Sn are the SNPs in the Model Catalog, they are in 
LD (r2) with each other (from HapMap data) and have been shown to have strong 
associations in GWAS with their respective diseases or traits (e.g. S2 to asthma). The 
odds ratio (OR) quantifies the strength of each of the relationships between the SNP 
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and the disease as derived from a GWAS.   In this figure, SNP S3 is multiply 
connected with S1 and S2 as parents and the disease Psoriasis has both SNPs S4 and S5 
as parents. However, each of these represent separate BNs derived from individual 
pieces of information and combined into a single BN.  The IsBIG strategy for 
deriving the parameters follows –  
 
 
Figure 4-6 Model DAG of SNP-Proxy SNP-Disease 
 
Computation of SNP – SNP BN Parameters 
 The task at hand is to compute the CPD of each SNP – we need to calculate the 
CPD of a SNP that has no parent (S1), 1 parent (S2) or many parents (S3). As shown in 
Table 4-7, the GWAS catalog lists a risk allele (RA) frequency (RAF) for each SNP to 
disease or trait association.  The normal allele (NA) frequency (NAF) is the complement 
of RAF, i.e. – (1-RAF). Therefore, for a SNP that has no parent (e.g. S1 in Figure 4-6), 
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the two cells in CPD of S1, i.e. P(S1 = RA) and (P(S1 = NA) is simply the prevalence of 
the RA, i.e. RAF and its complement (1-RAF).   
For a SNP like S2 that has S1 as a parent, i.e. S2 | S1, (Figure 4-6), the CPD can be 
constructed using the RAF and NAF of both SNPs and the correlation coefficient (r2), the 
linkage disequilibrium measure between the SNPs.  We need to compute the four cells 
for the CPD of S2, i.e. P(S2 = RA | S1 = RA), P(S2 = NA | S1 = RA),   P(S2 = NA | S1 = 
RA) and P(S2 = NA | S1 = NA).  By definition of LD (Table 4-10), if T1 and T2 are RAF 
for S1 and S2 from the catalog, the four cells in the CPD of S2 given S1 i.e. S2 | S1 can be 
computed by calculating the deviation measure (D) between the two SNPs.  D is a 
measure of deviation from linkage equilibrium which is a random association of the two 
SNP alleles and is calculated by equation 1. [90]. 
 
 
 
 
Table 4-10 CPD from Linkage Disequilibrium and Risk Allele Frequency 
 
    P (S2 | S1)     Risk Allele (RA)             Normal Allele (NA)           Total 
RA X = T1* T2 + D Y = T1* (1-T2) -  D T1 
NA V = (1 – T1) * T2 - D W = (1 - T1) * ( 1- T2) + D 1- T1 
 T2 1-T2 1 
 
For multiply connected SNP nodes, e.g. S3 in figure 4-6 which has 2 parents, S1 
and S2, we cannot use the simple approach as described above because of the SNP-SNP 
triangulations formed as in Figure 4-7. In such situations, we use partial correlations to 
first assess the strength of the relationship between SNP pairs as described below. 
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Computation of CPD for multiply connected SNP 
 
 
Figure 4-7 SNP-SNP Triangulations 
 
Partial correlation quantifies the correlation between two variables x and y when 
conditioning on one or several other variables [94], for example z.  The 0th order 
correlation is the regular correlation.  The 1st order partial correlation between variables 
x, y and z in Figure 4-7 is given by equation 2 below. For example, rxy-z is the correlation 
between parts of x and y that are uncorrelated with z.   
 
 
For calculating the CPD of a multiply connected SNP (e.g. S3 in Figure 4-6 which 
has 2 parents, S1 and S2), the 1st order partial correlations are computed, ignoring the 
directionality of the link to first assess whether the strength of the relationship between 
the pairs S1-S2, S2-S3 and S1-S3 are above a predetermined threshold value. If the partial 
correlation is below this threshold value (for example, 0.5), the link that has low partial 
correlation value in the S1-S2-S3 triangulation is removed thus breaking the triangulation.  
If no links are removed, we use partial correlation coefficients (r13-2, r23-1) for S1-S3 and 
S2-S3 links to calculate two deviation measures (D) in equation, one for each parent, i.e. 
P(S3| S1) and P(S3| S2). Now we have two sets of CPDs (four cells) for S3, one from each 
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parent that we need to combine. Since these are independent linkages, i.e. S1-S3 and S2-
S3, we can combine them assuming causal independence using a Noisy-OR calculation as 
described in Chapter 3.  We can apply the same calculations for more than two parents, 
however in our Model Catalog, the links were pruned and we rarely needed to calculate 
beyond the single deviation measure. 
Thus, applying partial correlations to our scenario pruned the links between SNPs 
when there were triangulations of SNPs present and reduced the computational 
complexity of calculating the CPDs of multiply connected SNPs. Specifically, links that 
were weaker than a predetermined threshold value of partial correlation coefficient were 
removed.  For our experiment, we used a threshold value of 0.2 for 1st order partial 
correlation.  As we show later in the results, the threshold of partial correlations defined 
how sparsely or densely the resulting network connected. 
 Computation of SNP – Disease BN Parameters 
For each SNP-disease association to be modeled from a GWAS, the only data that 
are available are the odds ratio (OR).  Given a prior probability (aka disease prevalence) 
of a disease or trait and the strength of the relationship (OR) from the GWAS, a posterior 
probability (CPD) can be derived. 
To derive a CPD from the prevalence P(Di), and an odds ratio, P(Di) must first be 
converted to the prior odds (Oprior) of the disease according to equation 3.  From there, the 
posterior odds of the disease Oposterior can be calculated using prior odds and the odds ratio 
reported in the GWA study (Ogwa) as in equation 4. [95]  
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From posterior odds of disease (or trait) we can find the probability Pi of the disease 
given the SNP, i.e. P(Di | SNP)  by equation 5 below. 
 
 
 
Pi is the link probability [27] of the SNP to the disease or trait node in absence of any 
other cause.  For disease or trait nodes that have multiple links from SNPs (e.g. S4 to IBD 
and Psoriasis in Figure 4-6), we assume causal independence of SNP to disease (as in the 
GWAS). Therefore, in those situations, we calculate the CPD of the disease given the 
SNPs, i.e. P (D | S1, S2…) using the Noisy-OR equation below (equation 6). 
)6()1(1   pi ip ss p)S|P(D  
 
The disease or trait’s prevalence P(Di) measure can either be specified by a 
domain expert or from data, for example, from an EMR. Since in this experiment we are 
developing the methodology, we arbitrarily assumed certain prevalence of common 
diseases. For a formal evaluation of the IsBIG model in the next chapter, we used 
prevalence measures from RMRS, our EMR. 
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Deriving Disease – Disease Map 
We have constructed two components of a BN: SNP to SNP and SNP to disease 
from two separate sources of information. Our goal in the next chapter will be to evaluate 
the predictive power of this BN against clinical data from the RMRS.  To do this, we 
wish to reduce the BN to a disease map by absorbing out the SNP nodes which are 
unobserved in clinical data. Node absorption is a network transform and is described in 
the experiments in Chapter 3. 
Results 
Our preliminary results show that from the data in our model catalog, the IsBIG 
model linked clinically related nodes of diseases or traits on absorbing the SNP nodes. 
For example, testicular germ cell tumor was linked to testicular cancer, and chronic 
obstructive pulmonary disease was linked to lung cancer, which was also linked to lung 
adenocarcinoma. Similarly, coronary disease was linked to early myocardial infarction. 
Some of the diseases the model linked are given in Table 4-11.  
Table 4-11 Disease linkage patterns from GWAS catalog 
 
Diet–Environment  Obesity, Type 2 diabetes 
Autoimmune1  Type 1 diabetes, Celiac disease, Inflammatory bowel disease 
Autoimmune2  Psoriasis, Crohn’s Disease, Inflammatory Bowel Disease 
Celiac Disease, Multiple Sclerosis 
Cardiac  Coronary Disease, early Myocardial infarction, Intracranial 
Aneurysm, LDL cholesterol
Lung  Lung cancer, Lung adenocarcinoma, Chronic obstructive 
pulmonary disease
Cancer  Colorectal cancer,  Prostate cancer
Traits  Blond vs Brown hair color, Skin sensitivity to sun, Freckles, 
Red vs non-red hair color, Melanoma  
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We conducted normative evaluation of the IsBIG model. We used two part 
criteria by varying the following network parameters – 1) LD threshold between SNPs 
and 2) Partial correlation threshold used for pruning the SNP links and their effect on the 
number of nodes and connectivity in the network.  
Linkage Disequilibrium Threshold  
LD threshold (r2) was chosen as r2 >= 0.1, r2 >= 0.3, and r2 >= 0.5, corresponding to 
weak and strong associations between SNPs.  Based on the LD threshold value used, we 
expected the number of SNPs brought in the model from the HapMap dataset to increase 
or decrease.  As a result of this variation, the number of disease pairs that became part of 
the model changed as well.  Table 4-12 below details the number of SNP-SNP pairs and 
disease pairs that entered the model based on the choice of LD threshold. 
As can be seen in Table 4-12 (from Disease Pairs column) changing the network 
parameter for linkage disequilibrium (LD) threshold between SNPs changes the number 
of disease nodes that become part of the model.  The number of disease nodes that 
entered the model varied inversely to the LD threshold value chosen. 
 
Table 4-12 Effect of LD Threshold on network size 
 
LD (r2) Threshold  SNP-SNP Pairs From HapMap  Disease 
Pairs  
High / Low 
LD 
>=0.5 9416 134 0.982/0.505 
>=0.3 16879 397 0.982/0.303 
>=0.1 41485 518 0.982/0.101 
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Partial Correlation Threshold  
Next we changed the partial correlation threshold values determining which links 
were pruned between the SNPs when the triangulations existed (Figure 4-7).  We 
expected the network to become sparse when the partial correlation threshold was set 
high ( >= 0.5) and to become dense when it was set low ( >= 0.2).  Figure 4-8 shows a 
sparsely connected DAG computed by IsBIG when 1st order partial correlation threshold 
is set at r2 = 0.8.  Figure 4-9 shows a computed DAG when 1st order partial correlation 
threshold is set at r2 = 0.2 and when the SNP nodes are absorbed.  
Discussion 
We outlined a methodology that we call “In-silico Bayesian Integration” and 
applied it to the domain of GWAS to build a model – In-silico Bayesian Integration of 
GWAS or IsBIG. The IsBIG model is able to find relationships qualitatively and 
quantitatively between various diseases or traits as inferred by the linked genetic 
determinants of the disease or traits in the GWAS catalog.  We made a few assumptions: 
1) Where the population was not defined in the catalog, we assumed European descent. 2) 
The strength of association between the SNP and the disease or trait (given by odds ratio) 
is assumed for a single copy of the allele; the GWAS catalog does not detail about the 
haplotype effect. 3) We focused on GWAS with discrete outcomes for diseases or traits 
(i.e. absent / present). A majority of studies in the GWAS catalog list discrete outcomes 
as opposed to the studies that describe change in a continuous trait like diastolic blood 
pressure measured as mm Hg increase / decrease and where the strength of the 
association is reported as a beta coefficient. 4) Lastly, we assumed independent causal 
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independence among SNPs affecting a disease or trait. This allowed us to combine the 
individual effect using a Noisy-OR gate as described before. 
Additionally, we made some empirical observations about the correlation 
thresholds.  These thresholds were chosen to keep the computational model tractable – 
values below these thresholds (i.e. LD threshold value below 0.3 and partial correlation 
threshold below 0.2) resulted in many more SNP nodes which had weaker associations. 
However when they were included, the algorithm generated out of memory exceptions 
when trying to absorb many more nodes due to the physical memory addressing 
limitation of the Java Virtual Machine (2GB on a 32 bit operating system.) Exploring this 
methodology on systems with greater memory addressing capacity was beyond the scope 
of this exploratory research. 
In Chapter 5 we evaluate our model quantitatively using data from our EMR, the 
RMRS to quantify the amount of variation among disease linkages that can be explained 
by studies currently cataloged in the domain of GWAS and to report any novel 
associations the model finds.  
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Figure 4-8 IsBIG DAG (SNP-SNP r2 = 0.3, 1st order partial r2 = 0.8) 
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Figure 4-9 IsBIG DAG (SNP-SNP r2 = 0.3, 1st order partial r2 = 0.2) 
 
 
Table 4-13 Effect of Partial LD Threshold on network connectivity 
 
Partial 
correlation 
LD(r2) 
Threshold 
# of 
triangulations  
# of cycles 
removed  
# of edges 
removed  
# of SNPs 
with > 1 
parent  
>=0.1  28  7  17  18  
>=0.2  28  6  30  13  
>=0.35  28  6  41  9  
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  Figure 4-10 In-silico Bayesian Integration of GWAS Algorithm  
Find unique SNP-Proxy Pairs order by descending r2 value in set M.  
Associate each SNP to its list of disease/traits and Proxy SNP to its list of disease 
trait in a hash map data structure D 
 
DrawDAG(): For each SNP in M  
Make SNP a parent node p(i) and Proxy a child node c(i), if the nodes do not 
already exist in DAG. Draw a link from p(i) to c(i) 
 Triangulate(): For each SNP-Proxy pair in M  
If SNP-Proxy have common child c(i)- mark it as a triangulation in set T 
RemoveCycles(): For each SNP-Proxy pair in M  
If proxy SNP has a child node c(i) that has the gwas SNP as a parent node p(i), 
reverse the link between c(i) and p(i) 
Prune(): For each traingulation in T  
Compute 1st order partial correlation of each pair. If 1st order partial correlation > 
defined threshold, keep the link otherwise mark it for removal in set R. Remove all 
links in set R, this results in SNP map DAG 
DrawDAG_DiseaseTraits(): For each SNP in M  
Make SNP a parent node p(i) and disease/trait a child node c(i), if the nodes do not 
already exist in DAG. Draw a link from p(i) to c(i) 
Compute_CPD(): For each SNP-Proxy pair in M  
Use known MAF of each SNP – Proxy duo from GWAS and LD (r2) value from 
HapMap data to compute P(S2|S1) as described using equation (1) and (2) 
ComputeCPD_Disease (): For each SNP-Proxy pair in M and each SNP-Disease 
pair in D 
Use equation (3)-(5) to compute P(D|Si). In cases where P(D|S1,S2), use Noisy-OR 
calculations using equation (6)  
CompileNet(): Netica builds a “junction tree” for fast belief updating. 
AbsorbSNP(): Absorb out all the SNP nodes in the compiled DAG 
WriteDAG(): Serialize the compiled and absorbed DAG 
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Chapter 5  VALIDATION AGAINST PRIMARY EMR DATA 
 
Introduction 
In this chapter we present our evaluation of the unified BN constructed using the In-
silico Bayesian Integration methodology described in the previous chapter. In particular 
we evaluate the In-silico Bayesian Integration of GWAS, hence forth called the IsBIG 
model (or I-Model) with data from our EMR, the Regenstrief Medical Record System 
(RMRS). [2] 
We evaluate the IsBIG model with the following hypotheses –  
1) IsBIG can discover disease-disease associations that are valid. These associations 
can be confirmed and quantified meaningfully by testing against a) data from our EMR 
and b) by evaluating against what has been published in the literature.  
2) IsBIG can discover novel disease-disease associations. These associations do not 
exist in the literature.  
3) Genetic data can only explain a small fraction of the risk of the disease. IsBIG 
model can quantify the proportion of risk of disease that can be explained by linked 
genetic determinants. 
Below we describe our methods to test the above three hypotheses. We believe 
this study is novel as it quantifies the degree of associations found among diseases 
determined by genetic linkages alone and compares it to a real world EMR.  
Methods 
For evaluation of disease-disease associations (hypothesis 1), we construct a 
mixed model (M-Model) where the structure of the IsBIG DAG remains the same but its 
conditional probability distributions (CPDs) are derived from our EMR, the RMRS. We 
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test the I-Model against this M-Model and PubMed searches. For evaluation of novel 
disease-disease associations (hypothesis 2), we evaluate I-Model against published 
literature in the PubMed database. To evaluate the proportion of the risk attributed to 
linked genetic determinants (hypothesis 3), we evaluate I-Model against a purely clinical 
model (C-Model) derived from RMRS. Below we describe each of these models but first 
we describe the dataset derived from RMRS that is used for this evaluation. 
EMR Data for evaluation  
With IRB approval we obtained de-identified data from the Regenstrief EMR 
(RMRS) for 169,711 individuals for 89 diseases. These diseases or proxies of these 
diseases were also listed in our Model Catalog described in the previous chapter. 
Extraction of these data was sought before the disease-disease relationships for I-Model 
were known. The data obtained for each patient were extracted from the last 15 years of 
the individual’s medical record, and for each disease each individual was coded as a case 
or control using the ICD-9 diagnostic codes. The ICD-9 diagnostic codes were selected to 
match the diseases in the GWAS catalog by a Regenstrief data core expert physician. 
Thus, in this dataset the same individual can be a case for one or more diseases and a 
control for others. The dataset had no missing values and henceforth is referred to as the 
“Regenstrief dataset”. We randomly split the Regenstrief dataset into 2/3 training set 
(112,829 records) and 1/3 test set (56,882 records) for our evaluation.  Next, we describe 
construction of each of the models, i.e. learning the parameters of the M-Model and 
deriving the DAG and parameters of the C-Model from the Regenstrief training set. 
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I-Model Construction 
The IsBIG model (I-model) was built using software developed by the author, 
using Java and Netica software [67] APIs. The software implements the IsBIG algorithm 
as described in Chapter 5 and produces a network file (.dne) suitable for representation 
and inference by Netica software. The Java code for the algorithm is included in 
Appendix A.9. The input for computing the model consisted of the following network 
parameters – LD threshold value of r2 >= 0.3 for SNP to SNP correlation and partial 
correlation threshold values = 0.2. These network parameters were chosen empirically to 
keep the computational model tractable and yet include weaker correlations of SNPs to 
test with a real world sub population using RMRS data. The pre– processed input (from 
the GWAS catalog and HapMap data) for the IsBIG algorithm is detailed in Appendix 
A.6, and its pre processing (association mining) is described in Chapter 5. The prevalence 
data for the modeled diseases was derived from our EMR. (Appendix A.7) 
M-Model Construction 
The mixed model retained the network structure that was derived from the IsBIG 
algorithm, i.e. the DAG structure of the I-Model. Using Netica’s “case file” interface, the 
2/3 training set was used to learn the conditional probability distributions (CPD) of each 
node (disease) in the I-Model DAG. Netica resets any CPDs to uninformed priors (50-50) 
for each of the nodes before a case file is incorporated. Thus, incorporating the training 
set transformed the IsBIG model (I-Model) to the mixed model (M-Model) with network 
structure derived from the GWAS and SNP data and conditional probability distributions 
learnt from the clinical data from RMRS. Similar to the I-Model, the M-Model was also 
evaluated for its discriminative power using the same test dataset from RMRS. 
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C-Model Construction 
Using the Winmine toolkit [68] and the 2/3 split training set (same as above), we 
mined the structure of a DAG that represents the clinical model or the C-Model (Figure 
5-1). In this DAG, 42 of the 89 diseases or traits from the initial dataset were connected 
by an edge with another disease or trait. The rest of the diseases were either disconnected 
or, because in the GWAS catalog they listed as a continuous trait, they could not be 
evaluated by the discrete Winmine algorithm.  
Winmine uses a greedy algorithm to mine the best structure for the DAG, given the 
data. This mined DAG was then implemented using Netica [67] Bayesian Network 
software. The conditional probability distributions for this DAG were learnt from the 
same 2/3 split training set from which the structure was mined. Thus this model 
represented the DAG structure and parameters; both learnt from clinical data and became 
our clinical model (C-Model). Similar to the other two models, the C-Model was 
evaluated for its discriminative or predictive power using the same test dataset from 
RMRS. 
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Figure 5-1 DAG Structure of C-Model learnt from RMRS Training set 
 
Performance measure 
We use Area Under the Curve (AUC) of Receiver Operating Characteristic 
(ROC) curves [57] as a performance measure for evaluating the discriminative power of 
the three BNs.  The ROC curve performance measure is described before in Chapter 2. A 
ROC with AUC of 0.5 score has no predictive value and is as good as chance. 
Computing Area under the Curve (AUC)  
We used Netica’s “test interface” and the randomly split 1/3 test set from RMRS 
to evaluate the performance for discrimination of cases and controls for each disease by 
calculating the AUCs for each of the 42 diseases or the subset of them in each of the 
DAGs.   
Testing for statistical significance  
We did a test of hypothesis for each model constructed above as follows. For each 
disease node, we tested whether the BN had statistically significant predictive power (i.e., 
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AUC significantly greater than 0.5) using the Hanley and McNeil method described in 
[96] for calculating the standard error from which z-scores can be calculated without 
distributional assumptions (i.e. based on the count of normal and abnormal cases in the 
test set). The results of these tests are listed in Appendix A.2 to A.4 and described below. 
Additionally, to compare the predictive power of the M-Model and the C-Model, 
we used the Hanley McNeil method for ROC derived from same cases [72] to compare 
ROCs for the same disease. Please note the that both these models differ in structure, but 
the conditional probability distributions were learnt from the same training set and they 
were tested using the same test set.  
Evaluation of IsBIG Compared to Published Literature 
To evaluate the I-Model, we evaluated direct pair wise associations (Appendix 
A.4) between diseases that the IsBIG algorithm found against – 1) PubMed database 
searches, 2) direct pair wise associations between diseases in C-Model, i.e. DAG derived 
from EMR and 3) against both of the above combined. We searched the PubMed 
database for articles linking the diseases found to be associated in the IsBIG DAG by 
searching for one disease as a keyword with a boolean AND condition to the second 
condition, for example – Primary Biliary Cirrhosis AND Crohn’s Disease. These 
searches were conducted in May 2010. The number of articles meeting these simple 
criteria was counted for our measure. 
Results 
I-Model Evaluation with Test set 
29 of the 42 diseases (Appendix A.2) from Regenstrief EMR were included in the 
I-Model construction by the IsBIG software with the chosen network parameters 
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described above.  With the 1/3 randomly split test set, the I-Model predicted 5 (17%) of 
the 29 diseases or traits with an area under the curve (AUC > 0.5, p < 0.05). In other 
words the network had the discriminative power to differentiate cases from controls from 
our EMR test set for 17% of diseases. The diseases that were predicted with statistical 
significance in I-Model are listed in Table 5-1 below and highlighted in Appendix A.2.  
Table 5-1 Discriminative power in IsBIG (I-Model) 
 
  Node  AUC p‐value 
1  Coronary Disease  0.6856 0
2  Lung cancer  0.6263 0
3  LDL Cholesterol (Elevated) 0.5823 0
4  Type 2 Diabetes  0.5431 0
5  Obesity  0.5192 4.73E‐09
 
M-Model Evaluation with Test set 
As described before, the I-Model was parameterized for its 29 nodes using the 2/3 
randomly split training set. This parameterization transformed the I-Model into the M-
Model. Using the same 1/3 test set (as before), the M-Model predicted 12 (41%) of the 29 
diseases or traits with an area under the curve (AUC > 0.5, p < 0.05). The diseases that 
were predicted with statistical significance in M-Model are listed in Table 5-2 below and 
highlighted in Appendix A.3.  
Table 5-2 Predictable diseases in Parameterized IsBIG (M-Model) 
 
  Node  AUC p‐value 
1  Myocardia l Infarction Early 0.937 0
2  Coronary Disease  0.7318 0
3  Psoriasis  0.6343 0
4  Lung cancer  0.6263 0
5  Systemic Lupus Erythematosus 0.5947 2.08E‐06
6  LDL Cholesterol Elevated 0.5945 0
7  Rheumatoid Arthritis 0.5871 0
8  Chronic Obstructive Pulmonary Disorder 0.533 1.2E‐10
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9  Asthma  0.5274 0
10  AIDS Progression  0.522 0.029809
11  Obesity  0.5192 4.73E‐09
12  Type 1 Diabetes  0.5098 0.038912
 
C-Model Evaluation with Test set 
We used the same test set (randomly 1/3 split from RMRS data) to evaluate the 
performance of the clinical model (C-Model). Please note that the structure of the C-
Model DAG was independently derived from the 2/3 training set. With the same test set, 
the C-Model predicted 31 (74%) of 42 disease or trait nodes with an area under the curve 
(AUC > 0.5, p < 0.05). The diseases that were predicted with statistical significance in 
this model are listed and highlighted in Appendix A.4.  
Comparing the I-Model to the M-Model  
Since the only difference between the I-Model and the M-Model is the conditional 
probability distributions of each node; (the I-Model contains the genetic linkage 
representation where as the M-Model contains both the genetic and clinical 
representation, therefore we compared the statistical significance of the I-Model with the 
M-Model. This enabled us to evaluate our hypothesis that the associations discovered by 
IsBIG model can be validated in our EMR. Table 5-3 below gives the counts of the 
number of diseases that were statistically significant in each model.  
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Figure 5-2 IsBIG Model performance, statistical significance denoted by  
 
Table 5-3 Number of statistically significant diseases predicted by each model  
 
    +   -  
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Predicted diseases denoted by + 
Of the 29 diseases, 5 were predictable by the I-Model and 12 were predictable by 
the M-Model (AUC > 0.5, p < 0.05). There were 4 diseases common to both the I-Model 
and the M-Model, i.e. the I-Model is 33% sensitive when compared to M-Model. There 
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were 17 diseases not predictable by the M-Model, of those, 16 were common to both the 
models i.e. I-Model is 94% specific when compared to the M-Model. The details of the 
disease nodes marked with a colored dot for statistical significance are in Figure 5-2 
above. 
Of the 4 diseases predictable by the I-Model and the M-Model, the networked 
performed the same for Obesity and Lung Cancer i.e. AUCs did not change on 
computation of conditional probability distributions (parameterization) of the nodes. For 
the other diseases, there was a modest gain (1 to 14%) in the discriminative power of the 
IsBIG DAG on parameterization with the EMR data i.e. in the M-Model (Figure 5-3).  
 
Figure 5-3 Change in IsBIG AUC on parameterization 
 
There were a few exceptions though, most notably for early detection of 
Myocardial infarction. The M-Model’s discriminative power (AUC) increased by 44%, 
i.e. a relative jump of 87% when compared to the I-Model. However, surprisingly on the 
‐5%0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Ty
pe
_2
_d
ia
be
te
s
Lu
ng
_c
an
ce
r
O
be
sit
y
Ty
pe
_1
_d
ia
be
te
s
LD
L_
ch
ol
es
te
ro
l
As
th
m
a
AI
DS
_p
ro
gr
es
sio
n
Ch
ro
ni
c_
O
bs
tr
uc
tiv
e_
…
Co
ro
na
ry
_d
ise
as
e
Rh
eu
m
at
oi
d_
ar
th
rit
is
Sy
st
em
ic
_l
up
us
_e
ry
th
…
Ps
or
ia
sis
M
yo
ca
rd
ia
l_
in
fa
rc
tio
n …
Difference in AUC between I‐Model and M‐
Model
Difference in AUC between I‐
Model and M‐Model
102 
 
other hand, the M-Model’s discriminative power decreased for Type 2 diabetes by 4% on 
parameterization with the clinical data.  
Compare the IsBIG Models (I-Model and M-Model) to the C-Model 
As expected, overall the C-Model derived from clinical data from our EMR 
outperformed the IsBIG models (Figure 5-4). The C-Model was able to discriminate 31 
diseases when compared to 5 and 12 diseases in the I-Model and the M-Model 
respectively. Furthermore, the AUCs of the C-Model were much bigger (p < 0.05) for all 
but one of the statistically significant diseases common in both the IsBIG models. The C-
Model had the same AUC for Systemic Lupus Erythematosus (or SLE) as in the M-
Model (p = 0.4095). Interestingly, the difference in AUCs for the early Myocardial 
infarction node between the M-Model and the C-Model was very small (~0.02) but it was 
statistically significant (p = 5.3 x 10-6), i.e. the discriminative powers of the two DAGs 
were very different.  
 
Figure 5-4 AUC comparison of models 
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Compare the I-Model against PubMed Literature searches 
We evaluated 117 direct pair wise (parent-child) associations (Appendix A.4) in the 
I-Model against the PubMed database literature searches. Twenty (17%) of the pair wise 
associations in the I-Model had no references in the literature and can be possibly 
considered novel. At least 1 of these associations (Rheumatoid Arthritis with Systemic 
Lupus Erythematosus) was also found in direct pair wise associations in the C-Model 
(Table 5-4).   
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Table 5-4 Novel Associations in IsBIG Model (I-Model)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** Also found in clinical model (C-Model) 
Compare I-Model pair wise associations to C-Model pair wise associations 
Of the 117 direct pair wise disease associations in the I-Model, 27 (23%) 
associations were also found in direct pair wise disease associations in the C-Model 
Table 5-5 below lists these associations. 
  
   Disease Node 1  Disease Node 2
***1  Rheumatoid arthritis  Systemic lupus erythematosus 
2  AIDS progression  Crohn’s disease
3  Glioma  Crohn’s disease
4  Glioma  Primary biliary cirrhosis
5  Glioma  Myeloproliferative neoplasms 
6  Intracranial aneurysm Crohn’s disease
7  Intracranial aneurysm Inflammatory bowel disease 
8  LDL cholesterol (Elevated) Crohn’s disease
9  Myeloproliferative neoplasms Colorectal cancer
10  Myeloproliferative neoplasms Crohn’s disease
11  Myeloproliferative neoplasms AIDS progression
12  Myeloproliferative neoplasms Primary biliary cirrhosis
13  Myeloproliferative neoplasms Asthma
14  Myocardial infarction  early  Crohn’s disease
15  Primary biliary cirrhosis Crohn’s disease
16  Primary biliary cirrhosis Colorectal cancer
17  Primary biliary cirrhosis Prostate cancer
18  Systemic lupus erythematosus Crohn’s disease
19  Systemic lupus erythematosus Primary biliary cirrhosis
20  Systemic lupus erythematosus Myeloproliferative neoplasms 
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Table 5-5 Associations common in IsBIG Model with C-Model  
(with literature reference count) 
 
   Disease Node 1  Disease Node 2
PubMED 
Ref count
1  Rheumatoid arthritis Systemic lupus erythematosus  0 
2  Coronary disease  Crohn’s disease 1 
3  LDL cholesterol (Elevated) AIDS progression 4 
4  Coronary disease  Glioma 5 
5  Asthma  AIDS progression 6 
6  Myocardial infarction  early  AIDS progression 9 
7  LDL cholesterol (Elevated) Glioma 11
8  LDL cholesterol (Elevated) Inflammatory bowel disease  12
9  Glioma  Asthma 24
10  Crohn’s disease  Ulcerative colitis 32
11  Inflammatory bowel disease Crohn’s disease 33
12  LDL cholesterol (Elevated) Psoriasis 33
13  LDL cholesterol (Elevated) Myocardial infarction  early   35
14  Myocardial infarction  early  Inflammatory bowel disease  38
15  Coronary disease  AIDS progression 50
16  Chronic Obstructive Pulmonary Lung cancer 51
17  Coronary disease  Inflammatory bowel disease  51
18  Coronary disease  Psoriasis 66
19  LDL cholesterol (Elevated) Coronary disease 160
20  Multiple sclerosis  Asthma 233
21  Asthma  Psoriasis 261
22  Inflammatory bowel disease Ulcerative colitis 262
23  Asthma  Inflammatory bowel disease  271
24  Obesity  Type 2 diabetes 320
25  Rheumatoid arthritis Asthma 894
26  Schizophrenia  Type 1 diabetes 931
27  Myocardial infarction  early  Coronary disease 54128
 
Literature Ref count of pair wise associations in I-Model (also found in C-Model) 
Of the 27 pair wise disease associations in the I-Model that were also found in the 
C-Model, 1 (4%) association had no literature reference, 5 (19%) had up to 10 references. 
These disease associations can be possibly considered as worth exploring further in future 
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studies. Additionally, 9 (33%) associations had only up to 50 references. The details are 
listed in Figure 5-4 below and Table 5-5 above.  
  
Figure 5-5 Reference count of IsBIG associations also found in C-Model 
 
Discussion 
We have described our IsBIG methodology and applied it to combine statistical 
correlations between SNPs and GWAS to generate a disease map of common diseases, 
the IsBIG model as inferred from genetic underpinnings. We evaluated the model against 
both raw clinical data and published literature.  
Our results show that IsBIG discovered disease-disease associations are valid.  
We tested this by training the IsBIG DAG with RMRS data and found that IsBIG 
correctly found 33% of the diseases in the M-Model; and of the associations found by 
IsBIG, 80% of them were confirmed in the M-Model. This essentially means that for the 
4 diseases or traits (Coronary Disease, Elevated LDL Cholesterol, Lung Cancer and 
Obesity) predictable by IsBIG, there is discriminative power in the model as inferred by 
genetic variations alone in the population. We also found that the IsBIG model has the 
same discriminative power for early detection of Myocardial Infarction as the same 
model trained on clinical data (i.e. M-Model).  
# of Associations in both PubMED 
and C‐Model
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IsBIG can discover novel disease-disease associations that have not been 
described.  We compared disease-disease associations to the PubMed database and found 
that many had never been described.  We believe these associations can be considered as 
hypotheses for future studies. Furthermore, we were able to confirm some of them in the 
clinical model (C-Model). At least one pair wise disease association (Rheumatoid 
arthritis and Systemic lupus Erythematosus) found by IsBIG had no reference in the 
literature and can be considered novel, and further, it can be confirmed by the C-Model 
derived from our EMR data. 
Finally, our results show that probabilistic methods can extract data from 
disparate sources and combine them in a normative way such that it correlates with what 
we may empirically find in an EMR.  Only a fraction of associations among diseases 
found in an EMR can be explained by genetics of SNP to disease linkage. We compared 
the AUCs of IsBIG and the C-Model and found that the C-Model AUCs were much 
bigger. Therefore, genetic data alone can only explain a small fraction of the risk of a 
disease.   
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Chapter 6  DISCUSSION 
 
Summary of findings 
In this work, we formed a methodology which we call In-silico Bayesian 
Integration, to integrate data from disparate sources using probabilistic modeling 
methods, specifically the Bayesian Network framework. We demonstrated that this 
methodology can combine information in a normative way and that the results can be 
validated against real world datasets from our EMR. Additionally, we demonstrated that 
the model built using this methodology discovers new knowledge that can be used as 
hypotheses for future studies.   
As an example of our approach, we combined two disparate sources – the genetic 
linkages (associations) found between Single Nucleotide Polymorphisms (SNP) in the 
human genome and the effect size linking a SNP with a disease or a trait found in 
Genome Wide Association Studies (GWAS). We call this model In-silico Bayesian 
Integration of GWAS (or IsBIG). IsBIG produces a map of disease-disease associations 
as inferred from their genetic underpinnings.  
Seventeen percent of disease-disease associations found by the IsBIG model are not 
described in the literature and can be considered novel, with at least one association 
confirmed in our EMR. Furthermore, our results show that IsBIG finds meaningful 
associations that can be empirically validated against our EMR. The IsBIG model is 33% 
sensitive, 94% specific and has a positive predictive value of 80% when we evaluate its 
discriminative power compared to our EMR data. We found from this evaluation that 
GWA studies in the domain of Obesity, Type 2 Diabetes, elevated LDL Cholesterol trait, 
Lung cancer and Coronary Disease have signal to detect effect of genetic variations to 
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disease likelihood in our clinical population and may have potential clinical applications. 
By generating a predictive distribution of disease-disease associations, the IsBIG model 
has also quantified that the simple linking of genetics to a disease only explains a fraction 
of the risk of disease in our EMR. 
Summary of contributions 
Applying Bayesian Networks to the real world task of integrating data from 
disparate sources required the use of causal independence assumptions (Independence of 
Causal Influence models, ICI) particularly the Noisy-OR model. Our empiric evaluations 
of the BN framework with ICI model using large datasets from our EMR produced 
comparable results to that of an expert. Therefore, in this research we have demonstrated 
that ICI models provide a successful strategy for computing conditional distributions of a 
large BN with many linked nodes in a tractable way. We believe the use of ICI models, 
particularly the use of Noisy-OR model seems to be robust under a broad range of 
conditions. To the best of our knowledge, this has not been demonstrated before, 
especially in the biomedical field.  
Additionally, we have also shown that the use of Noisy-OR model provides a 
successful strategy for combining disparate sources, where individual conditional 
distributions can be computed from effect sizes and statistical correlations. We have 
demonstrated it by utilizing odds ratios and correlation and partial correlation coefficients 
as strategies to translate genetic data from published GWAS into conditional probability 
distributions for disease associations. This has not been demonstrated before to the best 
of our knowledge. 
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There is no analytic method, to the best of our knowledge, which computationally 
combines disparate source of both raw data and summary measures in a quantitative 
framework. Applications of text mining using ontology [97] and more recently 
applications of semantic web technology coupled with graph algorithms [98] have been 
used to find associations between biological entities from different sources of 
information. However, they rely on purely qualitative associations; i.e. subject-predicate-
object relationships, for example, drug A may cause symptom B sometimes is 
represented by a triplet such as <A causes B>. However this representation does not 
account for the uncertainty (“may”) in the assertion.  The knowledge that the relationship 
between A and B exists say 2% of the times is not represented in this framework. Such 
frameworks lay out a graph of the associations but do not produce predictive distributions 
of these associations. On the other hand, quantitative methods such as meta-analysis of 
studies are able to give more precise estimates of the effect size by pooling effect sizes 
from a number of studies under assumptions, but they are not a computational model that 
can be used for future inference. They also do not permit for additional information to be 
incorporated as it becomes available. Other quantitative methods, in particular data 
mining methods which are computational and can generate predictive distributions, 
require a large numbers of cases for model building, training and testing. These datasets 
seldom exist in the biomedical domain for use in hypotheses generation tools. 
Therefore, due to the lack of these original datasets, in this work, we have 
developed a quantitative method using Bayesian Networks framework to combine both 
raw data and summary measures in a computational model. The method is able to 
discover new associations from disparate sources and is able to produce predictive 
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distributions for these associations. It is also able to incorporate new information as it 
becomes available.  Our evaluation of this method shows correlation to large real world 
datasets.  
On Use of Causal Independence Assumption (Noisy-OR) 
The Bayesian network framework does not constrain how a variable depends 
upon its parents. One interpretation is that the directed edges or arcs represent causal 
relationships among the parent and the child.  Thus the local structure encodes the 
dependencies and probability distributions of parent and child (conditioned upon 
parents). The probability distribution of the child node can be approximated assuming 
causal independence among the parents using a boolean function such as OR, but since 
the parent-child relationship is probabilistic, the relationship is “noisy”.   
The underlying assumption in this situation is that each parent acts independently 
as a cause to the child (effect) with an independent mechanism of action, and each parent 
can sufficiently cause the effect. In the absence of any parent, there is no effect, unless 
we assume a leaky model.   
Without the causal independence assumption, we had no way of combining the 
SNP’s effect size to a disease. These assumptions allowed us to combine the contribution 
of each existing cause (SNP) to the effect (disease) with fewer calculations then the 
calculations for full conditional probability distribution. Additionally they allowed the 
flexibility of tractably adding new causes in the future. It is these capabilities of Noisy-
OR that we exploited in this research to combine information (data or statistical 
summaries) in a causal (normative) way.  
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Limitations 
One of the limitations of our methodology is the approximation of the underlying 
data – we modeled only discrete variables. This assumption allowed us to compute 
conditional probability tables (CPTs) using a boolean function such as OR in the Noisy-
OR calculations. For this research, the boolean function “OR” and discrete data fitted our 
assumption of the real world datasets but may not hold true for other datasets. In future 
studies, there may be disparate sets that may need combinations of other boolean 
functions such as AND or XOR, besides OR. Nonetheless, similar methodology can be 
applied in such situations by replacing the Noisy-OR calculations with the one that fits 
the datasets. For example, if we make the assumption that both genetics and environment 
lead to a disease status, we may want to model it using a Noisy AND. For modeling 
continuous variables, methods similar to Monte Carlo simulations [99] assuming a-priori 
probability distributions can be applied. 
Another assumption in this study is that effect sizes or correlations are defined for 
one variable to the outcome variable. When using effect sizes (such as odds ratio) to link 
two different BNs to calculate CPTs, we are assuming the effect is attributable to a single 
variable.  For example, for the IsBIG study, it is the odds ratio or strength of association 
of single allele to the disease or trait in the study.  There may be situations, where this 
assumption does not hold true.  The effect size could result from more than one variable.  
For example, two copies of a specific allele may produce more than an additive effect as 
is the case in recessive traits.  In those situations, assuming causal independence between 
the two causal variables (for e.g. between alleles) and the outcome variable will not be 
justified.  
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Lastly, though the IsBIG study illustrated how disparate datasets, summary or 
statistical measures from different sources can be combined. However, the information in 
both the sources belonged to a similar population (i.e. European Ancestry).  We propose 
that as a variable, such as the LD measure, varies by a sub-population, this should be 
accounted for in the model when disparate sources are combined. 
Future Directions 
We believe our methodology has been successfully applied in integrating sub 
domains, especially in the biomedical domain and has many practical applications. We 
envision that using this method secondary data sources such as summary and statistical 
data from published sources can be merged with data from primary sources such as 
electronic health records to provide a  more normative and quantitative evaluation of the 
domain.  
We are envisioning one such application of this method for dynamic prioritization 
of the reminder prompts in our CHICA system. [59] CHICA’s static, global prioritization 
scheme limits the flexibility of the system by evaluating the predetermined prompts for 
primary care alerts from a set of guidelines for a specific age group.  At present there are 
many such guidelines and recommendations. [100-104] We plan to use Bayesian 
networks (BN) as a strategy for modeling a patient’s clinical status with the idea of 
calculating the expected value of making alternative recommendations to physicians in 
order to tailor prioritization to the patient, [63] using the research in this thesis. 
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APPENDICES 
Appendix A.1 Summary of Studies from GWAS Catalog  
Disease/Trait  Number of Studies 
Type 2 diabetes 67
Type 1 diabetes 62
Crohn's disease  61
Bipolar disorder  43
Multiple sclerosis  41
Prostate cancer 37
Amyotrophic lateral sclerosis  28
Rheumatoid arthritis  24
Schizophrenia  24
Ulcerative colitis  19
Acute lymphoblastic leukemia (childhood) 17
Breast cancer  16
Lung cancer  16
Colorectal cancer  15
Parkinson's disease  14
Smoking behavior  14
Obesity (extreme)  13
Psoriasis  12
Response to treatment for acute lymphoblastic 
leukemia  12
Systemic lupus erythematosus 12
Coronary disease  11
Celiac disease  10
Myocardial infarction (early onset) 9
Nonsyndromic cleft lip with or without cleft palate 9
Inflammatory bowel disease  8
AIDS  7
Alzheimer's disease  7
Glioma  7
Response to citalopram treatment 7
Alcohol dependence  6
Chronic lymphocytic leukemia 6
Drug‐induced liver injury (flucloxacillin) 6
Melanoma  6
Restless legs syndrome  6
Testicular germ cell tumor  6
Type 2 diabetes and other traits 6
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Atrial fibrillation  5
Blond vs. brown hair color  5
Hypertension  5
Lung adenocarcinoma  5
Obesity  5
Primary biliary cirrhosis  5
Stroke  5
Blue vs. green eyes  4
Coronary artery disease  4
Freckles  4
Inflammatory bowel disease (early onset) 4
Intracranial aneurysm  4
Autism  3
Exercise (leisure time)  3
Glioma (high‐grade)  3
Male‐pattern baldness  3
Skin pigmentation  3
Skin sensitivity to sun  3
Alzheimer's disease (late onset) 2
Arthritis (juvenile idiopathic)  2
Asthma  2
Atrial fibrillation/atrial flutter  2
Basal cell carcinoma (cutaneous) 2
Chronic Obstructive Pulmonary Disease 2
Kawasaki disease  2
Knee osteoarthritis  2
Left ventricular mass  2
Nicotine dependence  2
Response to Hepatitis C treatment 2
Thyroid cancer  2
Urinary bladder cancer  2
Age‐related macular degeneration 1
Age‐related macular degeneration (wet) 1
AIDS progression  1
Asthma (childhood onset)  1
Atopic dermatitis  1
Atopy  1
Bladder cancer  1
Blue vs. brown eyes  1
Burning and freckling  1
Crohn's disease and Sarcoidosis (combined) 1
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Diabetic nephropathy  1
Disease/Trait  1
End‐stage renal disease  1
Essential tremor  1
Follicular lymphoma  1
Gallstones  1
Glaucoma (exfoliation)  1
Height  1
Ischemic stroke  1
Kidney stones  1
LDL cholesterol  1
Major depressive disorder  1
Myeloproliferative neoplasms 1
Myocardial infarction  1
Narcolepsy  1
Neuroblastoma  1
Neuroblastoma (high‐risk)  1
Neuroticism  1
Obesity (early onset extreme) 1
Osteonecrosis of the jaw  1
Otosclerosis  1
Ovarian cancer  1
Pancreatic cancer  1
Parkinson's disease (familial)  1
Periodontitis  1
QT interval prolongation  1
Red vs. non‐red hair color  1
Red vs. non‐red hair color  1
Renal function and chronic kidney disease 1
Response to antipsychotic treatment 1
Response to statin therapy  1
Response to ximelagatran treatment 1
Testicular cancer  1
Venous thromboembolism  1
  807
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Appendix A.2 AUC and p-values in IsBIG model (I-Model) 
  Node  AUC p‐value 
1  Coronary Disease  0.6856 0 
2  Lung cancer  0.6263 0 
3  LDL  0.5823 0 
4  Type 2 Diabetes  0.5431 0 
5  Obesity  0.5192 4.73E‐09 
6  AIDS Progression  0.4917 0.234547 
7  Psoriasis  0.4976 0.351112 
8  Asthma  0.4998 0.470214 
9  MI_Early  0.5 0.5 
10  SLE  0.5 0.5 
11  Type 1 Diabetes  0.5 0.5 
12  Prostate Cancer  0.5 0.5 
13  RA  0.5 0.5 
14  COPD  0.5 0.5 
15  Ulcerative Colitis  0.5 0.5 
16  Testicular cancer  0.5 0.5 
17  Schizophrenia  0.5 0.5 
19  Primary Biliary Cirrhosis  0.5 0.5 
19  Myeloproliferative Neoplasms 0.5 0.5 
20  Melanoma 0.5 0.5 
21  Intracranial Aneurysm  0.5 0.5 
22  Inflammatory Bowel Disease 0.5 0.5 
23  Crohn’s Disease  0.5 0.5 
24  Colorectal cancer  0.5 0.5 
25  Celiac Disease  0.5 0.5 
26  Autism  0.5 0.5 
27  Atrial Fibrillation  0.5 0.5 
28  Multiple Sclerosis  0.5 0.5 
29  Glioma  0.4703 0.13301 
118 
 
Appendix A.3 AUC and p-values in Mixed model (M-Model) 
  Node  AUC p‐value 
1  Myocardial Infarction Early 0.937 0 
2  Coronary Disease  0.7318 0 
3  Psoriasis  0.6343 0 
4  Lung cancer  0.6263 0 
5  Systemic  Lupus  Erythematosus 0.5947 2.08E‐06 
6  LDL Cholesterol Elevated  0.5945 0 
7  Rheumatoid Arthritis  0.5871 0 
8  Chronic Obstructive Pulmonary Disorder 0.533 1.2E‐10 
9  Asthma  0.5274 0 
10  AIDS Progression  0.522 0.029809 
11  Obesity  0.5192 4.73E‐09 
12  Type 1 Diabetes  0.5098 0.038912 
13  Type 2 Diabetes  0.5025 0.30807 
14  Prostate Cancer  0.5012 0.476679 
15  Ulcerative Colitis  0.5 0.5 
16  Testicular cancer  0.5 0.5 
17  Schizophrenia  0.5 0.5 
18  Primary Biliary Cirrhosis  0.5 0.5 
19  Myeloproliferative Neoplasms 0.5 0.5 
20  Melanoma  0.5 0.5 
21  Intracranial Aneurysm  0.5 0.5 
22  Inflammatory Bowel Disease 0.5 0.5 
23  Crohn’s Disease  0.5 0.5 
24  Colorectal cancer  0.5 0.5 
25  Celiac Disease  0.5 0.5 
26  Autism  0.5 0.5 
27  Atrial Fibrillation  0.5 0.5 
28  Multiple Sclerosis  0.4987 0.479927 
29  Glioma  0.4958 0.438703 
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Appendix A.4 AUC and p-value in Clinical Model (C-Model)  
 Node AUC p-value 
1 Crohn’s Disease 0.9985 0 
2 Ulcerative Colitis 0.9969 0 
3 Myocardial  Infarction Early 0.9568 0 
4 Coronary Disease 0.8906 0 
5 Type 1 Diabetes 0.8766 0 
6 Schizophrenia 0.862 0 
7 Type 2 Diabetes 0.8581 0 
8 Atrial Fibrilliation 0.8577 0 
9 Asthma 0.853 0 
10 LDL Cholesterol Elevated 0.8392 0 
11 Bipolar 0.8268 0 
12 Chronic Obstructive Pulmonary Disorder 0.8192 0 
13 Obesity 0.8034 0 
14 Nicotine Dependence 0.8013 0 
15 Psoriasis 0.7947 0 
16 Lung cancer 0.788 0 
17 Breast cancer 0.7805 0 
18 Ischemic Stroke 0.7603 0 
19 Autism 0.7501 0 
20 AIDS Progression 0.7423 0 
21 Venous thromboembolism 0.7239 0 
22 Colorectal Cancer 0.7051 0.001966 
23 Knee osteoarthritis 0.7003 0 
24 Rheumatoid Arthritis 0.6908 0 
25 Prostate Cancer 0.6702 0 
26 Glioma 0.6546 2.29E-08 
27 Restless Leg Syndrome 0.6241 0.000132 
28 Testicular cancer 0.6139 0.001118 
29 Systemic Lupus Erythematosus 0.6 5.93E-07 
30 Intracranial Aneurysm 0.5884 0.006792 
31 Pancreatic Cancer 0.5757 0.005877 
32 Follicular Lymphoma 0.5526 0.122542 
33 Myeloproliferative Neoplasms 0.5433 0.111934 
34 Melanoma 0.5268 0.173608 
35 Acute Leukemia 0.5 0.5 
36 Otosclerosis 0.5 0.5 
37 Celiac Disease 0.5 0.5 
38 Chronic Leukemia 0.5 0.5 
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39 IBD 0.5 0.5 
40 Multiple Sclerosis 0.5 0.5 
41 Parkinson 0.5 0.5 
42 Primary Biliary Cirrhosis 0.5 0.5 
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Appendix A.5 Relationships evaluated in IsBIG Model (I-Model) 
   Disease Node 1  Disease Node 2
Lit 
Ref 
 count 
RMRS 
Eval
1  Rheumatoid arthritis  Systemic lupus erythematosus  0  Yes
2  AIDS progression  Crohn s disease 0  No
3  Glioma  Crohn s disease 0  No
4  Glioma  Primary biliary cirrhosis 0  No
5  Glioma  Myeloproliferative neoplasms  0  No
6  Intracranial aneurysm  Crohn s disease 0  No
7  Intracranial aneurysm  Inflammatory bowel disease 0  No
8  LDL cholesterol (Elevated) Crohn s disease 0  No
9  Myeloproliferative neoplasms Colorectal cancer 0  No
10  Myeloproliferative neoplasms Crohn s disease 0  No
11  Myeloproliferative neoplasms AIDS progression 0  No
12  Myeloproliferative neoplasms Primary biliary cirrhosis 0  No
13  Myeloproliferative neoplasms Asthma 0  No
14  Myocardial infarction  early  Crohn s disease 0  No
15  Primary biliary cirrhosis Crohn s disease 0  No
16  Primary biliary cirrhosis Colorectal cancer 0  No
17  Primary biliary cirrhosis Prostat cancer 0  No
18  Systemic lupus erythematosus Crohn s disease 0  No
19  Systemic lupus erythematosus Primary biliary cirrhosis 0  No
20  Systemic lupus erythematosus Myeloproliferative neoplasms  0  No
21  Coronary disease  Crohn’s disease 1  Yes
22  Asthma   Crohn’s disease 1  No
23  Intracranial aneurysm  Psoriasis 1  No
24  Intracranial aneurysm  AIDS progression 1  No
25  Myeloproliferative neoplasms Psoriasis 1  No
26  Primary biliary cirrhosis AIDS progression 1  No
27  Psoriasis   Crohn’s disease 1  No
28  Glioma  AIDS progression 2  No
29  Myeloproliferative neoplasms Prostat cancer 2  No
30  Myeloproliferative neoplasms Ulcerative colitis 2  No
31  AIDS progression  Ulcerative colitis 3  No
32  Glioma  Psoriasis 3  No
33  Myeloproliferative neoplasms Inflammatory bowel disease 3  No
34  LDL cholesterol (Elevated) AIDS progression 4  Yes
35  Glioma  Ulcerative colitis 4  No
36  Glioma  Inflammatory bowel disease 4  No
37  Intracranial aneurysm  Ulcerative colitis 4  No
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38  Rheumatoid arthritis   Crohn’s disease 4  No
39  Coronary disease  Glioma 5  Yes
40  Colorectal cancer   Crohn’s disease 5  No
41  Intracranial aneurysm  LDL cholesterol (Elevated) 5  No
42  Asthma  AIDS progression 6  Yes
43  Colorectal cancer  AIDS progression 6  No
44  Myocardial infarction  early  Glioma 7  No
45  Systemic lupus erythematosus AIDS progression 8  No
46  Myocardial infarction  early  AIDS progression 9  Yes
47  Prostate cancer  AIDS progression 10  No
48  LDL cholesterol (Elevated) Glioma 11  Yes
49  Asthma  Primary biliary cirrhosis 11  No
50  Colorectal cancer  Psoriasis 11  No
51  Glioma  Systemic lupus erythematosus  11  No
52  Intracranial aneurysm  Prostat cancer 11  No
53  LDL cholesterol (Elevated) Ulcerative colitis 11  No
54  LDL cholesterol (Elevated) Inflammatory bowel disease 12  Yes
55  AIDS progression  Psoriasis 12  No
56  AIDS progression  Inflammatory bowel disease 12  No
57  Prostate cancer  Psoriasis 15  No
58  Celiac disease  Type 1 diabetes 17  No
59  Multiple sclerosis  Systemic lupus erythematosus  17  No
60  Primary biliary cirrhosis Psoriasis 19  No
61  Prostate cancer  Ulcerative colitis 23  No
62  Glioma  Asthma 24  Yes
63  Prostate cancer  Inflammatory bowel disease 28  No
64   Crohn’s disease  Ulcerative colitis 32  Yes
65  Inflammatory bowel disease  Crohn’s disease 33  Yes
66  LDL cholesterol (Elevated) Psoriasis 33  Yes
67  Multiple sclerosis  Primary biliary cirrhosis 33  No
68  LDL cholesterol (Elevated) Myocardial infarction  early  35  Yes
69  Myocardial infarction  early  Inflammatory bowel disease 38  Yes
70  Intracranial aneurysm  Colorectal cancer 41  No
71  Myocardial infarction  early  Ulcerative colitis 47  No
72  Coronary disease  AIDS progression 50  Yes
73  Chronic Obstructive Pulmonary Lung cancer 51  Yes
74  Coronary disease  Inflammatory bowel disease 51  Yes
75  Multiple sclerosis  Rheumatoid arthritis 58  No
76  Coronary disease  Psoriasis 66  Yes
77  Celiac disease  Asthma 66  No
78  Celiac disease  Multiple sclerosis 68  No
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79  Glioma  Colorectal cancer 68  No
80  Schizophrenia  Celiac disease 71  No
81  Inflammatory bowel disease Psoriasis 80  No
82  Myocardial infarction  early  Psoriasis 82  No
83  Celiac disease  Primary biliary cirrhosis 86  No
84  Celiac disease  Systemic lupus erythematosus  96  No
85  Type 1 diabetes  Primary biliary cirrhosis 100  No
86  Intracranial aneurysm  Coronary disease 104  No
87  Intracranial aneurysm  Glioma 110  No
88  Intracranial aneurysm  Myocardial infarction  early  117  No
89  Primary biliary cirrhosis Inflammatory bowel disease 117  No
90  Intracranial aneurysm  Type 2 diabetes 137  No
91  Glioma  Prostat cancer 138  No
92  Primary biliary cirrhosis Ulcerative colitis 145  No
93  Coronary disease  Ulcerative colitis 151  No
94  LDL cholesterol (Elevated) Coronary disease 160  Yes
95  Intracranial aneurysm  Systemic lupus erythematosus  166  No
96  Celiac disease  Rheumatoid arthritis 178  No
97  Systemic lupus erythematosus Inflammatory bowel disease 182  No
98  Rheumatoid arthritis  Primary biliary cirrhosis 184  No
99  Psoriasis  Ulcerative colitis 201  No
100  Systemic lupus erythematosus Ulcerative colitis 207  No
101  Multiple sclerosis  Asthma 233  Yes
102  Asthma  Ulcerative colitis 238  No
103  Asthma  Psoriasis 261  Yes
104  Inflammatory bowel disease Ulcerative colitis 262  Yes
105  Asthma  Inflammatory bowel disease 271  Yes
106  Obesity  Type 2 diabetes 320  Yes
107  Systemic lupus erythematosus Psoriasis 521  No
108  Prostate cancer  Colorectal cancer 882  No
109  Rheumatoid arthritis  Asthma 894  Yes
110  Type 1 diabetes  Systemic lupus erythematosus  894  No
111  Schizophrenia  Type 1 diabetes 931  Yes
112  Colorectal cancer  Ulcerative colitis 1019  No
113  Type 1 diabetes  Multiple sclerosis 1032  No
114  Type 1 diabetes  Rheumatoid arthritis 1990  No
115  Intracranial aneurysm  Myeloproliferative neoplasms  4126  No
116  Colorectal cancer  Inflammatory bowel disease 37538  No
117  Myocardial infarction  early  Coronary disease 54128  Yes
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Appendix A.6 Input to the IsBIG Algorithm for constructing I-Model 
  SNP1   SNP2
LD 
(r2)
SNP1 
OR
SNP2 
OR
SNP1 
RAF 
SNP2 
RAF 
1  rs564398  rs1412829 0.983 1.13 1.42 0.56  0.39 
2  rs11190140  rs10883365 0.983 1.2 1.18 0.48  0.48 
3  rs11190140  rs10883365 0.983 1.2 1.2 0.48  0.48 
4  rs10883365  rs11190140 0.983 1.18 1.2 0.48  0.48 
5  rs10883365  rs11190140 0.983 1.2 1.2 0.48  0.48 
6  rs1412829  rs564398 0.983 1.42 1.13 0.39  0.56 
7  rs4263839  rs6478109 0.982 1.22 1.36 0.68  0.69 
8  rs6478109  rs4263839 0.982 1.36 1.22 0.69  0.68 
9  rs6074022  rs4810485 0.977 1.2 1.15 0.25  0.25 
10  rs4810485  rs6074022 0.977 1.15 1.2 0.25  0.25 
11  rs13277113  rs2736340 0.976 1.39 1.19 0.23  0.24 
12  rs2736340  rs13277113 0.976 1.19 1.39 0.24  0.23 
13  rs3135388  rs9271366 0.974 2.75 2.78 0.22  0.15 
14  rs3135388  rs9271366 0.974 1.99 2.78 0.23  0.15 
15  rs9271366  rs3135388 0.974 2.78 2.75 0.15  0.22 
16  rs9271366  rs3135388 0.974 2.78 1.99 0.15  0.23 
17  rs2981582  rs1219648 0.966 1.26 1.2 0.38  0.4 
18  rs7931342  rs10896449 0.966 1.19 1.1 0.51  0.52 
19  rs2241880  rs10210302 0.966 1.45 1.19 0.55  0.48 
20  rs10210302  rs2241880 0.966 1.19 1.45 0.48  0.55 
21  rs1219648  rs2981582 0.966 1.2 1.26 0.4  0.38 
22  rs10896449  rs7931342 0.966 1.1 1.19 0.52  0.51 
23  rs1335532  rs2300747 0.964 1.28 1.3 0.87  0.88 
24  rs2300747  rs1335532 0.964 1.3 1.28 0.88  0.87 
25  rs4506565  rs7901695 0.96 1.36 1.37 0.32  NR 
26  rs7901695  rs4506565 0.96 1.37 1.36 NR  0.32 
27  rs6931514  rs7756992 0.958 1.25 1.2 NR  0.26 
28  rs7756992  rs6931514 0.958 1.2 1.25 0.26  NR 
29  rs3197999  rs9858542 0.956 1.2 1.17 0.27  0.29 
30  rs3197999  rs9858542 0.956 1.2 1.09 0.27  0.28 
31  rs9858542  rs3197999 0.956 1.17 1.2 0.29  0.27 
32  rs9858542  rs3197999 0.956 1.09 1.2 0.28  0.27 
33  rs9941349  rs1121980 0.95 1.48 1.66 0.43  0.41 
34  rs907092  rs2872507 0.95 1.29 1.12 0.45  0.47 
35  rs2872507  rs907092 0.95 1.12 1.29 0.47  0.45 
36  rs1121980  rs9941349 0.95 1.66 1.48 0.41  0.43 
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37  rs11755527  rs3757247 0.949 1.13 1.13 0.47  NR 
38  rs3757247  rs11755527 0.949 1.13 1.13 NR  0.47 
39  rs477515  rs2395185 0.948 1.38 1.52 0.69  0.67 
40  rs2395185  rs477515 0.948 1.52 1.38 0.67  0.69 
41  rs2903692  rs12708716 0.941 1.54 1.19 0.62  0.65 
42  rs2903692  rs12708716 0.941 1.54 1.23 0.62  0.68 
43  rs12708716  rs2903692 0.941 1.19 1.54 0.65  0.62 
44  rs12708716  rs2903692 0.941 1.23 1.54 0.68  0.62 
45  rs2201841  rs10889677 0.94 1.13 1.29 0.3  0.3 
46  rs10889677  rs2201841 0.94 1.29 1.13 0.3  0.3 
47  rs3764021  rs11052552 0.933 1.57 1.49 0.47  0.49 
48  rs11052552  rs3764021 0.933 1.49 1.57 0.49  0.47 
49  rs3828309  rs2241880 0.932 1.25 1.45 0.53  0.55 
50  rs2241880  rs3828309 0.932 1.45 1.25 0.55  0.53 
51  rs10210302  rs3828309 0.932 1.19 1.25 0.48  0.53 
52  rs8050136  rs1421085 0.932 1.3 1.39 NR  0.4 
53  rs8050136  rs1421085 0.932 1.17 1.39 0.38  0.4 
54  rs8050136  rs1421085 0.932 1.23 1.39 0.4  0.4 
55  rs8050136  rs1421085 0.932 1.15 1.39 NR  0.4 
56  rs3828309  rs10210302 0.932 1.25 1.19 0.53  0.48 
57  rs1421085  rs8050136 0.932 1.39 1.3 0.4  NR 
58  rs1421085  rs8050136 0.932 1.39 1.17 0.4  0.38 
59  rs1421085  rs8050136 0.932 1.39 1.23 0.4  0.4 
60  rs1421085  rs8050136 0.932 1.39 1.15 0.4  NR 
61  rs2814707  rs3849942 0.931 1.22 1.23 0.23  0.23 
62  rs3849942  rs2814707 0.931 1.23 1.22 0.23  0.23 
63  rs7903146  rs4506565 0.921 1.38 1.36 0.3  0.32 
64  rs7903146  rs4506565 0.921 1.31 1.36 NR  0.32 
65  rs7903146  rs4506565 0.921 1.49 1.36 NR  0.32 
66  rs7903146  rs4506565 0.921 1.71 1.36 NR  0.32 
67  rs7903146  rs4506565 0.921 1.34 1.36 0.18  0.32 
68  rs7903146  rs4506565 0.921 1.38 1.36 0.26  0.32 
69  rs7903146  rs4506565 0.921 1.65 1.36 0.3  0.32 
70  rs7903146  rs4506565 0.921 1.37 1.36 NR  0.32 
71  rs7903146  rs4506565 0.921 1.48 1.36 0.27  0.32 
72  rs4506565  rs7903146 0.921 1.36 1.48 0.32  0.27 
73  rs4506565  rs7903146 0.921 1.36 1.38 0.32  0.3 
74  rs4506565  rs7903146 0.921 1.36 1.31 0.32  NR 
75  rs4506565  rs7903146 0.921 1.36 1.49 0.32  NR 
76  rs4506565  rs7903146 0.921 1.36 1.71 0.32  NR 
77  rs4506565  rs7903146 0.921 1.36 1.34 0.32  0.18 
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78  rs4506565  rs7903146 0.921 1.36 1.38 0.32  0.26 
79  rs4506565  rs7903146 0.921 1.36 1.65 0.32  0.3 
80  rs4506565  rs7903146 0.921 1.36 1.37 0.32  NR 
81  rs7901695  rs7903146 0.919 1.37 1.34 NR  0.18 
82  rs7901695  rs7903146 0.919 1.37 1.38 NR  0.26 
83  rs7901695  rs7903146 0.919 1.37 1.65 NR  0.3 
84  rs7901695  rs7903146 0.919 1.37 1.37 NR  NR 
85  rs7901695  rs7903146 0.919 1.37 1.48 NR  0.27 
86  rs4474514  rs995030 0.919 3.07 2.55 NR  0.8 
87  rs4474514  rs995030 0.919 3.07 2.69 NR  0.83 
88  rs995030  rs4474514 0.919 2.55 3.07 0.8  NR 
89  rs995030  rs4474514 0.919 2.69 3.07 0.83  NR 
90  rs599839  rs646776 0.917 1.29 1.19 0.23  0.81 
91  rs599839  rs646776 0.917 0.95 1.19 0.24  0.81 
92  rs646776  rs599839 0.917 1.19 1.29 0.81  0.23 
93  rs646776  rs599839 0.917 1.19 0.95 0.81  0.24 
94  rs2981579  rs1219648 0.916 1.17 1.2 0.41  0.4 
95  rs1219648  rs2981579 0.916 1.2 1.17 0.4  0.41 
96  rs1000113  rs11747270 0.905 1.54 1.33 0.07  0.09 
97  rs11209026  rs11465804 0.905 2.92 2.5 0.92  0.93 
98  rs11209026  rs11465804 0.905 2.56 2.5 0.94  0.93 
99  rs11209026  rs11465804 0.905 3.84 2.5 0.93  0.93 
100  rs11209026  rs11465804 0.905 1.79 2.5 0.93  0.93 
101  rs11465804  rs11209026 0.905 2.5 2.92 0.93  0.92 
102  rs11465804  rs11209026 0.905 2.5 2.56 0.93  0.94 
103  rs11465804  rs11209026 0.905 2.5 3.84 0.93  0.93 
104  rs11465804  rs11209026 0.905 2.5 1.79 0.93  0.93 
105  rs11747270  rs1000113 0.905 1.33 1.54 0.09  0.07 
106  rs1121980  rs1421085 0.902 1.66 1.39 0.41  0.4 
107  rs6983267  rs10505477 0.902 1.24 1.17 0.48  0.5 
108  rs6983267  rs10505477 0.902 1.27 1.17 0.49  0.5 
109  rs6983267  rs10505477 0.902 1.42 1.17 0.49  0.5 
110  rs6983267  rs10505477 0.902 1.26 1.17 0.5  0.5 
111  rs6983267  rs10505477 0.902 1.28 1.17 0.53  0.5 
112  rs1421085  rs1121980 0.902 1.39 1.66 0.4  0.41 
113  rs10505477  rs6983267 0.902 1.17 1.24 0.5  0.48 
114  rs10505477  rs6983267 0.902 1.17 1.27 0.5  0.49 
115  rs10505477  rs6983267 0.902 1.17 1.42 0.5  0.49 
116  rs10505477  rs6983267 0.902 1.17 1.26 0.5  0.5 
117  rs10505477  rs6983267 0.902 1.17 1.28 0.5  0.53 
118  rs4977574  rs1333049 0.9 1.29 1.36 0.56  0.47 
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119  rs4977574  rs1333049 0.9 1.29 1.47 0.56  0.47 
120  rs1333049  rs4977574 0.9 1.36 1.29 0.47  0.56 
121  rs1333049  rs4977574 0.9 1.47 1.29 0.47  0.56 
122  rs8034191  rs1051730 0.899 1.4 1.31 0.33  0.35 
123  rs8034191  rs1051730 0.899 1.29 1.31 NR  0.35 
124  rs8034191  rs1051730 0.899 1.3 1.31 0.34  0.35 
125  rs8034191  rs1051730 0.899 1.3 1.31 NR  0.35 
126  rs8034191  rs1051730 0.899 1.38 1.31 NR  0.35 
127  rs8034191  rs1051730 0.899 1.29 1.35 NR  NR 
128  rs8034191  rs1051730 0.899 1.3 1.35 0.34  NR 
129  rs8034191  rs1051730 0.899 1.3 1.35 NR  NR 
130  rs8034191  rs1051730 0.899 1.38 1.35 NR  NR 
131  rs8034191  rs1051730 0.899 1.4 1.35 0.33  NR 
132  rs1051730  rs8034191 0.899 1.31 1.4 0.35  0.33 
133  rs1051730  rs8034191 0.899 1.35 1.4 NR  0.33 
134  rs1051730  rs8034191 0.899 1.35 1.29 NR  NR 
135  rs1051730  rs8034191 0.899 1.35 1.3 NR  0.34 
136  rs1051730  rs8034191 0.899 1.35 1.3 NR  NR 
137  rs1051730  rs8034191 0.899 1.35 1.38 NR  NR 
138  rs1051730  rs8034191 0.899 1.31 1.29 0.35  NR 
139  rs1051730  rs8034191 0.899 1.31 1.3 0.35  0.34 
140  rs1051730  rs8034191 0.899 1.31 1.3 0.35  NR 
141  rs1051730  rs8034191 0.899 1.31 1.38 0.35  NR 
142  rs17221417  rs2076756 0.892 1.29 1.71 0.29  0.27 
143  rs2076756  rs17221417 0.892 1.71 1.29 0.27  0.29 
144  rs2981582  rs2981579 0.884 1.26 1.17 0.38  0.41 
145  rs2981579  rs2981582 0.884 1.17 1.26 0.41  0.38 
146  rs9941349  rs1421085 0.884 1.48 1.39 0.43  0.4 
147  rs9941349  rs8050136 0.884 1.48 1.3 0.43  NR 
148  rs9941349  rs8050136 0.884 1.48 1.17 0.43  0.38 
149  rs9941349  rs8050136 0.884 1.48 1.23 0.43  0.4 
150  rs9941349  rs8050136 0.884 1.48 1.15 0.43  NR 
151  rs1421085  rs9941349 0.884 1.39 1.48 0.4  0.43 
152  rs8050136  rs9941349 0.884 1.3 1.48 NR  0.43 
153  rs8050136  rs9941349 0.884 1.17 1.48 0.38  0.43 
154  rs8050136  rs9941349 0.884 1.23 1.48 0.4  0.43 
155  rs8050136  rs9941349 0.884 1.15 1.48 NR  0.43 
156  rs4975616  rs401681 0.882 1.15 1.15 NR  NR 
157  rs401681  rs4975616 0.882 1.15 1.15 NR  NR 
158  rs8050136  rs1121980 0.87 1.3 1.66 NR  0.41 
159  rs8050136  rs1121980 0.87 1.17 1.66 0.38  0.41 
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160  rs8050136  rs1121980 0.87 1.23 1.66 0.4  0.41 
161  rs8050136  rs1121980 0.87 1.15 1.66 NR  0.41 
162  rs1121980  rs8050136 0.87 1.66 1.3 0.41  NR 
163  rs1121980  rs8050136 0.87 1.66 1.17 0.41  0.38 
164  rs1121980  rs8050136 0.87 1.66 1.23 0.41  0.4 
165  rs1121980  rs8050136 0.87 1.66 1.15 0.41  NR 
166  rs1701704  rs2292239 0.851 1.25 1.28 0.35  0.34 
167  rs2292239  rs1701704 0.851 1.28 1.25 0.34  0.35 
168  rs3135388  rs3129934 0.847 2.75 3.3 0.22  NR 
169  rs3135388  rs3129934 0.847 1.99 3.3 0.23  NR 
170  rs3129934  rs3135388 0.847 3.3 2.75 NR  0.22 
171  rs3129934  rs3135388 0.847 3.3 1.99 NR  0.23 
172  rs2943641  rs2943634 0.843 1.19 1.21 0.63  0.65 
173  rs2943634  rs2943641 0.843 1.21 1.19 0.65  0.63 
174  rs774359  rs2814707 0.831 1.19 1.22 0.25  0.23 
175  rs2814707  rs774359 0.831 1.22 1.19 0.23  0.25 
176  rs2872507  rs7216389 0.826 1.12 1.45 0.47  0.52 
177  rs7216389  rs2872507 0.826 1.45 1.12 0.52  0.47 
178  rs9271366  rs3129934 0.824 2.78 3.3 0.15  NR 
179  rs3129934  rs9271366 0.824 3.3 2.78 NR  0.15 
180  rs401681  rs31489 0.821 1.15 1.12 NR  0.59 
181  rs31489  rs401681 0.821 1.12 1.15 0.59  NR 
182  rs3849942  rs774359 0.811 1.23 1.19 0.23  0.25 
183  rs4788084  rs8049439 0.811 1.09 1.14 0.42  0.37 
184  rs8049439  rs4788084 0.811 1.14 1.09 0.37  0.42 
185  rs774359  rs3849942 0.811 1.19 1.23 0.25  0.23 
186  rs907092  rs7216389 0.808 1.29 1.45 0.45  0.52 
187  rs7216389  rs907092 0.808 1.45 1.29 0.52  0.45 
188  rs947474  rs4750316 0.796 1.1 1.14 0.19  0.2 
189  rs4750316  rs947474 0.796 1.14 1.1 0.2  0.19 
190  rs258322  rs1805007 0.783 1.67 2.34 0.09  0.08 
191  rs258322  rs1805007 0.783 1.67 4.37 0.09  0.05 
192  rs258322  rs1805007 0.783 1.67 12.47 0.09  NR 
193  rs258322  rs1805007 0.783 1.67 2.94 0.09  0.06 
194  rs1805007  rs258322 0.783 2.34 1.67 0.08  0.09 
195  rs1805007  rs258322 0.783 4.37 1.67 0.05  0.09 
196  rs1805007  rs258322 0.783 12.47 1.67 NR  0.09 
197  rs1805007  rs258322 0.783 2.94 1.67 0.06  0.09 
198  rs7193343  rs2106261 0.776 1.21 1.25 NR  0.174 
199  rs2106261  rs7193343 0.776 1.25 1.21 0.174  NR 
200  rs31489  rs4975616 0.74 1.12 1.15 0.59  NR 
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201  rs4975616  rs31489 0.74 1.15 1.12 NR  0.59 
202  rs7501939  rs4430796 0.734 1.41 1.22 0.57  0.49 
203  rs7501939  rs4430796 0.734 1.41 1.19 0.57  0.52 
204  rs7501939  rs4430796 0.734 1.41 1.18 0.57  0.54 
205  rs4430796  rs7501939 0.734 1.22 1.41 0.49  0.57 
206  rs4430796  rs7501939 0.734 1.19 1.41 0.52  0.57 
207  rs4430796  rs7501939 0.734 1.18 1.41 0.54  0.57 
208  rs4977756  rs1412829 0.724 1.24 1.42 0.6  0.39 
209  rs1412829  rs4977756 0.724 1.42 1.24 0.39  0.6 
210  rs7756992  rs7754840 0.722 1.2 1.12 0.26  0.31 
211  rs7756992  rs7754840 0.722 1.2 1.12 0.26  0.36 
212  rs7754840  rs7756992 0.722 1.12 1.2 0.31  0.26 
213  rs7754840  rs7756992 0.722 1.12 1.2 0.36  0.26 
214  rs4712523  rs7756992 0.722 1.2 1.2 0.32  0.26 
215  rs10946398  rs7756992 0.722 1.18 1.2 NR  0.26 
216  rs10946398  rs7756992 0.722 1.16 1.2 0.32  0.26 
217  rs7756992  rs4712523 0.722 1.2 1.2 0.26  0.32 
218  rs7756992  rs10946398 0.722 1.2 1.18 0.26  NR 
219  rs7756992  rs10946398 0.722 1.2 1.16 0.26  0.32 
220  rs564398  rs4977756 0.71 1.13 1.24 0.56  0.6 
221  rs4977756  rs564398 0.71 1.24 1.13 0.6  0.56 
222  rs2201841  rs11805303 0.7 1.13 1.39 0.3  0.68 
223  rs11805303  rs2201841 0.7 1.39 1.13 0.68  0.3 
224  rs6931514  rs4712523 0.688 1.25 1.2 NR  0.32 
225  rs6931514  rs10946398 0.688 1.25 1.18 NR  NR 
226  rs6931514  rs10946398 0.688 1.25 1.16 NR  0.32 
227  rs4712523  rs6931514 0.688 1.2 1.25 0.32  NR 
228  rs10946398  rs6931514 0.688 1.18 1.25 NR  NR 
229  rs10946398  rs6931514 0.688 1.16 1.25 0.32  NR 
230  rs7754840  rs6931514 0.688 1.12 1.25 0.31  NR 
231  rs7754840  rs6931514 0.688 1.12 1.25 0.36  NR 
232  rs6931514  rs7754840 0.688 1.25 1.12 NR  0.31 
233  rs6931514  rs7754840 0.688 1.25 1.12 NR  0.36 
234  rs10758593  rs7020673 0.674 1.13 1.14 NR  0.5 
235  rs2292239  rs11171739 0.674 1.28 1.34 0.34  0.42 
236  rs7020673  rs10758593 0.674 1.14 1.13 0.5  NR 
237  rs11171739  rs2292239 0.674 1.34 1.28 0.42  0.34 
238  rs6932590  rs13194053 0.653 1.16 1.28 0.78  0.82 
239  rs6932590  rs13194053 0.653 1.16 1.22 0.78  0.86 
240  rs13194053  rs6932590 0.653 1.28 1.16 0.82  0.78 
241  rs13194053  rs6932590 0.653 1.22 1.16 0.86  0.78 
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242  rs10889677  rs11805303 0.649 1.29 1.39 0.3  0.68 
243  rs11805303  rs10889677 0.649 1.39 1.29 0.68  0.3 
244  rs12722489  rs2104286 0.626 1.25 1.16 0.85  0.73 
245  rs12722489  rs2104286 0.626 1.25 1.15 0.85  0.76 
246  rs2104286  rs12722489 0.626 1.16 1.25 0.73  0.85 
247  rs2104286  rs12722489 0.626 1.15 1.25 0.76  0.85 
248  rs11171739  rs1701704 0.618 1.34 1.25 0.42  0.35 
249  rs1701704  rs11171739 0.618 1.25 1.34 0.35  0.42 
250  rs4598195  rs4730276 0.614 1.23 1.22 0.54  0.39 
251  rs4730276  rs4598195 0.614 1.22 1.23 0.39  0.54 
252  rs2076756  rs5743289 0.612 1.71 1.46 0.27  0.17 
253  rs5743289  rs2076756 0.612 1.46 1.71 0.17  0.27 
254  rs4977574  rs1333040 0.603 1.29 1.29 0.56  0.55 
255  rs1333040  rs4977574 0.603 1.29 1.29 0.55  0.56 
256  rs2180439  rs1160312 0.602 1.82 1.6 0.43  0.43 
257  rs1160312  rs2180439 0.602 1.6 1.82 0.43  0.43 
258  rs9888739  rs11574637 0.556 1.62 1.33 0.13  0.19 
259  rs11574637  rs9888739 0.556 1.33 1.62 0.19  0.13 
260  rs1333049  rs1333040 0.555 1.36 1.29 0.47  0.55 
261  rs1333049  rs1333040 0.555 1.47 1.29 0.47  0.55 
262  rs1333040  rs1333049 0.555 1.29 1.36 0.55  0.47 
263  rs1333040  rs1333049 0.555 1.29 1.47 0.55  0.47 
264  rs4730276  rs4730273 0.551 1.22 1.22 0.39  0.7 
265  rs4730273  rs4730276 0.551 1.22 1.22 0.7  0.39 
266  rs17221417  rs5743289 0.546 1.29 1.46 0.29  0.17 
267  rs5743289  rs17221417 0.546 1.46 1.29 0.17  0.29 
268  rs7014346  rs10505477 0.541 1.19 1.17 0.18  0.5 
269  rs10505477  rs7014346 0.541 1.17 1.19 0.5  0.18 
270  rs477515  rs9272346 0.512 1.38 5.49 0.69  0.61 
271  rs9272346  rs477515 0.512 5.49 1.38 0.61  0.69 
272  rs9465871  rs7756992 0.509 1.18 1.2 0.18  0.26 
273  rs7756992  rs9465871 0.509 1.2 1.18 0.26  0.18 
274  rs17696736  rs653178 0.505 1.22 1.21 0.42  0.48 
275  rs17696736  rs653178 0.505 1.34 1.21 0.42  0.48 
276  rs653178  rs17696736 0.505 1.21 1.22 0.48  0.42 
277  rs653178  rs17696736 0.505 1.21 1.34 0.48  0.42 
278  rs9272346  rs2395185 0.497 5.49 1.52 0.61  0.67 
279  rs2395185  rs9272346 0.497 1.52 5.49 0.67  0.61 
280  rs2412973  rs5753037 0.493 1.15 1.1 0.46  0.39 
281  rs5753037  rs2412973 0.493 1.1 1.15 0.39  0.46 
282  rs7014346  rs6983267 0.488 1.19 1.42 0.18  0.49 
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283  rs7014346  rs6983267 0.488 1.19 1.26 0.18  0.5 
284  rs7014346  rs6983267 0.488 1.19 1.28 0.18  0.53 
285  rs6983267  rs7014346 0.488 1.24 1.19 0.48  0.18 
286  rs6983267  rs7014346 0.488 1.27 1.19 0.49  0.18 
287  rs6983267  rs7014346 0.488 1.42 1.19 0.49  0.18 
288  rs6983267  rs7014346 0.488 1.26 1.19 0.5  0.18 
289  rs6983267  rs7014346 0.488 1.28 1.19 0.53  0.18 
290  rs7014346  rs6983267 0.488 1.19 1.24 0.18  0.48 
291  rs7014346  rs6983267 0.488 1.19 1.27 0.18  0.49 
292  rs4763879  rs11052552 0.484 1.09 1.49 0.37  0.49 
293  rs11052552  rs4763879 0.484 1.49 1.09 0.49  0.37 
294  rs6897932  rs1445898 0.467 1.12 1.12 0.75  0.55 
295  rs6897932  rs1445898 0.467 1.18 1.12 0.75  0.55 
296  rs6897932  rs1445898 0.467 1.12 1.12 0.71  0.55 
297  rs1445898  rs6897932 0.467 1.12 1.12 0.55  0.75 
298  rs1445898  rs6897932 0.467 1.12 1.18 0.55  0.75 
299  rs1445898  rs6897932 0.467 1.12 1.12 0.55  0.71 
300  rs4763879  rs3764021 0.451 1.09 1.57 0.37  0.47 
301  rs3764021  rs4763879 0.451 1.57 1.09 0.47  0.37 
302  rs10038113  rs4307059 0.45 1.33 1.19 0.59  0.61 
303  rs4307059  rs10038113 0.45 1.19 1.33 0.61  0.59 
304  rs4977756  rs4977574 0.446 1.24 1.29 0.6  0.56 
305  rs4977574  rs4977756 0.446 1.29 1.24 0.56  0.6 
306  rs9296249  rs3923809 0.442 1.67 1.9 0.76  0.66 
307  rs3923809  rs9296249 0.442 1.9 1.67 0.66  0.76 
308  rs10484554  rs2395029 0.432 2.8 3.47 0.15  0.03 
309  rs12191877  rs2395029 0.432 2.64 3.47 0.15  0.03 
310  rs12191877  rs2395029 0.432 2.64 45 0.15  0.05 
311  rs10484554  rs2395029 0.432 2.8 45 0.15  0.05 
312  rs10484554  rs2395029 0.432 2.8 4.1 0.15  0.03 
313  rs12191877  rs2395029 0.432 2.64 4.1 0.15  0.03 
314  rs2395029  rs10484554 0.432 3.47 2.8 0.03  0.15 
315  rs2395029  rs10484554 0.432 45 2.8 0.05  0.15 
316  rs2395029  rs10484554 0.432 4.1 2.8 0.03  0.15 
317  rs2395029  rs12191877 0.432 4.1 2.64 0.03  0.15 
318  rs10974944  rs10758669 0.477 3.1 1.12 NR  0.35 
319  rs10758669  rs10974944 0.477 1.12 3.1 0.35  NR 
320  rs9465871  rs6931514 0.473 1.18 1.25 0.18  NR 
321  rs6931514  rs9465871 0.473 1.25 1.18 NR  0.18 
322  rs6897932  rs1445898 0.467 1.12 1.12 0.75  0.55 
323  rs6897932  rs1445898 0.467 1.18 1.12 0.75  0.55 
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324  rs6897932  rs1445898 0.467 1.12 1.12 0.71  0.55 
325  rs1445898  rs6897932 0.467 1.12 1.12 0.55  0.75 
326  rs1445898  rs6897932 0.467 1.12 1.18 0.55  0.75 
327  rs1445898  rs6897932 0.467 1.12 1.12 0.55  0.71 
328  rs4763879  rs3764021 0.451 1.09 1.57 0.37  0.47 
329  rs3764021  rs4763879 0.451 1.57 1.09 0.47  0.37 
330  rs10038113  rs4307059 0.45 1.33 1.19 0.59  0.61 
331  rs4307059  rs10038113 0.45 1.19 1.33 0.61  0.59 
332  rs4977756  rs4977574 0.446 1.24 1.29 0.6  0.56 
333  rs4977574  rs4977756 0.446 1.29 1.24 0.56  0.6 
334  rs9296249  rs3923809 0.442 1.67 1.9 0.76  0.66 
335  rs3923809  rs9296249 0.442 1.9 1.67 0.66  0.76 
336  rs10484554  rs2395029 0.432 2.8 3.47 0.15  0.03 
337  rs12191877  rs2395029 0.432 2.64 3.47 0.15  0.03 
338  rs12191877  rs2395029 0.432 2.64 45 0.15  0.05 
339  rs10484554  rs2395029 0.432 2.8 45 0.15  0.05 
340  rs10484554  rs2395029 0.432 2.8 4.1 0.15  0.03 
341  rs12191877  rs2395029 0.432 2.64 4.1 0.15  0.03 
342  rs2395029  rs10484554 0.432 3.47 2.8 0.03  0.15 
343  rs2395029  rs10484554 0.432 45 2.8 0.05  0.15 
344  rs2395029  rs10484554 0.432 4.1 2.8 0.03  0.15 
345  rs2395029  rs12191877 0.432 4.1 2.64 0.03  0.15 
346  rs2395029  rs12191877 0.432 3.47 2.64 0.03  0.15 
347  rs2395029  rs12191877 0.432 45 2.64 0.05  0.15 
348  rs6010620  rs2315008 0.428 1.28 1.36 0.23  0.69 
349  rs6010620  rs2315008 0.428 1.52 1.36 0.77  0.69 
350  rs2315008  rs6010620 0.428 1.36 1.28 0.69  0.23 
351  rs2315008  rs6010620 0.428 1.36 1.52 0.69  0.77 
352  rs10488631  rs12537284 0.426 1.52 1.54 NR  0.13 
353  rs12537284  rs10488631 0.426 1.54 1.52 0.13  NR 
354  rs2187668  rs9272219 0.4 7.04 1.14 0.14  0.72 
355  rs9272219  rs2187668 0.4 1.14 7.04 0.72  0.14 
356  rs660895  rs477515 0.389 3.62 1.38 0.21  0.69 
357  rs477515  rs660895 0.389 1.38 3.62 0.69  0.21 
358  rs2158836  rs4598195 0.388 1.21 1.23 0.35  0.54 
359  rs4598195  rs2158836 0.388 1.23 1.21 0.54  0.35 
360  rs9465871  rs10946398 0.385 1.18 1.18 0.18  NR 
361  rs9465871  rs10946398 0.385 1.18 1.16 0.18  0.32 
362  rs9465871  rs4712523 0.385 1.18 1.2 0.18  0.32 
363  rs9465871  rs7754840 0.385 1.18 1.12 0.18  0.31 
364  rs9465871  rs7754840 0.385 1.18 1.12 0.18  0.36 
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NR – Not Reported – assume RAF = 0.5 
 
Disease /Trait associated with each SNP (from above) 
  SNP1 - Disease SNP2 - Disease
1  Type 2 diabetes Glioma (high‐grade)
2  Crohn's disease Crohn's disease
3  Crohn's disease Crohn's disease
4  Crohn's disease Crohn's disease
365  rs7754840  rs9465871 0.385 1.12 1.18 0.31  0.18 
366  rs7754840  rs9465871 0.385 1.12 1.18 0.36  0.18 
367  rs4712523  rs9465871 0.385 1.2 1.18 0.32  0.18 
368  rs10946398  rs9465871 0.385 1.18 1.18 NR  0.18 
369  rs10946398  rs9465871 0.385 1.16 1.18 0.32  0.18 
370  rs1333049  rs4977756 0.384 1.36 1.24 0.47  0.6 
371  rs1333049  rs4977756 0.384 1.47 1.24 0.47  0.6 
372  rs4977756  rs1333049 0.384 1.24 1.36 0.6  0.47 
373  rs4977756  rs1333049 0.384 1.24 1.47 0.6  0.47 
374  rs660895  rs2395185 0.381 3.62 1.52 0.21  0.67 
375  rs2395185  rs660895 0.381 1.52 3.62 0.67  0.21 
376  rs4730273  rs4598195 0.374 1.22 1.23 0.7  0.54 
377  rs4598195  rs4730273 0.374 1.23 1.22 0.54  0.7 
378  rs9929218  rs1728785 0.368 1.1 1.17 0.29  0.76 
379  rs1728785  rs9929218 0.368 1.17 1.1 0.76  0.29 
380  rs17594526  rs9960767 0.35 1.44 1.23 0.03  0.06 
381  rs9960767  rs17594526 0.35 1.23 1.44 0.06  0.03 
382  rs660895  rs6457617 0.344 3.62 2.36 0.21  0.49 
383  rs660895  rs6457620 0.344 3.62 2.55 0.21  0.5 
384  rs6457617  rs660895 0.344 2.36 3.62 0.49  0.21 
385  rs6457620  rs660895 0.344 2.55 3.62 0.5  0.21 
386  rs9272346  rs9271366 0.331 5.49 2.78 0.61  0.15 
387  rs9271366  rs9272346 0.331 2.78 5.49 0.15  0.61 
388  rs3135388  rs9272346 0.322 2.75 5.49 0.22  0.61 
389  rs3135388  rs9272346 0.322 1.99 5.49 0.23  0.61 
390  rs9272346  rs3135388 0.322 5.49 2.75 0.61  0.22 
391  rs9272346  rs3135388 0.322 5.49 1.99 0.61  0.23 
392  rs9272346  rs3129934 0.315 5.49 3.3 0.61  NR 
393  rs3129934  rs9272346 0.315 3.3 5.49 NR  0.61 
394  rs11805303  rs7517847 0.314 1.39 1.61 0.68  0.56 
395  rs7517847  rs11805303 0.314 1.61 1.39 0.56  0.68 
396  rs11228565  rs10896449 0.303 1.23 1.1 0.2  0.52 
397  rs10896449  rs11228565 0.303 1.1 1.23 0.52  0.2 
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5  Crohn's disease Crohn's disease
6  Glioma (high‐grade) Type 2 diabetes
7  Crohn's disease
Inflammatory bowel 
disease
8 
Inflammatory bowel 
disease  Crohn's disease
9  Multiple sclerosis Rheumatoid arthritis
10  Rheumatoid arthritis Multiple sclerosis
11 
Systemic lupus 
erythematosus Rheumatoid arthritis
12  Rheumatoid arthritis
Systemic lupus 
erythematosus
13  Multiple sclerosis Multiple sclerosis
14  Multiple sclerosis Multiple sclerosis
15  Multiple sclerosis Multiple sclerosis
16  Multiple sclerosis Multiple sclerosis
17  Breast cancer Breast cancer
18  Prostate cancer Prostate cancer
19  Crohn's disease Crohn's disease
20  Crohn's disease Crohn's disease
21  Breast cancer Breast cancer
22  Prostate cancer Prostate cancer
23  Multiple sclerosis Multiple sclerosis
24  Multiple sclerosis Multiple sclerosis
25  Type 2 diabetes Type 2 diabetes
26  Type 2 diabetes Type 2 diabetes
27  Type 2 diabetes Type 2 diabetes
28  Type 2 diabetes Type 2 diabetes
29  Crohn's disease Crohn's disease
30  Crohn's disease Crohn's disease
31  Crohn's disease Crohn's disease
32  Crohn's disease Crohn's disease
33  Obesity (extreme)
Obesity (early onset 
extreme)
34  Primary biliary cirrhosis Crohn's disease
35  Crohn's disease Primary biliary cirrhosis
36 
Obesity (early onset 
extreme)  Obesity (extreme)
37  Type 1 diabetes Type 1 diabetes
38  Type 1 diabetes Type 1 diabetes
39 
Inflammatory bowel 
disease  Ulcerative colitis
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40  Ulcerative colitis
Inflammatory bowel 
disease
41  Type 1 diabetes Type 1 diabetes
42  Type 1 diabetes Type 1 diabetes
43  Type 1 diabetes Type 1 diabetes
44  Type 1 diabetes Type 1 diabetes
45  Psoriasis  Ulcerative colitis
46  Ulcerative colitis Psoriasis
47  Type 1 diabetes Type 1 diabetes
48  Type 1 diabetes Type 1 diabetes
49  Crohn's disease Crohn's disease
50  Crohn's disease Crohn's disease
51  Crohn's disease Crohn's disease
52  Type 2 diabetes Obesity
53  Type 2 diabetes Obesity
54  Type 2 diabetes Obesity
55  Type 2 diabetes Obesity
56  Crohn's disease Crohn's disease
57  Obesity  Type 2 diabetes
58  Obesity  Type 2 diabetes
59  Obesity  Type 2 diabetes
60  Obesity  Type 2 diabetes
61 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
62 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
63  Type 2 diabetes Type 2 diabetes
64  Type 2 diabetes Type 2 diabetes
65  Type 2 diabetes Type 2 diabetes
66  Type 2 diabetes Type 2 diabetes
67  Type 2 diabetes Type 2 diabetes
68  Type 2 diabetes Type 2 diabetes
69  Type 2 diabetes Type 2 diabetes
70  Type 2 diabetes Type 2 diabetes
71 
Type 2 diabetes and 
other traits  Type 2 diabetes
72  Type 2 diabetes
Type 2 diabetes and other 
traits
73  Type 2 diabetes Type 2 diabetes
74  Type 2 diabetes Type 2 diabetes
75  Type 2 diabetes Type 2 diabetes
76  Type 2 diabetes Type 2 diabetes
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77  Type 2 diabetes Type 2 diabetes
78  Type 2 diabetes Type 2 diabetes
79  Type 2 diabetes Type 2 diabetes
80  Type 2 diabetes Type 2 diabetes
81  Type 2 diabetes Type 2 diabetes
82  Type 2 diabetes Type 2 diabetes
83  Type 2 diabetes Type 2 diabetes
84  Type 2 diabetes Type 2 diabetes
85  Type 2 diabetes
Type 2 diabetes and other 
traits
86  Testicular cancer Testicular germ cell tumor 
87  Testicular cancer Testicular germ cell tumor 
88 
Testicular germ cell 
tumor  Testicular cancer
89 
Testicular germ cell 
tumor  Testicular cancer
90  Coronary disease
Myocardial infarction 
(early onset)
91  LDL cholesterol
Myocardial infarction 
(early onset)
92 
Myocardial infarction 
(early onset) Coronary disease
93 
Myocardial infarction 
(early onset) LDL cholesterol
94  Breast cancer Breast cancer
95  Breast cancer Breast cancer
96  Crohn's disease Crohn's disease
97  Crohn's disease Crohn's disease
98 
Inflammatory bowel 
disease  Crohn's disease
99 
Inflammatory bowel 
disease  Crohn's disease
100  Ulcerative colitis Crohn's disease
101  Crohn's disease Crohn's disease
102  Crohn's disease
Inflammatory bowel 
disease
103  Crohn's disease
Inflammatory bowel 
disease
104  Crohn's disease Ulcerative colitis
105  Crohn's disease Crohn's disease
106 
Obesity (early onset 
extreme)  Obesity
107  Colorectal cancer Colorectal cancer
108  Colorectal cancer Colorectal cancer
137 
 
109  Prostate cancer Colorectal cancer
110  Prostate cancer Colorectal cancer
111  Prostate cancer Colorectal cancer
112  Obesity 
Obesity (early onset 
extreme)
113  Colorectal cancer Colorectal cancer
114  Colorectal cancer Colorectal cancer
115  Colorectal cancer Prostate cancer
116  Colorectal cancer Prostate cancer
117  Colorectal cancer Prostate cancer
118 
Myocardial infarction 
(early onset) Coronary disease
119 
Myocardial infarction 
(early onset) Coronary disease
120  Coronary disease
Myocardial infarction 
(early onset)
121  Coronary disease
Myocardial infarction 
(early onset)
122 
Chronic Obstructive 
Pulmonary Disease Lung adenocarcinoma
123  Lung cancer Lung adenocarcinoma
124  Lung cancer Lung adenocarcinoma
125  Lung cancer Lung adenocarcinoma
126  Lung cancer Lung adenocarcinoma
127  Lung cancer Lung cancer
128  Lung cancer Lung cancer
129  Lung cancer Lung cancer
130  Lung cancer Lung cancer
131 
Chronic Obstructive 
Pulmonary Disease Lung cancer
132  Lung adenocarcinoma
Chronic Obstructive 
Pulmonary Disease
133  Lung cancer
Chronic Obstructive 
Pulmonary Disease
134  Lung cancer Lung cancer
135  Lung cancer Lung cancer
136  Lung cancer Lung cancer
137  Lung cancer Lung cancer
138  Lung adenocarcinoma Lung cancer
139  Lung adenocarcinoma Lung cancer
140  Lung adenocarcinoma Lung cancer
141  Lung adenocarcinoma Lung cancer
142  Crohn's disease Crohn's disease
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143  Crohn's disease Crohn's disease
144  Breast cancer Breast cancer
145  Breast cancer Breast cancer
146  Obesity (extreme) Obesity
147  Obesity (extreme) Type 2 diabetes
148  Obesity (extreme) Type 2 diabetes
149  Obesity (extreme) Type 2 diabetes
150  Obesity (extreme) Type 2 diabetes
151  Obesity  Obesity (extreme)
152  Type 2 diabetes Obesity (extreme)
153  Type 2 diabetes Obesity (extreme)
154  Type 2 diabetes Obesity (extreme)
155  Type 2 diabetes Obesity (extreme)
156  Lung cancer Lung cancer
157  Lung cancer Lung cancer
158  Type 2 diabetes
Obesity (early onset 
extreme)
159  Type 2 diabetes
Obesity (early onset 
extreme)
160  Type 2 diabetes
Obesity (early onset 
extreme)
161  Type 2 diabetes
Obesity (early onset 
extreme)
162 
Obesity (early onset 
extreme)  Type 2 diabetes
163 
Obesity (early onset 
extreme)  Type 2 diabetes
164 
Obesity (early onset 
extreme)  Type 2 diabetes
165 
Obesity (early onset 
extreme)  Type 2 diabetes
166  Type 1 diabetes Type 1 diabetes
167  Type 1 diabetes Type 1 diabetes
168  Multiple sclerosis Multiple sclerosis
169  Multiple sclerosis Multiple sclerosis
170  Multiple sclerosis Multiple sclerosis
171  Multiple sclerosis Multiple sclerosis
172 
Type 2 diabetes and 
other traits  Coronary disease
173  Coronary disease
Type 2 diabetes and other 
traits
174 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
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175 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
176  Crohn's disease Asthma
177  Asthma  Crohn's disease
178  Multiple sclerosis Multiple sclerosis
179  Multiple sclerosis Multiple sclerosis
180  Lung cancer Lung adenocarcinoma
181  Lung adenocarcinoma Lung cancer
182 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
183  Type 1 diabetes
Inflammatory bowel 
disease (early onset)
184 
Inflammatory bowel 
disease (early onset) Type 1 diabetes
185 
Amyotrophic lateral 
sclerosis 
Amyotrophic lateral 
sclerosis
186  Primary biliary cirrhosis Asthma
187  Asthma  Primary biliary cirrhosis
188  Type 1 diabetes Rheumatoid arthritis
189  Rheumatoid arthritis Type 1 diabetes
190  Melanoma  Blond vs. brown hair color 
191  Melanoma  Freckles
192  Melanoma  Red vs non‐red hair color
193  Melanoma  Skin sensitivity to sun
194 
Blond vs. brown hair 
color  Melanoma
195  Freckles  Melanoma
196 
Red vs non‐red hair 
color  Melanoma
197  Skin sensitivity to sun Melanoma
198  Atrial fibrillation Atrial fibrillation
199  Atrial fibrillation Atrial fibrillation
200  Lung adenocarcinoma Lung cancer
201  Lung cancer Lung adenocarcinoma
202  Prostate cancer Prostate cancer
203  Prostate cancer Prostate cancer
204  Prostate cancer Prostate cancer
205  Prostate cancer Prostate cancer
206  Prostate cancer Prostate cancer
207  Prostate cancer Prostate cancer
208  Glioma  Glioma (high‐grade)
209  Glioma (high‐grade) Glioma
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210  Type 2 diabetes Type 2 diabetes
211  Type 2 diabetes Type 2 diabetes
212  Type 2 diabetes Type 2 diabetes
213  Type 2 diabetes Type 2 diabetes
214 
Type 2 diabetes and 
other traits  Type 2 diabetes
215  Type 2 diabetes Type 2 diabetes
216  Type 2 diabetes Type 2 diabetes
217  Type 2 diabetes
Type 2 diabetes and other 
traits
218  Type 2 diabetes Type 2 diabetes
219  Type 2 diabetes Type 2 diabetes
220  Type 2 diabetes Glioma
221  Glioma  Type 2 diabetes
222  Psoriasis  Crohn's disease
223  Crohn's disease Psoriasis
224  Type 2 diabetes
Type 2 diabetes and other 
traits
225  Type 2 diabetes Type 2 diabetes
226  Type 2 diabetes Type 2 diabetes
227 
Type 2 diabetes and 
other traits  Type 2 diabetes
228  Type 2 diabetes Type 2 diabetes
229  Type 2 diabetes Type 2 diabetes
230  Type 2 diabetes Type 2 diabetes
231  Type 2 diabetes Type 2 diabetes
232  Type 2 diabetes Type 2 diabetes
233  Type 2 diabetes Type 2 diabetes
234  Type 1 diabetes Type 1 diabetes
235  Type 1 diabetes Type 1 diabetes
236  Type 1 diabetes Type 1 diabetes
237  Type 1 diabetes Type 1 diabetes
238  Schizophrenia Schizophrenia
239  Schizophrenia Schizophrenia
240  Schizophrenia Schizophrenia
241  Schizophrenia Schizophrenia
242  Ulcerative colitis Crohn's disease
243  Crohn's disease Ulcerative colitis
244  Multiple sclerosis Multiple sclerosis
245  Multiple sclerosis Multiple sclerosis
246  Multiple sclerosis Multiple sclerosis
247  Multiple sclerosis Multiple sclerosis
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248  Type 1 diabetes Type 1 diabetes
249  Type 1 diabetes Type 1 diabetes
250  Ulcerative colitis Ulcerative colitis
251  Ulcerative colitis Ulcerative colitis
252  Crohn's disease
Inflammatory bowel 
disease
253 
Inflammatory bowel 
disease  Crohn's disease
254 
Myocardial infarction 
(early onset) Intracranial aneurysm
255  Intracranial aneurysm
Myocardial infarction 
(early onset)
256  Male‐pattern baldness Male‐pattern baldness
257  Male‐pattern baldness Male‐pattern baldness
258 
Systemic lupus 
erythematosus
Systemic lupus 
erythematosus
259 
Systemic lupus 
erythematosus
Systemic lupus 
erythematosus
260  Coronary disease Intracranial aneurysm
261  Coronary disease Intracranial aneurysm
262  Intracranial aneurysm Coronary disease
263  Intracranial aneurysm Coronary disease
264  Ulcerative colitis Ulcerative colitis
265  Ulcerative colitis Ulcerative colitis
266  Crohn's disease
Inflammatory bowel 
disease
267 
Inflammatory bowel 
disease  Crohn's disease
268  Colorectal cancer Colorectal cancer
269  Colorectal cancer Colorectal cancer
270 
Inflammatory bowel 
disease  Type 1 diabetes
271  Type 1 diabetes
Inflammatory bowel 
disease
272  Type 2 diabetes Type 2 diabetes
273  Type 2 diabetes Type 2 diabetes
274  Type 1 diabetes Celiac disease
275  Type 1 diabetes Celiac disease
276  Celiac disease Type 1 diabetes
277  Celiac disease Type 1 diabetes
278  Type 1 diabetes Ulcerative colitis
279  Ulcerative colitis Type 1 diabetes
280  Inflammatory bowel  Type 1 diabetes
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disease (early onset)
281  Type 1 diabetes
Inflammatory bowel 
disease (early onset)
282  Colorectal cancer Prostate cancer
283  Colorectal cancer Prostate cancer
284  Colorectal cancer Prostate cancer
285  Colorectal cancer Colorectal cancer
286  Colorectal cancer Colorectal cancer
287  Prostate cancer Colorectal cancer
288  Prostate cancer Colorectal cancer
289  Prostate cancer Colorectal cancer
290  Colorectal cancer Colorectal cancer
291  Colorectal cancer Colorectal cancer
292  Type 1 diabetes Type 1 diabetes
293  Type 1 diabetes Type 1 diabetes
294  Multiple sclerosis Type 1 diabetes
295  Multiple sclerosis Type 1 diabetes
296  Type 1 diabetes Type 1 diabetes
297  Type 1 diabetes Multiple sclerosis
298  Type 1 diabetes Multiple sclerosis
299  Type 1 diabetes Type 1 diabetes
300  Type 1 diabetes Type 1 diabetes
301  Type 1 diabetes Type 1 diabetes
302  Autism  Autism
303  Autism  Autism
304  Glioma 
Myocardial infarction 
(early onset)
305 
Myocardial infarction 
(early onset) Glioma
306  Restless legs syndrome Restless legs syndrome
307  Restless legs syndrome Restless legs syndrome
308  Psoriasis  AIDS progression
309  Psoriasis  AIDS progression
310  Psoriasis 
Drug‐induced liver injury 
(flucloxacillin)
311  Psoriasis 
Drug‐induced liver injury 
(flucloxacillin)
312  Psoriasis  Psoriasis
313  Psoriasis  Psoriasis
314  AIDS progression Psoriasis
315 
Drug‐induced liver 
injury (flucloxacillin) Psoriasis
143 
 
316  Psoriasis  Psoriasis
317  Psoriasis  Psoriasis
318 
Myeloproliferative 
neoplasms  Crohn's disease
319  Crohn's disease
Myeloproliferative 
neoplasms
320  Type 2 diabetes Type 2 diabetes
321  Type 2 diabetes Type 2 diabetes
322  Multiple sclerosis Type 1 diabetes
323  Multiple sclerosis Type 1 diabetes
324  Type 1 diabetes Type 1 diabetes
325  Type 1 diabetes Multiple sclerosis
326  Type 1 diabetes Multiple sclerosis
327  Type 1 diabetes Type 1 diabetes
328  Type 1 diabetes Type 1 diabetes
329  Type 1 diabetes Type 1 diabetes
330  Autism  Autism
331  Autism  Autism
332  Glioma 
Myocardial infarction 
(early onset)
333 
Myocardial infarction 
(early onset) Glioma
334  Restless legs syndrome Restless legs syndrome
335  Restless legs syndrome Restless legs syndrome
336  Psoriasis  AIDS progression
337  Psoriasis  AIDS progression
338  Psoriasis 
Drug‐induced liver injury 
(flucloxacillin)
339  Psoriasis 
Drug‐induced liver injury 
(flucloxacillin)
340  Psoriasis  Psoriasis
341  Psoriasis  Psoriasis
342  AIDS progression Psoriasis
343 
Drug‐induced liver 
injury (flucloxacillin) Psoriasis
344  Psoriasis  Psoriasis
345  Psoriasis  Psoriasis
346  AIDS progression Psoriasis
347 
Drug‐induced liver 
injury (flucloxacillin) Psoriasis
348  Glioma 
Inflammatory bowel 
disease
349  Glioma (high‐grade) Inflammatory bowel 
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disease
350 
Inflammatory bowel 
disease  Glioma
351 
Inflammatory bowel 
disease  Glioma (high‐grade)
352  Primary biliary cirrhosis
Systemic lupus 
erythematosus
353 
Systemic lupus 
erythematosus Primary biliary cirrhosis
354  Celiac disease Schizophrenia
355  Schizophrenia Celiac disease
356  Rheumatoid arthritis
Inflammatory bowel 
disease
357 
Inflammatory bowel 
disease  Rheumatoid arthritis
358  Ulcerative colitis Ulcerative colitis
359  Ulcerative colitis Ulcerative colitis
360  Type 2 diabetes Type 2 diabetes
361  Type 2 diabetes Type 2 diabetes
362  Type 2 diabetes
Type 2 diabetes and other 
traits
363  Type 2 diabetes Type 2 diabetes
364  Type 2 diabetes Type 2 diabetes
365  Type 2 diabetes Type 2 diabetes
366  Type 2 diabetes Type 2 diabetes
367 
Type 2 diabetes and 
other traits  Type 2 diabetes
368  Type 2 diabetes Type 2 diabetes
369  Type 2 diabetes Type 2 diabetes
370  Coronary disease Glioma
371  Coronary disease Glioma
372  Glioma  Coronary disease
373  Glioma  Coronary disease
374  Rheumatoid arthritis Ulcerative colitis
375  Ulcerative colitis Rheumatoid arthritis
376  Ulcerative colitis Ulcerative colitis
377  Ulcerative colitis Ulcerative colitis
378  Colorectal cancer Ulcerative colitis
379  Ulcerative colitis Colorectal cancer
380  Schizophrenia Schizophrenia
381  Schizophrenia Schizophrenia
382  Rheumatoid arthritis Rheumatoid arthritis
383  Rheumatoid arthritis Rheumatoid arthritis
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384  Rheumatoid arthritis Rheumatoid arthritis
385  Rheumatoid arthritis Rheumatoid arthritis
386  Type 1 diabetes Multiple sclerosis
387  Multiple sclerosis Type 1 diabetes
388  Multiple sclerosis Type 1 diabetes
389  Multiple sclerosis Type 1 diabetes
390  Type 1 diabetes Multiple sclerosis
391  Type 1 diabetes Multiple sclerosis
392  Type 1 diabetes Multiple sclerosis
393  Multiple sclerosis Type 1 diabetes
394  Crohn's disease
Inflammatory bowel 
disease
395 
Inflammatory bowel 
disease  Crohn's disease
396  Prostate cancer Prostate cancer
397  Prostate cancer Prostate cancer
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Appendix A.7 Disease prevalence from RMRS data 
Disease / Trait (listed in GWAS) Prevalence (%) in RMRS 
Acute_lymphoblastic_leukemia_ 0.0002 
AIDS_progression 0.01 
Amyotrophic_lateral_sclerosis 0.0006 
Asthma  0.29 
Atrial_fibrillation  0.0374 
Atrial_fibrillation_atrial_fl 0.0374 
Autism  0.0004 
Biochemical_measures 0.01 
Bipolar_disorder  0.19 
Black_vs__red_hair_color 0.01 
Blond_vs__brown_hair_color 0.01 
Body_mass_index 0.01 
Breast_cancer  0.017 
C_reactive_protein 0.1 
Celiac_disease  0.0004 
Cholesterol__total 0.01 
Chronic_lymphocytic_leukemia 0.00001 
Chronic_Obstructive_Pulmonary 0.06 
Colorectal_cancer 0.0004 
Coronary_disease 0.13 
Crohn_s_disease  0.0064 
Cutaneous_nevi  0.01 
Diastolic_blood_pressure 0.1 
Drug_induced_liver_injury__fl 0.01 
F_cell_distribution 0.01 
Folate_pathway_vitamin_levels 0.1 
Follicular_lymphoma 0.01 
Freckles  0.01 
Glioma  0.0002 
Glioma__high_grade_ 0.00002 
HDL_cholesterol  0.01 
Height  0.1 
Hematocrit  0.01 
Hemoglobin  0.1 
Hemoglobin_levels 0.1 
Inflammatory_bowel_disease 0.01 
Inflammatory_bowel_disease__e 0.01 
Intracranial_aneurysm 0.0012 
147 
 
Ischemic_stroke  0.024 
Knee_osteoarthritis 0.027 
LDL_cholesterol  0.18 
Lung_adenocarcinoma 0.00015 
Lung_cancer  0.015 
Male_pattern_baldness 0.01 
Mean_corpuscular_hemoglobin 0.01 
Mean_corpuscular_volume 0.01 
Melanoma  0.002 
Menarche__age_at_onset_ 0.1 
Multiple_sclerosis 0.0024 
Myeloproliferative_neoplasms 0.0014 
Myocardial_infarction__early_ 0.04 
Nicotine_dependence 0.23 
Nonsyndromic_cleft_lip_with_o 0.01 
Obesity  0.16 
Obesity__early_onset_extreme_ 0.0016 
Obesity__extreme_ 0.0016 
Obesity_related_traits 0.0016 
Other_metabolic_traits 0.01 
Otosclerosis  0.0035 
Pancreatic_cancer 0.0018 
Parkinson_s_disease 0.00025 
Plasma_eosinophil_count 0.01 
Plasma_level_of_vitamin_B12 0.01 
Plasma_levels_of_liver_enzyme 0.01 
Primary_biliary_cirrhosis 0.00035 
Prostate_cancer  0.0037 
Psoriasis  0.04 
Pulmonary_function_measures 0.01 
Quantitative_traits 0.01 
Recombination_rate__females_ 0.01 
Recombination_rate__males_ 0.01 
Red_vs_non_red_hair_color 0.5 
Restless_legs_syndrome 0.01 
Rheumatoid_arthritis 0.01 
Schizophrenia  0.067 
Serum_iron_concentration 0.01 
Serum_markers_of_iron_status 0.01 
Skin_sensitivity_to_sun 0.01 
Systemic_lupus_erythematosus 0.01 
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Systolic_blood_pressure 0.01 
Testicular_cancer 0.01 
Testicular_germ_cell_tumor 0.01 
Triglycerides  0.01 
Type_1_diabetes  0.05 
Type_2_diabetes  0.064 
Type_2_diabetes_and_other_tra 0.0006 
Ulcerative_colitis  0.0035 
Venous_thromboembolism 0.02 
Waist_circumference_and_relat 0.01 
Weight  0.01 
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Appendix A.8 Java code for RNOR Subroutine 
 
public Float calculateRNORTrue(NodeList nList, int[] pStates, Node 
nodeForRNOR) 
    { 
     Float retValTrue = 0.0f; 
     Node n1, n2; 
     Float f1,f2,probScoreTrue; 
     NodeList subtractList, numeratorList, denominatorList; 
      
     float[] cptRow = {0.0f, 0.0f}; 
     float [] vecp = {0.0f, 0.0f};  
      
     try {   
      if(nList.size() == 1) 
      { 
       n1 = (Node) nList.get(0); 
       vecp = nodeForRNOR.getCPTable(pStates, null); 
       if(vecp[0] == 0.5) 
       { 
        retValTrue = linkProbsTrue.get(n1.getName()); 
       } 
       else 
       { 
        retValTrue = vecp[0]; 
       } 
       linkProbsTrue.put(nList.toString(), 
retValTrue);        // also save it for further calculations 
printProbsTrue.put(getParentStateName(pStates), 
retValTrue); 
      } 
      else if(nList.size() == 2) 
      { 
        n1 = (Node) nList.get(0); 
        n2 = (Node) nList.get(1); 
        f1 = linkProbsTrue.get(n1.getName()); 
        f2 = linkProbsTrue.get(n2.getName()); 
         
        vecp = nodeForRNOR.getCPTable(pStates, null); 
        if(vecp[0] == 0.5) 
        { 
retValTrue = retValTrue = 1 - ( (1 - f1)* (1 - 
f2)) ;  
        } 
        else 
        { 
        retValTrue = vecp[0]; 
        }  
                
linkProbsTrue.put(nList.toString(), retValTrue);    
// also save it for further calculations 
printProbsTrue.put(getParentStateName(pStates), 
retValTrue); 
      } 
 
/************************* RNOR Algorithm ************************/ 
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         else 
      { 
       subtractList = new NodeList(tempNet); 
       Node nodeToSubtract, nodeToSubtractPlusOne; 
ArrayList<Float> resultProbs = new 
ArrayList<Float>(); 
ArrayList<Float> resultProbsTrue = new 
ArrayList<Float>(); 
        
       for(int i=0; i< nList.size(); i++) 
       { 
        nodeToSubtract = nList.getNode(i); 
        subtractList.clear(); 
        // Numerator 
        numeratorList = new NodeList(nList); 
        subtractList.add((Node) nodeToSubtract); 
 setSubtract(numeratorList, subtractList);  
//After the call numeratorSet = nList - subtractList 
         
        // Denominator 
        subtractList.clear(); 
        denominatorList = new NodeList(nList); 
        subtractList.add((Node) nodeToSubtract); 
        if((nList.size() - i) == 1)   
// Are we at the end of the list, then the plus 
one subtract node needs to be wrapped 
        { 
nodeToSubtractPlusOne = nList.getNode(0); 
        } 
        else 
        { 
nodeToSubtractPlusOne = 
nList.getNode(i+1); 
        } 
subtractList.add((Node) nodeToSubtractPlusOne); 
setSubtract(denominatorList, subtractList);  
//After the call denominatorSet = nList - 
subtractList 
         
probScoreTrue = 
calculateTrueProbScore(numeratorList, 
denominatorList, pStates, nodeForRNOR); 
        resultProbsTrue.add(probScoreTrue); 
               
       } 
        
 
// Now mulitply indivdual scores and subtract from 1 
       retValTrue = resultProbsTrue.get(0); 
       for(int i=1; i < resultProbsTrue.size(); i++) 
       { 
retValTrue = retValTrue*resultProbsTrue.get(i); 
       } 
       retValTrue = 1 - retValTrue; 
        
       if(retValTrue == 0) 
 
151 
 
       { 
        retValTrue = 0.0f;  
       } 
       else if(retValTrue == 1) 
       { 
        retValTrue = 1.0f; 
       } 
        
       //if(retValTrue >= 0.0f && retValTrue <= 1.0f)      
  
 { 
if(!linkProbsTrue.containsKey(nList.toString()))   // we store it 
for future calculations if needed 
 { 
linkProbsTrue.put(nList.toString(), retValTrue);    // also save 
it for further calculations 
     
 printProbsTrue.put(getParentStateName(pStates), retValTrue); 
 } 
 } 
 //else 
 if(retValTrue < 0.0f || retValTrue > 1.0f)     
 { 
  try { 
writerError.write("Combination -VE or +VE for:" + 
getParentStateName(pStates) + ":" + retValTrue.toString()); 
  writerError.write("\n"); 
   
  for(int i=0; i < resultProbsTrue.size(); i++) 
  { 
writerError.write("val_" + i + ": "  + 
resultProbsTrue.get(i)); 
   writerError.write("\n"); 
          
  } 
 } catch (IOException e) { 
  
// TODO Auto-generated catch block 
  try { 
   writer.write(e.toString()); 
  } catch (IOException e1) { 
  // TODO Auto-generated catch block 
   e1.printStackTrace(); 
  } 
   e.printStackTrace(); 
  } 
 
      } 
      } 
       
     } catch (NeticaException e) { 
   // TODO Auto-generated catch block 
   e.printStackTrace(); 
  }   
  return retValTrue; 
    } 
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Appendix A.9 Java code for IsBIG Subroutine 
 
public void processRequest (String filename_org, String filename_other, 
String filename_trait_prevalance, Double threshold)  
{ 
       
      logBuf = ""; //resets log 
   
      assocFileName = filename_org; 
      outputFileName = filename_other; 
      initTraitPrevalance(filename_trait_prevalance); 
      partialAssociationElement.setThreshold(threshold); 
       
      try{     
          //-- Do Netica stuff 
          try { 
       if (env == null) { 
           env = Environ.getDefaultEnviron(); 
           if (env == null) { 
        String errMsg = initSession(); 
        if (env == null) { 
            System.out.println( errMsg ); 
            return; //no point in continuing 
        } 
           } 
       } 
      } catch (Exception e) { 
    System.out.println( e.getMessage() ); 
      } 
 
totalSNPs = 0; 
      totalTraits = 0; 
      parseAssocFile(assocFileName); 
      if(printDebug) 
      { 
System.out.println("/********************************************
****************/"); 
      System.out.println("Total Duplicate Associations Found for input: 
" + myAssociations.getDuplicateAssociation()); 
      System.out.println("Total Associations Found: " + 
myAssociations.getTotalAssociation()); 
      Iterator<Map.Entry<String, associationElement>> assocIterator = 
myAssociations.getIterator(); 
      while(assocIterator.hasNext()) 
    { 
       System.out.println(assocIterator.next().getKey()); 
    } 
System.out.println("/**************************************************
**********/"); 
      } 
       
      drawDAG(); 
      System.out.println("Writing to File Total SNPs: " + totalSNPs); 
       
String  fn = outputFileName.substring(0, 
outputFileName.indexOf(".")); 
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      Streamer os1 = new Streamer(fn + "_SNP.dne" ); 
 tempNet.write(os1); 
 triangulate(); 
      prune(); 
       
      System.out.println("Writing to File Pruned SNPs Network: "); 
       
      Streamer os2 = new Streamer(fn + "_PrunedSNP.dne" ); 
 tempNet.write(os2); 
  
   Iterator<snp> snpListIterator= snpListByRSquare.iterator(); 
   if(printDebug) 
  { 
       while(snpListIterator.hasNext()) 
     { 
        System.out.println(snpListIterator.next().getName()); 
     } 
System.out.println("/**************************************
**********************/"); 
        } 
        drawDAG_traits(); 
        System.out.println("Total Traits: " + totalTraits); 
   Iterator<String> traitListIterator= traitList.iterator(); 
   if(printDebug) 
        { 
    while(traitListIterator.hasNext()) 
     { 
        System.out.println(traitListIterator.next()); 
     } 
System.out.println("/**************************************
**********************/"); 
         } 
 removeCyclesBeforeCPT(); 
      computeCPT(); 
      computeCPTofTraits(); 
       
boolean compiled = false; 
      while(!compiled)  
      { 
      try{ 
      
       tempNet.compile(); 
       compiled = true; 
   } catch(NeticaException e) 
   { 
     if(e.getMessage().contains("is a cycle (containing link")) 
        { 
         String [] msg = e.getMessage().split("->"); 
         String [] n = msg[0].split("link"); 
         String [] msgg = msg[1].split("\n"); 
         String c_name = msgg[0].trim(); 
        String n2 = c_name.substring(0,c_name.length()-1); 
         Node child = (Node) tempNet.getNode(n2); 
   Node parent = (Node) tempNet.getNode(n[1].trim()); 
       removeCycles(parent, child); 
        } 
   else if(e.getMessage().contains("doesn't have a CPT table")) 
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        { 
         String [] msg = e.getMessage().split("node"); 
         String [] n = msg[0].split("rs"); 
         String [] msgg = msg[1].split("\n"); 
String c_name = 
msgg[0].substring(2,msgg[0].indexOf("doesn't")-2); 
          
         Node Odd_n = (Node) tempNet.getNode(c_name); 
         int size = Odd_n.getParents().size(); 
         float[] cptRow = new float [size*2*2]; 
         for(int i=0; i<cptRow.length; i++) 
         { 
          cptRow[i] = 0.5f; 
         } 
         Odd_n.setCPTable(cptRow); 
         } 
        else 
        { 
         System.out.println(e.getMessage()); 
        } 
      } 
     } 
      double size = tempNet.sizeCompiled();   
System.out.println("Total compiled size: " + 
Double.toString(size)); 
      double memSize = tempNet.getEnviron().getMemoryUsageLimit();  
System.out.println("Total memory size: " + 
Double.toString(memSize)); 
      Streamer os = new Streamer(outputFileName); 
 tempNet.write(os); 
    
   Net netToAbsorb = new Net(new Streamer (outputFileName)); 
    
  //Absorb nodes 
   NodeList nodes = new NodeList (netToAbsorb); 
  Iterator<snp> snpNodeListIterator= 
snpListByRSquare.iterator(); 
 while(snpNodeListIterator.hasNext()) 
 { 
        snp thisSNP = snpNodeListIterator.next(); 
        String name = thisSNP.getName(); 
         
        nodes.add(netToAbsorb.getNode(name)); 
 }  
  netToAbsorb.absorbNodes (nodes); 
   
 Streamer os_mod = new Streamer(fn + "_absorbed.dne"); 
 netToAbsorb.write(os_mod); 
 netToAbsorb.finalize(); 
   
 tempNet.finalize(); 
 tempNet = null; 
       }  
catch (Exception e) { 
      
System.out.println( e.getMessage() ); 
     }    
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